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Abstract  
Pathogenesis of Crimean-Congo haemorrhagic fever (CCHF) - interaction of immune response, 
viral load and clinical course. 
Introduction 
Crimean-Congo haemorrhagic fever a potentially fatal acute viral disease that is geographically 
widespread across southern areas of Africa and Eastern Europe, Russia and the Middle East. It is 
a major emerging infectious diseases threat, but limited data exist on the clinical course, host 
immune response, viral dynamics and associated coagulopathy. 
Aims  
A cohort of adults with PCR positive CCHF in Turkey was recruited to determine the viral load 
dynamics and coagulopathy over the course of clinical infection and to investigate the host 
immune response through serial measurement of cytokine/chemokine levels and quantitative 
serological response, related to disease severity and clinical outcomes.  
Methods 
Prospective observational cohort study. Demographic, clinical and laboratory data were 
collected from patients admitted with confirmed CCHF in Turkey, between May 2014 and 
August 2015. Diagnosis was confirmed on admission by a positive CCHF polymerase chain 
reaction (PCR) or IgM enzyme-linked immunosorbent assay. Quantitative RT-PCR, serology, 
luminex flow cytometry and rotational thromboelastometry (ROTEM) was undertaken at 
admission, during acute illness and in convalescence.  
Results 
During the study period 104/144 patients recruited were confirmed to have CCHF. The majority 
were male (66/104) and had mild disease (63/104), with a median age of 50 years. Median 
temperature at admission was 37.50C with fever, headache, myalgia, lethargy and vomiting the 
most frequent symptoms reported. 23% of participants had an episode of bleeding and 37% 
received blood product transfusion. Higher CCHF viral load at admission was associated with 
increased disease severity (p=0.02), lower platelet counts (p=0.02) and fatal outcome (p=0.01). 
APTT, PT, LDH, CK and creatinine correlated with CCHF viral load. Median clearance of CCHFV 
from plasma was 5 days, occurring more rapidly in mild disease. Urine is rarely PCR positive in 
acute infection (8/578 samples) or in convalescence (0/101 samples). 
At admission 43/102 (42.2%) participants had a positive CCHFV IgM and 51/102 (50.0%) had a 
positive CCHFV IgG. 13/61 (21%) participants remained IgM positive at 1 year after infection. IL-
10, IP-10, GM-CSF, IL-12, IL-17A and IL-8 were significantly elevated in moderate/severe cases, 
with IL-10, IL-6, IL-8, TNF-α and MCP-1 higher in fatal cases. TNF-α, IL-6, IFN-Α2, IL-15, IL-8 and 
MIP-1β correlated with CCHF viral load. At admission, EXTEM S clotting time (CT), amplitude 10 
minutes (A10), clot formation time (CFT) and maximum clot firmness (MCF) were significantly 
different between mild and moderate/severe cases. EXTEM S MCF and A10 were lowest on days 
4-6 of illness. There were no significant differences in FIBTEM A10/MCF by severity and no 
hyperfibrinolysis. 
Conclusions 
CCHF frequently occurs in remote resource-limited settings and has been designated a priority 
for research development by WHO. CCHF viral load at baseline is an important prognostic 
indicator that is associated with more severe disease and prolonged viraemia, whilst urine is 
rarely RT-PCR positive. CCHF is characterised by a pro-inflammatory and early adaptive host 
immune response. ROTEM analysis has demonstrated that the coagulopathy in CCHF is 
predominantly in clot development/stabilisation suggesting platelet dysfunction.  
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Chapter 1: Introduction  
1.1 Research questions and aims. 
Research Questions: 
Crimean-Congo haemorrhagic fever (CCHF) is an emerging infectious disease threat and causes 
significant mortality: 
1. What is the relationship between CCHF viral dynamics, immune response and disease 
severity? 
2. Does severe/fatal CCHF disease correlate with a sepsis model of cytokine network 
deregulation? 
Specific Aims: 
A cohort of adults with PCR positive CCHF in Turkey was recruited to: 
1. Determine the viral load dynamics in serum and urine over the course of clinical 
infection (day 1-7, 14 and 30). 
2. Investigate the hypothesis that: (1) initial viral load and (2) rate of viral load reduction 
are correlated with disease severity and clinical outcome. 
3. Investigate the host immune response to clinical infection through serial measurement 
of cytokine/chemokine levels and quantitative serological response, related to disease 
severity and clinical outcomes. 
4. Test the hypothesis that severe/fatal CCHF is associated with a deregulated cytokine 
network characterised by an exaggerated pro-inflammatory cytokine response (IL-
1βeta, IL-6, IL-8 and tumour necrosis factor alpha [TNF-α], and reduced IL-12). 
5. Undertake ROTEM analysis alongside conventional coagulation testing to investigate 
the coagulopathy in CCHF. 
General Aims: This extensive preliminary study also aimed to establish a platform and 
framework for future therapeutic intervention studies in CCHF, including identification of 
surrogate markers and development of a library of clinical isolates for future research. 
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1.2 Background 
1.2.1 Crimean-Congo Haemorrhagic Fever Virus (CCHFV) 
CCHFV is an arbovirus of the Orthonairovirus genus in the Nairoviridae family. The family 
Bunyaviridae was reclassified by the ICTV in 2017 to the order Bunyavirales. The 5 previous 
genera: Hantavirus; Nairovirus; Orthobunyavirus; Phlebovirus; and Tospovirus 1 are now novel 
viral families. Bunyavirales are predominantly vector borne viruses transmitted by specific 
mosquitoes, ticks, midges, or biting flies. No arthropod vector has been demonstrated for 
hantaviruses that are transmitted to humans predominantly via inhalation of virus-
contaminated excreta from specific rodent reservoir hosts 2. Tospoviruses only infect plants but 
several viruses within the remaining families cause significant severe disease in humans such as 
Rift Valley fever.  
CCHFV is an enveloped RNA virus and virions are spherical and approximately 90-100nm in 
diameter 3. They have a lipid bilayer envelope approximately 5–7nm thick, through which 
protrude glycoprotein spikes 8–10nm in length. Negative stain electron microscopy has shown 
CCHF virions to be distinct from other viruses within the Bunyavirales order, as they possess 
very small morphologic surface units, with no central holes unlike other Bunyavirales 3 (Figure 
1.1). 
CCHFV has a negative sense single stranded RNA genome, and in common with all Bunyavirales, 
is divided into 3 distinct segments designated the small (S), medium (M) and large (L). The total 
genome size is approximately 20kb in length (larger than other Bunyavirales) and the S segment 
codes for the nucleocapsid protein, the M segment codes for the 2 envelope glycoproteins (Gn 
and Gc), and the L segment codes for the RNA dependent polymerase 4. The small segment also 
codes for a non-structural S protein (NSS) in the positive sense5 (Figure 1.2).  
The first complete viral genomes were determined in 2006, and a high degree of genetic 
diversity amongst CCHFV strains is observed with strains clustering in 7 distinct groups, based 
on S segment sequences 4. The 7 groups or clades have a strong geographical distribution with 
clades Africa 1, Africa 2 and Africa 3 containing strains predominantly from Africa. Europe 1 has 
strains from Turkey, Russia, Kosovo, Greece, Bulgaria and Albania, whilst Europe 2 has a single 
AL92 strain isolated in Greece. Asia 1 has strains isolated from the Middle East, whilst Asia 2 has 
isolates from China, Tajikistan, Kazakhstan, and Uzbekistan. 
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Bunyavirales families  
Nairoviridae CCHFV 
Dugbe virus 
Phenuiviridae 
(previously Phlebovirus) 
Sandfly fever Sicilian virus, Toscana virus  
Rift Valley Fever virus 
Severe fever with thrombocytopenia syndrome virus (SFTSV) 
Bhanje virus 
Peribunyaviridae 
(previously 
Orthobunyavirus) 
Bunyamwera virus 
California encephalitis virus - La Crosse virus 
Oropouche virus (OROV)  
Bwamba Fever virus (BWAV) 
Hantaviridae Hemorrhagic fever with renal syndrome (HFRS) 
Hantavirus Pulmonary Syndrome (HPS) 
Table 1.1 Major Bunyavirales causing disease in Humans   
 
 
Figure 1.1 Electron micrograph of negatively stained particles of Crimean-Congo haemorrhagic 
fever virus (CCHFV). The bar represents 100 nm. (From C. S. Schmaljohn. Bunyaviradae, Fields 
virology 2014)1  
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Figure 1.2 CCHFV genome (From Zivcec et al. Molecular Insights into Crimean-Congo 
Hemorrhagic Fever Virus. Viruses 2016) 6 
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1.2.2 Emergence of CCHF 
Crimea 
CCHF was first recognised and described in the Spring and Summer of 1944, when a febrile 
illness was observed in up to 200 Soviet army troops and agricultural workers in Crimea. Small 
clusters of similar cases were then reported annually in the same region. An investigation and 
description of the first outbreak was made by military physicians and subsequently by a 
scientific expedition led by Professor Mikhail Chumakov of the USSR Academy of Medical 
Science 7. Chumakov went on to be a pivotal figure in developing the oral polio vaccine. He had 
also previously been part of a team that discovered the viral aetiology of tick-borne encephalitis 
(TBE), accidentally becoming infected after cutting his finger during an autopsy, leading to a 
permanent loss of hearing and paralysis of the right arm 8.  
Chumakov and colleagues named the syndrome Crimean haemorrhagic fever (CHF) and 
reported that it consisted of fever and a range of haemorrhagic complications, mainly 
gastrointestinal, combined with hypotension and shock. Initial case fatality rates were 8% in 
1944 and it is believed that CCHF emerged in the Crimea at this point due to favourable 
environmental factors during the wartime period including: neglected agricultural lands; 
introduction of a new non-immune population and a local resurgence of the hare population 
due to reduced hunting. Russian investigators also recognised the similarity between CHF and 
earlier 12th century reports of a severe febrile illness that was reported by the Tadzhik physician 
and philosopher Dzhurdzhani 9. In Uzbekistan a similar haemorrhagic disease was known as 
‘karakhalak’ meaning black death 10. 
Initial research by Russian scientists to develop an animal model and establish the aetiology of 
CHF were unsuccessful despite attempts in white mice, guinea pigs, rabbits, monkeys and cats. 
In 1945-46 psychiatric patients were directly injected with samples from clinical cases in the 
Crimea, as pyrogenic therapy. Samples from a pulverised and filtered suspension from 
Hyalomma marginatum nymphs were also injected resulting in a characteristic CHF illness 11.  
The first reliable animal model in the USSR was developed in 1967 in the Institute of 
Poliomyelitis and Viral Encephalitides in Moscow utilizing newborn white mice brains, allowing 
serial passage and virus isolation. Russian investigators also reported that the majority of cases 
were occurring in milk maids and agricultural workers, with many reporting that they frequently 
removed and crushed engorged ticks from their cattle between their fingers. They also reported 
the role of ground feeding birds as tick hosts, recognising the risk of the potential introduction 
and establishment into new geographical areas 12. 
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Congo 
In 1956 in the Democratic Republic of Congo (Belgian Congo), Dr Ghislaine Courtois was the 
head of the provincial medical laboratory in Stanleyville, when he reviewed a 13 year old boy 
with fever, headache, nausea, vomiting, back pain, arthralgia and photophobia 13. He took a 
blood sample, injected this into 3-day old mice, and then began serially passaging the virus 
through new-born mouse brains. A month later he did the same with his own sample when he 
became unwell with a febrile illness. He passed the sample through a seitz filter to establish it as 
a virus, but as he had no dry ice or freezer available he was forced to maintain the virus through 
serial passage (35 and 46 times) 13.  
He subsequently sent the mouse brains to the East African Virus research institute in Entebbe 
Uganda where they remained in a freezer for 4 years. These were then found by John Woodall 
in 1961 and after he was unable to confirm the identity of the virus using haemagglutination-
inhibition and complement fixation, the samples were sent to the Rockefeller Foundation Virus 
Laboratory in New York. Dr Jordi Casals tested it there against reference strains, finding it 
identical to another unnamed strain from Uganda and contacted Dr Courtois who asked for it to 
be called Congo virus. Details of the virus were first published in 1967 in the East African 
Medical Journal 14, including 12 cases of CCHF, of which 5 were due to laboratory exposure at 
the Uganda Virus Research Institute (UVRI). The International Committee for the Taxonomy of 
Viruses named it Crimean-Congo Haemorrhagic Fever virus (CCHFV), although a number of 
reports still refer to it as Congo-Crimean Haemorrhagic fever.  
Turkey 
In 2002 health facilities in Tokat located in the central Anatalolia region of Turkey reported that 
a significant number of patients were being seen with fever, rash and thrombocytopenia. In 
2003 a joint investigation was undertaken by the Ministry of Health and the Ministry of Food, 
Agriculture and Livestock, which found that the majority of patients reported a history of tick 
bite and worked in animal husbandry 15. A common clinical syndrome was recognised including 
non-specific febrile illness, thrombocytopenia, leucopenia and elevated liver enzymes, that 
initial reports suggested was treated successfully with tetracyclines. In 2002, serum samples 
from 19 patients were sent to the WHO Collaborating centre for Rickettsial Reference and 
Research Laboratory in Marseille where 7 of them were reported as acute Q fever, while 8 of 
them were reported as previous Q fever cases 16.  
Cases continued in 2003 with increased haemorrhage and a lack of tetracycline response also 
reported. Samples were then sent to the WHO Collaborating Centre for Arboviruses and Viral 
Haemorrhagic Fevers in France, which diagnosed CCHF, that was confirmed by testing of 
previous legacy samples 17. RT-PCR positive cases were also confirmed by Karti et al 18 at the 
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same time at Karadeniz technical University in collaboration with the Centers for Disease 
Control and Prevention, Atlanta.  
 
1.2.3 Epidemiology  
Although CCHFV has been isolated from a range of tick species, only ticks from the from the 
genera Dermacentor, Hyalomma, and Rhipicephalus have been confirmed as vectors. Its spread 
is aligned with the distribution of its main vector Hyalomma ticks with Hyalomma marginatum 
considered to be the most important vector for transmission of CCHF virus in Europe 19. Ticks 
also act a natural reservoir for CCHFV, tending to occur in areas of warmer climate with high 
fragmentation of the landscape vegetation. Although they can exist in a range of habitats, in 
Europe the Alps and Balkan mountains seem to act as natural barrier to their distribution 20. 
Climatic factors such as mild winters, reduced rainfall and changes of reservoir species can 
result in increase in suitable habitats for ticks 21. Human behaviour can also have a direct 
influence on emergence through the neglect of agricultural land or deforestation, and changes 
in hunting activities that may result in increased wildlife and ticks; this was suggested to have 
happened prior to its emergence in Russia and also in Turkey 15,21. Both larvae and nymphs feed 
without leaving the host, and as a result may be attached to hosts for long periods. This long 
attachment allows them to be passively transported by migratory birds: this has also been 
suggested to play a role in in the possible spread of CCHFV, as initially suspected by Russian 
researchers and later demonstrated in Turkey 22,23. Introduction of Hyalmoma marginatum ticks 
to the United Kingdom by migratory birds has also been demonstrated 19.   
Antibody production and transient viraemia lasting 7-15 days has been demonstrated in a range 
of wild and domestic vertebrates that have an asymptomatic infection. Cattle, sheep and goats 
have been investigated in the largest seroprevalence studies, with combined international data 
reporting CCHFV seroprevalences of 19%, 24% and 28% respectively. Antibody production to 
CCHFV has not been detected in birds or reptiles with the exception of ostriches and guinea 
fowl 24–28. CCHFV has a wide geographical distribution with cases mainly occurring in Asia, the 
Middle East, South-Eastern Europe and Africa. Since its emergence in 2002, Turkey has been the 
epicentre of activity worldwide reporting up to 1000 cases annually. Russia, Iran, Pakistan and 
Afghanistan are the other countries where the disease has been reported most often in the last 
decade 15. More than 30 countries worldwide have reported human cases with Spain recently 
reporting cases of autochthonous transmission 29.  
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Africa Asia Middle East Europe 
Democratic Republic 
of Congo 14 
Pakistan 30 Iran 31  
 
Russian Federation 32 
 
South Africa 33 Afghanistan34 Iraq 35  Georgia 3637 
Nigeria 38 Tajikistan 39 United Arab Emirates36 Bulgaria 40 
Senegal 41 Uzbekistan42 Saudi Arabia 43  Macedonia 44 
Uganda 14 Kazakhstan45 Oman 46 Albania 47 
Tanzania 33 China 48  Kosovo 49 
Mauritania 50 India 51  Turkey 15 
Kenya 52   Greece 53 
Burkina Faso 54   Spain 29 
Namibia 55   Hungary 56 
Sudan 57,58   Serbia 59 
Central African 
Republic 60 
   
Ghana 61    
Benin 62    
Madagascar 63    
Mali 64    
 
Table 1.2 . Countries that have reported cases of CCHF or have serological evidence in Humans. 
NB in addition Niger 65, Azerbaijan 66, Armenia 67, Hungary 56, Somalia 68, Zimbabwe 33 and Egypt 
69 have serological evidence of CCHF in animals.  
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Figure 1.3. Worldwide distribution of CCHF (modified from WHO with permission) 
 
 
 
 
Genotype Countries 
Africa 1 Western Africa (Senegal, Mauritania) 
Africa 2 Central Africa (Uganda, Democratic Republic of Congo) 
Africa 3 South Africa, Nigeria, Uganda 
Asia 1 The Middle East (Iran, Iraq, Oman, United Arab 
Emirates), Pakistan, Afghanistan 
Asia 2 Far East and Central Asia (Tajikistan, Uzbekistan, 
Kazakhstan, China), Iran 
Europe 1 Eastern Europe (Albania, Kosovo, Bulgaria, Russia, 
Turkey, Greece), Iran 
Europe 2 Greece (AP92 strain), Turkey  
 
Table 1.3 Geographic distribution of CCHF virus according to S-segment analysis. The 
phylogenetic grouping of S RNA segments illustrates that the pattern of genetic diversity 
observed is largely related to the geographical distribution of the viruses. (Leblebicioglu H 
uptodate.com) 
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1.3 Pathogenesis of Crimean-Congo Haemorrhagic Fever 
Although CCHF is widely distributed and increasingly reported, the pathogenesis of disease is 
poorly understood. This is mainly due to the necessity to perform research in advanced 
biosafety laboratories (termed containment level 4 (CL-4) in the UK), the poor availability of 
animal models and the occurrence of infections in areas where research facilities are limited. 
The role of ribavirin antiviral therapy is controversial, and improved understanding of disease 
pathogenesis should inform new approaches to improving clinical outcomes. 
When CCHFV penetrates into the body it will be encountered first by the innate immune system 
that will act ‘quasi-automatically’ generating inflammation 70,71. The key cells involved are 
monocytes/macrophages, neutrophils, eosinophils, basophils and natural killer cells. These 
leucocytes are activated by binding of molecules from CCHFV, pathogen-associated molecular 
patterns (PAMPs) or from necrotic cells, damage-associated molecular patterns (DAMPs) to 
pattern recognition receptors (PRRs). PRRs include Toll-like receptors (TLRs)s, nbod-like 
receptors, RIG-like receptors and C-type lectin receptors (Figure 1.4). TLRs are the best studied 
and trigger a cascade of activation generating release of inflammatory cytokines.  
 
Figure 1.4 – Cytokine cascade during sepsis. (From Chousterholm et al. Seminars in 
Immunopathology 2017) 70. 
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CCHFV amplifies in dendritic cells and macrophages that facilitates spread and the replication 
process for CCHFV is similar to those of many other enveloped viruses 72. The viral glycoproteins 
are believed to be responsible for recognition of receptor sites on susceptible cells. Viruses 
which attach to receptors on susceptible cells are then internalized by endocytosis, with 
replication occurring in the cytoplasm 73. Virions mature by budding through endoplasmic 
reticulum into cytoplasmic vesicles in the Golgi region, which are presumed to fuse with the 
plasma membrane to release virus 74,75.  
One of the first and most effective immune defences against viral infections are Type 1 
Interferons. After cells detect viral replication products through complex signalling pathways, 
Type 1 IFN is synthesized and secreted, that further upregulates interferon-stimulated genes 
(ISGs) 76,77. The action of the ISGs activates a complex host defence program that results in an 
antiviral state in the cell and neighbouring cell 78. Interferons also act to induce apoptosis and 
cellular resistance to infection, inhibit cell proliferation and activate natural killer cells and the 
adaptive immune response 79,80. Bunyavirales, including CCHFV, have developed mechanisms to 
evade the IFN induced antiviral state. CCHFV has been shown to delay the production of 
interferon in infected cells by impeding activation of the Interferon regulator factor 3 pathway. 
The L segment of CCHFV contains an ovarian tumor (OTU) domain, which is thought to suppress 
immune signalling, modulate virulence and counteract the effects of IFN induced antiviral 
proteins 81. This domain has also been shown to inhibit NF-Kb 81, a major rapidly acting 
transcription factor that regulates genes responsible for both the innate and adaptive immune 
response, including apoptotic genes 82.  
The regulation of apoptosis through suppression or induction during acute viral infection is also 
important for virus survival and dissemination 83. Apoptosis can be started by an extrinsic (death 
receptor mediated) or intrinsic pathway (mitochondria mediated). CCHFV has been shown to 
induce caspase-3 and modulate both intrinsic and extrinsic pathways in cell cultures 5,84. 
Elevated apoptotic markers have been demonstrated in a paediatric cohort of CCHF 85, and 
modulation of apoptotic gene expression facilitating apoptosis, shown in a cohort of 20 patients 
in Turkey 86. In this study dominant extrinsic pathway activation, mostly with TNF family 
members was observed, with additional intrinsic pathway activation in severe and fatal cases.  
In animal models CCHFV initially replicates in blood, liver and spleen, before wider 
dissemination to lung, kidney and brain 87,88. CCHF is characterized by haemorrhage and 
increased vascular permeability indicating the involvement of endothelial cells, and CCHFV has 
been demonstrated to have direct and indirect effects on endothelial cells upon infection 89. 
Indirect effects are through virus mediated host immune response (e.g. cytokines) or directly by 
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virus infection and replication in endothelial cells 90. Endothelial cells also play a key role in 
haemostasis influencing coagulation, platelet adhesion and activation, fibrinolysis, platelet 
disintegration and vasoregulation 91. 
1.3.1 Pathogenesis – CCHF Viral load 
Viral load at admission has been shown to be an important prognostic indicator in Ebola virus 
disease (EVD) 92,93 and Lassa Fever 94. A correlation between initial serum viral load and disease 
severity/outcome in CCHF has also been shown in 11 studies to date that have reported CCHF 
viral load data (Table 1.4). Cevik et al 95 and Duh et al 96 first reported viral load data from 
Turkey and Kosovo respectively in 2007 that showed CCHF viral loads were higher in fatal than 
surviving cases. Both studies demonstrated that a VL greater than 1 x 109 copies/ml was 
indicative of a fatal outcome. This has been confirmed by a number of further studies 97–99, 
some of which also demonstrated differences in viral load by severity score. A limited number 
of studies have investigated viral loads serially with daily sampling. The largest by Bodur et al 
100, measured viral loads daily in 50 patients, 10 of whom received ribavirin. By day 3 of 
admission 50% of patients had cleared virus, with only 1/42 having a positive PCR on day 6. This 
is consistent with Cevik et al’s 95 first report and Ergunay et al’s 101 more recent data 
demonstrating that virtually all patients had cleared viraemia within 6 days of admission, with 
patients being admitted 3-5 days after onset of symptoms.  
The largest study undertaken evaluating CCHF VL at baseline was published by Hasanoglu et al 
99 in 2016. It included 126 patients (14 with fatal disease) recruited over 6 years from Ankara. 
They demonstrated significant differences in mean viral load between fatal and surviving cases 
(4.6 × 109 copies/ml vs 8.3 × 107 copies/ml, p<0.005), and also that blood product transfusion 
was used significantly more frequently in patients who had viral load >108 copies/ml, as was 
haemodialysis. One report by Papa et al 102 also demonstrated that CCHF viral loads were higher 
in primary than secondary cases, although the sample size was small and all primary cases had 
severe disease with haemorrhage. The viral load dynamics in urine remain unclear, with 
potential infection prevention control and diagnostic implications. Prolonged viraemia in both 
serum and urine (>30 days post disease onset) has been demonstrated in one report from 
Kosovo, that included patients with serial positive/negative/positive results 103. CCHFV has also 
been detected in one other study in urine and the saliva of plasma CCHFV PCR positive patients 
104.  
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Publication Study 
period 
Study design Country Number of 
participants 
Day of 
tests 
Results 
Cevik et al. 
2007 95 
2006 Prospective Turkey 36 patients 
(9 fatal) 
 
Daily In 8 /9 patients with fatal outcomes, VL >1x 10 9 copies/ml 
In 25/26 patients with non-fatal outcomes, VL < 1x109 copies/mL (P <0.001). 
All surviving patients cleared viraemia by day 6 hospital admission 
Duh et al. 
200796 
2001, 
2003, 
2005 
Retrospective Kosovo 24 patients 
(9 fatal) 
Admission VL fatal group log10 9.25 (1.8 × 109) 
VL survivor groups log10 6.91 (8.1 × 106) 
Wolfel et 
al. 2007 105 
NS Retrospective South Africa, 
Iran, 
Pakistan 
21 patients Mix Correlation between viral load and duration of symptoms 
Papa et al. 
2007 102 
2003-
2006 
Retrospective Albania 12 patients Admission VL higher in primary than secondary cases 
Saksida et 
al. 201097 
2001-
2007 
Retrospective Kosovo 46 patients 
(11 fatal) 
Admission VL fatal group: 9.31 log10 copies/ml 
VL survivor group: 6.31 log10 copies/ml (p<0.001). 
Fatal groups 9/10 VL >1x108 copies/ml 
Survivor groups 30/32 VL <1 x 108copies/ml (p<0.001). 
Higher VL in severe (mean, 6.97 log10 copies/ml) than moderate disease course 
(mean, 5.65 log10 copies/ml) (p= 0.006) 
Bodur et 
al. 2011 100 
2006-
2008 
Prospective 
case control 
study 
Turkey 50 patients, 
10 ribavirin 
(2/10 fatal) 
40 control 
(6/40 fatal) 
Daily Positive VL by day admission and ribavirin 
Day 1: 10/10 and 40/40 
Day 2: 9/10 and 30/39 
Day 3: 5/9 and 22/39 
Day 4: 2/9 and 12/37 
Day 5: 1/9 and 4/34 
Day 6: 1/8 and 0/34 
Kubar A et 
al. 2011 106 
NS Prospective Turkey 26 patients – 
given 
hyperimmun
e serum 
Daily Low VL (<107copies/ml): 8/11 cleared by 38h, 11/11 cleared by 72h 
High VL (108copies/ml): 15/15 pos 48 hrs, 6/15 pos 96h, 1 pos 144h. 
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Table 1.4. Published studies investigating CCHF viral load 
Kaya S et 
al 201498 
NS, Prospective Turkey 31 patients 
(11 fatal) 
Daily 7 
days 
VL in fatal group 5.5 x 109 copies/mL 
VL survivor group 5.7 x 108 copies/mL (p<0.001) 
CCHF VL was significantly and positively correlated with serum IL-6, TNF-α and blood 
CRP levels, PT, aPTT, INR values and DIC scores 
In contrast to fatal patients, a clear declining trend was observed for serum VL in 
survivors 
Ergunay K 
et al 2014 
101 
2012 Prospective Turkey 20 patients Daily 17/20 RNA pos 
Viraemia lasted median 3 days admission 
Papa et al. 
2015 107 
2011-
2013 
Retrospective Bulgaria and 
Turkey 
35 patients 
(4 fatal) 
16 controls 
Admission VL mean 1.47x107copies/ml 
VL correlated with day of illness 
Hasanoglu 
et al. 2016 
99 
2008-
2013 
Prospective Turkey 126 (14 
fatal) 
Admission VL survived 8.3 × 107 copy/ml 
VL fatal group 4.6 × 109 copy/ml 
No patient survived VL >2 × 109 copy/ml 
Blood product transfusions were significantly used more in patients who had viral 
load >108 copy/ml. 
Patients with 108 copy/ml or higher viral load: Diarrhoea, headache, 
unconsciousness, bleeding, seizures, and haemodialysis were significantly more 
frequent (p<0.05). 
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1.3.2 Pathogenesis – CCHFV antibody 
Antibody production against CCHFV is hypothesized to be important in survival, with weak or no 
antibody response demonstrated in fatal cases. Early studies using indirect immunofluorescence 
assays demonstrated the presence of IgG and IgM antibodies on days 7 to 9 of illness with the 
highest antibody titre reached in the second to third week of illness 26,108. In a study of 20 
Turkish CCHF cases, nucleoprotein-specific IgM antibodies were detectable a median of 2-3 days 
after disease onset, followed by GPC-specific IgM (4-6 days) and IgG antibodies (5-6 days) 101. 
Duh et al 96 evaluated CCHF IgG and IgM levels in 43 samples from 24 patients showing that 
quantitative IgG correlated with viral loads, with none of the 9 fatal cases (day of illness, median 
6, range 2-9) developing positive IgG titres. In contrast 9/21 acute samples from survivors with 
moderate and severe disease in the same cohort were positive for IgG but taken at later time 
points (median 9, range 2-13). Only one of the 9 survivor samples with a positive IgG result was 
taken less than 9 days after disease onset (at day 6). No correlation with IgM positivity and 
death or viral load was demonstrated.  
Saksida et al 97 also investigated CCHF antibody responses in admission samples from 46 
patients from Kosovo. No IgG response was detected in 11 fatal cases (median sample time 6 
days, range 3-9 days), whilst 5/34 survivor samples had a positive IgG titre (median 6 days, 
range -2-12 days, positive IgG results occurred at days 6,6,9,12 and 12 of illness). There was no 
relationship between IgM status and outcome in this study. Kaya et al 98 evaluated serial 
antibody responses in 31 patients with CCHF in Turkey, including 11 fatal cases. They showed 
that all survivors demonstrated a positive IgG titre within 9 days of onset, whereas none of the 
fatal cases did by the same timepoint.  
The role of cell-mediated adaptive immunity in CCHF infection has not been well studied. 
Goedhals et al 109 recently demonstrated CCHF memory T cell responses persisting for up to 13 
years post infection in 11 survivors. Increased circulating CD3+ and CD8+ T cells has been shown 
in fatal CCHF disease110, with little known about functional T cell responses (Th1/Th2) and their 
role in disease severity and outcome. 
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1.3.3 Pathogenesis – Cytokines 
Cytokines are a broad category of small proteins involved in cell signalling, that have a broad 
range of functions including immunomodulatory. They can be divided into several categories: 
interleukins; chemokines; interferons; tumor necrosis factor; and growth factors 70,111. A tightly 
regulated cytokine network is crucial for elimination of invading pathogens and restricting 
excessive tissue damage 112,113, and sepsis syndrome in general has been shown to develop 
when this initial host response becomes amplified and deregulated 114–117. Release of 
inflammatory cytokines induces new cytokine production and release, and this ‘cytokine storm ‘ 
or ‘cytokine cascade’ is likely responsible for the many diverse and local effects of the ‘sepsis 
syndrome’ 70. This has been demonstrated in a range of viral and bacterial infections, and was 
recently popularised largely in the context of avian influenza 118.  
Numerous pro-inflammatory cytokines have been identified during sepsis with IL-1β, IL-6, IL-12, 
and IL-17 being of crucial importance. However despite large progress in the research of sepsis 
utilising the ‘omics’ (genomic, proteomic, metabolomic and transcriptomic), therapeutic clinical 
trials targeting cytokines and the immune response in sepsis have failed 70. The failure of 
immunomodulatory trials and current lack of clear understanding in the organisation of host 
response reflects the fact that septic patients do not represent a homogeneous group. Patients 
have different pathogens, presentations and levels of severity that make direct comparisons 
and clinical trials focussed on immune response modification challenging.  
Cytokines in viral haemorrhagic fevers/CCHF 
In viral haemorrhagic fevers, a common pathogenic feature is the ability of the virus to disable 
the host immune response by attacking and manipulating macrophages and dendritic cells 
(90,91). In severe cases of CCHF, it has been suggested that this, combined with the 
deregulation and excessive pro-inflammatory cytokine release leads to toxic endothelium 
effects, increased vascular permeability, multi-organ failure, and shock 87. A significant number 
of studies have evaluated the role of cytokines in CCHF, most frequently through analysis of 
baseline admission samples and direct comparison of severity groups or fatal/non-fatal disease 
(Table 1.5). Fourteen of the 18 studies identified are from Turkey, with the largest study 
including 80 patients. Only one study of 31 patients evaluated a panel of 4 cytokines daily for 7 
days, demonstrating IL-6 and TNF-α were consistently higher in fatal cases. A recent study of 52 
patients evaluated a panel of cytokines every 3 days (119 samples in total) demonstrating that 
IL-6, IL-8, IL-10, IL-10/ 12, IFN-γ, MCP-1, and MIP-1β were higher in patients with CCHF than 
controls, and that IL-6 and IL-8 were higher in the first 5 days of illness in fatal cases.  
Evaluation of the combined data from a number of studies broadly demonstrates that high 
serum levels of pro-inflammatory cytokines, particularly IL-6 and TNF-α, have been implicated 
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as negative prognostic factors in CCHF/ VHF 97,98,119–124. IL-10 is an anti-inflammatory cytokine 
that has also been shown to be higher is severe/fatal disease in some studies 119,123,125, but not 
in others 120,126. IL-12 production has demonstrated a mixed picture in relationship to CCHF 
disease and severity compared to controls 97,121,126. Other studies have investigated endothelial 
adhesion mediators showing sVCAM-1 and sICAM-1 to be higher in severe cases 127,128, and 
other markers of endothelial dysfunction to be higher in haemorrhagic cases 129.  
Overall the ability to draw prognostic inferences from these studies is limited in most cases due 
to their retrospective design, incomplete data sampling, size and the evaluation of cytokines at 
only one time point. Patients with CCHF present at different stages of illness and whilst baseline 
evaluation of cytokines may be to useful to incorporate variables into prognostic severity 
scores, larger longitudinal studies are required to provide greater insights into the dynamic host 
immune response over time. Sample integrity for cytokine measurement is also important, and 
benefits from early processing and storage in ultra-low freezers. Repeated freeze-thaw cycles of 
legacy samples taken in different outbreaks may affect cytokine results and the ability to draw 
clear and valid conclusions. Due to the number of cytokines involved, use of multiplex would be 
extremely beneficial, but technically difficult due to the highly pathogenic nature of VHFs.  
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Publication Study 
period 
Study design Country Number of 
participants 
Day of tests Results  
Papa et al.  
2006 130 
2003 Retrospective Albania 16 patients 
(1 fatal) 
26 controls 
Diagnostic 
samples – day 5  
TNF-α and IL 6 in cases raised vs control 
IL10 raised in fatal case 
Ergonul et al. 
2006 120  
2002-
2004 
Retrospective  Turkey  30 patients Admission  IL6 and TNF-α higher in fatal cases – no difference in IL-10 
IL6 and TNF-α correlated with higher DIC scores, IL10 neg correlated 
Pinar et al. 
2008 131  
2006 Not reported  Turkey  51 patients  
30 controls 
Admission  Neopterin higher in cases than controls (15 x) and higher in fatal cases (3x) 
Bodur et al. 
2010 127 
2007 Prospective 
case -control  
Turkey  75 patients 
88 controls  
Admission  sVCAM-1, sL-selectin and MIF higher CCHF vs controls 
sICAM-1, sP-selectin, sE-selectin, and VEGF lower CCHF vs controls 
sVCAM-1 and sICAM-1 higher in severe cases, VEGF lower in severe cases 
Ozturk et al. 
2010 128 
2007-
2008 
Not reported Turkey 61 patients  
(8 fatal)  
Admission and 
discharge 
HA, sICAM-1, sVCAM-1, and VEGF-A levels higher in fatal cases.  
HA, sICAM-1 higher in acute vs conv samples. 
Saksida et al. 
2010 97 
2001-
2007 
Retrospective Kosovo 46 patients  
(11 fatal) 
Admission  IL10 IFN gamma and TNF-α higher fatal outcome, and linear relationship with VL 
IL12 reduced in all patients 
Ozsurekci et 
al. 2013 126 
2010-
2011 
Not reported Turkey  34 children 36 
adults 
30 controls 
Admission IFN-γ, TNF-α, IL-1β, IL-2, IL-4, IL-5, IL- 6, IL-9, IL-10, IL-12 p70, IL-13, IL-17A, and IL-22 – no 
difference in adults or children vs controls or difference in severity in children.  
Higher IL-2, IL-5, IL-9, IL-12 p70, and IL-13 in fatal adults (n=3) vs survivor adults 
Erturk et al 
2014. 132 
Not 
reported  
Not reported  Turkey 42 patients 
40 controls 
Not reported  Resistin higher in CCHF vs controls, and recovery time.  
Kaya et al. 
2014 98 
Not 
reported 
Prospective Turkey  31 patients 
(11 fatal) 
Longitudinal – 
daily for 7 days  
IL-6 and TNF-α higher in fatal cases  
Sancakdar et 
al. 2014121 
Not 
reported 
Not reported Turkey  52 children 
34 controls 
Acute samples 
<7 days onset 
disease 
IL-10 and ET-1 levels higher in severe group vs non-severe 
IL-6 and TNF-α levels higher in sever than controls 
IL-12 no diff controls or severity 
Arasli et al. 
2015. 133 
2010-
2011 
Retrospective 
Cases vs 
controls  
Turkey  29 adults 
32 children  
Not reported Adults - median CCL2, CCL3, CCL4, CXCL8, and CXCL9 higher CCHF vs controls 
Children median CCL4 and G-CSF levels higher CCHF vs controls 
Papa A et al 
2015 107 
2011-
2013 
Retrospective Bulgaria 
and 
Turkey 
35 patients 
(4 fatal) 
16 controls 
Admission  CXCL10 (IP-10) raised in cases and correlated with VL.  
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Parlak et al. 
2015. 122 
2012-
2013 
Prospective 
case control 
Turkey 80 patients  
(5 fatal) 
100 controls 
Admission  IL-2, IL-6, IL-10 higher in patients vs controls. 
IL-10, IL-6 higher severe and fatal cases 
 
Yilmaz et al. 
2015134 
2008-
2011 
Retrospective Turkey 53 patients  
36 controls 
Admission  Resistin and ghrelin levels higher in severe vs non-severe CCHF 
Demirpence 
et al. 2016 135 
Not 
reported 
Prospective 
case control 
Turkey  59 patients  
28 controls 
Admission  Presepsin higher in CCHF vs controls and higher in severe CCHF disease 
Papa et al. 
2016. 123 
2003-
2011 
Retrospective Turkey, 
Albania 
and 
Greece 
29 patients 
16 controls 
Admission  IP-10 and MCP-1 raised in severe vs non-severe cases 
IL-1β, IL-6, IL-10, IP-10, MCP-1, TNF-α raised in fatal cases 
Low levels of RANTES in fatal cases 
Arslan et al. 
2017.129 
2010-
2012 
Prospective Turkey  73 patients  Admission and 
5th day admission 
Endothelial dysfunction markers higher in CCHF vs controls * ADMA, ET-1, TM, vWF, 
ICAM-1). TM and vWF >in haemorrhagic cases.  
Ergonul et al 
2017 124 
2007-
2009 
Retrospective. Turkey  52 patients 
(119 samples) 
10 controls 
Admission and 
every 3 days  
IL-6, IL-8, IL-10, IL-12, IFN-γ, MCP-1, and MIP-1β higher in CCHF than controls. 
IL-6 and IL-8 higher in first 5 days in fatal cases. 
Table 1.5. Published studies investigating cytokines/chemokines in CCHF
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1.4 Clinical presentation of Crimean-Congo Haemorrhagic Fever 
The clinical spectrum of illness and disease severity in patients with CCHF is broad, and it is 
estimated that up to 88% of infections may be sub-clinical 136. In highly endemic areas such as 
Tokat and Sivas provinces in Turkey, the CCHF IgG seroprevalence has been shown to be as high 
as 12.8% in rural populations 137. Case fatality rates in laboratory confirmed cases have been 
around 5% in Turkey, independent of ribavirin use, but consistently higher in other countries 
and have exceeded 50% in smaller outbreaks 15,138,139. This is in part due to differences in access 
to supportive care, but probably also reflects different severity of disease in different 
cohorts/settings due to limited surveillance activities and access to diagnostic support. Turkey 
has an active community engagement program with annual education campaigns to 
communities and healthcare facilities in endemic areas, combined with access to a network of 
reference laboratories. As a result, it identifies a significant number of mild severity CCHF cases 
annually, often in patients that present with a history of only tick bite and fever, and mild 
thrombocytopenia. By contrast in Pakistan a significant proportion of cases have travelled from 
Afghanistan for treatment, and reflect a more severely unwell cohort, often with haemorrhage 
and higher associated case fatality rates 140.  
The majority of the patients with CCHF report a history of tick bite (70%)141. The incubation 
period ranges from 1-13 days (typically 1-3 days after tick bite), and has been shown to be 
shorter in fatal cases 50,142. Data from a large cohort in Turkey (n=1670) showed that the most 
common complaints at presentation were fever (90%), fatigue (90%), headache (70%), myalgia 
(70%) and nausea (65%). Haemorrhagic manifestations were reported in 23% of patients at 
admission141. Leucopenia (88.9%), thrombocytopenia (93.2%) and elevated transaminases 
(85.9%), LDH (75.8%) and CK (65.9) were the most common laboratory abnormalities at 
presentation.  
The first study evaluating prognostic indicators in CCHF was by Swanepoel et al 143 in South 
Africa in 1989. They reported that the occurrence of any of the following factors during the first 
5 days of illness was >90% predictive of a fatal outcome: Leucocyte counts >10 x 109/L; platelet 
counts <20 x 109(/L; AST >200 IU/L; ALT >150IU/L; APTT >60 seconds; and fibrinogen <110 
mg/dL. Subsequent studies have evaluated a range of clinical and laboratory valuables 
prognostically 99,144–147. The main clinical features associated with mortality by multivariate 
analysis include impaired consciousness 144,148,149, diarrhoea 149,150 and haemorrhagic 
manifestations 148,150. Elevated APTT147–150 and elevated ALT 147,150,151 are the most consistently 
abnormal laboratory parameters in multivariate analysis, with raised LDH an independent 
predictor of death in 2 studies 147,150 and platelet count <20 x 109/L a predictor in one study 148.  
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Two severity scoring systems for CCHF have been developed, utilising these and additional 
laboratory parameters (Table 1.6). The severity grading score (SGS) system was first reported by 
Bakir et al in 2012152, and then validated by data from over 400 patients from multiple centres 
in Turkey 153. It divides patients into low (0%), intermediate (20%) or high-risk group (100%) for 
mortality based on 12 parameters in the first 5 days of illness (ALT, AST, LDH, WBC, platelets, PT, 
INR, aPTT, age, bleeding, hepatomegaly and organ failure). The second CCHF severity scoring 
system developed is the severity scoring index (SSI) reported by Dokuzoguz et al 154 that grades 
patients as mild, moderate or severe disease at admission utilising 5 parameters (platelets, 
aPTT, fibrinogen, bleeding and somnolence). The SSI system has the advantage in that it is 
based on admission data, and therefore can be used in patients that present after 5 days of 
illness, but also has the downside of including fibrinogen which is not widely available or 
routinely measured in all patients. A simpler scoring system for CCHF, incorporating CCHFV viral 
load, that has consistently been shown to be associated with severe and fatal disease 96,97,99, 
may be useful.  
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Table 1.6 CCHF severity scoring systems   
Swanepoel criteria 
- 1st 5 days of illness  
- Any of following 
>90% predictive fatal 
outcome  
Severity grading system  
- 1st 5 days of illness 
- 0-4 Low risk 
- 5-8 Intermediate risk 
- >9 High risk  
Severity scoring index 
- At admission  
- 0-2 Mild 
- 3-9 Moderate 
- 10-13 Severe  
Platelet count ≤20 X 109 /L Platelet count 
≥100,000 cells/μL = 0  
≥50,000, <100,000 cells/μL = 1 
<50,000 cells/μL = 2 
 
Platelet count (×103/mm3 ) 
>150 = 0 
150–50 = 1 
 49–20  = 2 
<20 = 3 
APTT ≥ 60 seconds 
 
 
aPTT (seconds) 
<70 = 0 
≥70 = 1 
aPTT (seconds) 
≤34 = 0 
35–45 = 1 
46–59 = 2  
>60 = 3 
Aspartate transaminase ≥200 
U/L 
Aspartate transaminase  
< 5×ULNV = 0 
≥ 5×ULNV = 1 
Lactate dehydrogenase  
<3×ULNV = 0 
≥3×ULNV= 1 
Fibrinogen level, mg/dL  
≥180 = 0 
179–160 = 1  
159–120 = 2  
<120 = 3  
Alanine transaminase ≥150 
U/L 
Alanine transaminase  
<ULNV = 0 
≥ULNV = 1 
 
Bleeding  
No = 0  
Petechia = 1 
Ecchymosis = 2  
Bleeding = 3  
White blood cells ≥10,000 
cells/μL 
White blood cells 
<10,000 cells /μL = 0  
≥10,000 cells /μL = 1 
Somnolence  
No = 0  
Yes = 1 
Fibrinogen <110 mg/dL. Organ failure 
No = 0 
Yes = 1 
 
 Bleeding 
No = 0 
Yes = 1 
 
 Age  
<60 = 0 
>60 = 1 
 
 Prolongation of PT  
<3 s = 0 
≥3s, <6 s = 1 
≥6s = 2 
 
 Hepatomegaly  
No = 0 
Yes = 1 
 
 INR 
<1.6 = 0 
≥1.6 = 1 
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1.5 Treatment of Crimean-Congo Haemorrhagic Fever 
The case management of CCHF is largely supportive with a focus on the provision of blood 
component therapy to prevent bleeding and critical care support when it is required for severe 
cases. Haematological support is predominantly with platelet and fresh frozen plasma 
transfusions, guided by the clinical picture and laboratory results. Additional measures used to 
reduce the risk of haemorrhage include avoidance of non-steroidal anti-inflammatories and 
anti-platelet medication, and stress-ulcer prophylaxis provided to severe cases or those with a 
history of peptic ulcer disease 155. The majority of patients receive supplemental intravenous 
fluid and electrolyte replacement, but the volumes required and the electrolyte imbalance that 
occurs in most cases is significantly less than in other VHFs such as EVD 92,156.  
Higher levels of supportive care are required as the disease progresses with severe cases 
requiring access to intensive care support including renal replacement therapy and mechanical 
ventilation. Somnolence and confusion are noted to be poor prognostic indicators with cerebral 
oedema and haemorrhage reported in fatal cases 72,157. Ventilatory support can be provided 
safely and results in better outcomes, but presents a risk of aerosol generation and must be 
carefully planned and managed to prevent nosocomial transmission 157,158. Renal replacement 
therapy is also regularly provided to patients with CCHF in Turkey 159,160 with standard 
precautions applied in dialysis units. Surgical interventions to control haemorrhage such as 
endoscopy have been undertaken successfully in endemic settings (Sener Barut personal 
communication 2016), as have a number of caesarean sections in pregnant woman, although 
this has also led to nosocomial infections 161. Antibiotics are not routinely administered, and it 
has been shown that co-infection with bacteraemia only rarely occurs and is predominantly 
related to intravenous catheter related infections 162. 
Ribavirin is a synthetic nucleoside analogue that shows in vitro activity against some RNA and 
DNA viruses 163. Its mechanism of action against CCHFV is unknown but it has demonstrated in 
vitro activity 164 and had mixed results in animal models 165,166. Although it has not been 
approved for use in CCHF by the US Food and Drug Administration (FDA) or the European 
Medicines Agency (EMA), it is listed as being of potential benefit in CCHF by the World Health 
Organisation. It is included on the WHO model list of essential medicines, due to its clearer 
evidence base in the treatment of Lassa fever and Argentinian Haemorrhagic fever and the early 
reports of benefit in CCHF 167–169. Since the emergence of CCHF in Turkey and Iran there have 
been a number of studies evaluating ribavirin treatment, although most of these have been 
retrospective and consequently affected by confounding factors and bias 146,170,171. One 
randomised controlled trial of 136 patient undertaken between 2004-2007 failed to show any 
reduction in mortality, or positive effect on clinical or laboratory parameters 172. A subsequent 
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meta-analysis by Ascioglu et al 173 included 8 studies and 731 patients and did not demonstrate 
that ribavirin conferred any survival benefit or additional benefit such as shorter hospital stay, 
earlier improvement of laboratory values or decreased requirement for blood products. A 
recent meta-analysis undertaken by the Cochrane infectious diseases group concluded that the 
benefit of ribavirin in treating CCHF was unknown and highlighted the risk of bias from non-
randomised observational studies 174. 
Ribavirin does have a more established role in post-exposure prophylaxis (PEP) for healthcare 
workers that have a had a high risk CCHFV exposure such as a needle stick injury. A large 
multicentre retrospective cross-sectional study undertaken in Turkey, covering the years 2012-
2014 identified 51 HCW exposures 175. Post-exposure ribavirin prophylaxis was administered 
after 19/44 cases of known CCHF exposure, with 0/19 developing laboratory confirmed 
infection or clinical disease, compared to 18/25 untreated cases that developed laboratory-
confirmed infection, of which 11/18 developed clinical disease. Underlying bias may have 
influenced cases selected for ribavirin PEP, and it is not possible to adjust for other factors that 
may have influenced the results, but it may be that PEP is effective when there is a smaller 
inoculum post-exposure, but it is ineffective in treating the high virus loads seen in clinical 
disease.  
Hyperimmune serum has been evaluated in one study of 26 patients 106. Although the trial had 
no control group it did report a low case fatality rate in 15 high risk patients (with a CCHFV viral 
load >108 copies/ml) and requires further evaluation in a randomised clinical trial. 
Corticosteroids have also been utilised in severe cases with a suggested rationale of reducing an 
exaggerated host immune response and ‘cytokine storm’. Retrospective analysis of 281 cases of 
which 44 received ribavirin and corticosteroids suggested a possible benefit of corticosteroids in 
severe disease, but is limited by potential confounding factors and missing data 154. Steroids 
have also not been shown to clearly reduce mortality in sepsis and septic shock generally in 
larger meta-analyses 176–178.  
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Chapter 2 Methods 
2.1 Scientific and ethical approval 
Research and Ethical committee (REC) approval for the study was obtained in advance by the 
Ministry of Defence Research and Ethical Committee (MoDREC) in the UK (571) and Ondokus 
Mayis University REC in Samsun, Turkey (OMU KAEK 739). 
2.2 Study design - Prospective observational cohort study.  
The study was conducted between May 2015 and August 2016 in Turkey at Ondokus Mayis 
University (OMU) Hospital, Tokat State Hospital and Tokat University Hospital. Both university 
hospitals are Ministry of Health designated specialist CCHF referral centres in close proximity to 
the hyperendemic region in mid-Anatolia. CCHF cases in Turkey are seasonal occurring 
predominantly during May-September allowing for focused and efficient screening procedures.  
 
 
Figure 2.1 CCHF hyperendemic region in Turkey by state with study sites.  
Ondokus Mayis University is a large 1000-bed teaching hospital in Samsun, Northern Turkey on 
the Black Sea coast. It serves a city of over half a million people in Samsun and is a major port city. 
It is famous historically as the location where Mustafa Kemal Ataturk started the Turkish war of 
Independence on the 19th May 1919. The Infectious diseases department at Ondokus Mayis 
University Hospital is large and receives referrals of patients with severe/complicated CCHF from 
Amasya, Tokat and Corum. Tokat State and University Hospitals are large tertiary hospitals 
located in the CCHF hyperendemic region and collectively manage the most confirmed CCHF 
cases annually of any centre worldwide. 
Suspected cases are admitted directly from the Emergency Department to the units and also 
through a regional referral network. During the study adults with suspected CCHF were identified 
and managed according to Turkish national guidelines at the Infectious Diseases units at each 
hospital. Infectious diseases specialists at each hospital were responsible for the clinical 
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management of patients. At each location a study team was trained by the Principal investigator, 
and study sites opened sequentially to allow training and quality assurance in recruitment and 
sample processing (Ondokus Mayis University Hospital – 15th May 2015, Tokat State Hospital – 
22nd June 2015 and Tokat University Hospital – 29th June 2015).  
2.3 Participant Recruitment 
Study materials, patient information leaflets and consent documents were available in both 
English and Turkish. Participants or an appropriate relative/guardian were approached by the 
research team staff trained in consent procedures, were provided with a participant information 
leaflet, and provided written informed consent. Participants were generally recruited on the first 
or second day of hospital admission, with first sampling occurring on day 1-3. 
Inclusion criteria for participants: 
1. Suspected or confirmed infection with CCHF admitted to hospital 
Exclusion criteria for participants: 
1. Refusal by participant, parent or appropriate representative. 
2.   Age <18 years 
Children (aged <18yrs) were not recruited as participants in this study. Paediatric cases of CCHF 
do occur but are less frequent and managed by paediatricians, as opposed to adult CCHF 
infectious diseases specialists. Although recognising the importance of studying the pathogenesis 
of CCHF in all age groups, recruitment of paediatric participants presents additional challenges 
and has a different clinical disease pattern. It would require specific sub-group analysis and would 
need a larger multi-centre study for adequate sample size and power that was not within the 
scope of this fellowship. 
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Figure 2.2 Recruitment, investigation and follow-up of CCHF cohort 
Follow-up 
Participants were invited to additional follow-up at 14, 30 and 365 days with repeat sampling at 
each time point. Follow up was either in the hospital infectious diseases department or mobile in 
the community dependent on the geographical location of the patient. 
2.4 Participant sampling  
The volume of blood collected was dependent on the weight of the participant, to prevent 
excessive volume sampling from small adults (Table 2.1). Blood samples required for medical 
management had priority over samples taken for research tests, and attending physicians 
decided on the combination of routine blood tests that were undertaken daily on clinical grounds, 
disease severity and hospital location. Whenever practical, research samples were timed to 
coincide with routine clinical sampling. Daily venepuncture is part of the standard protocol for 
the medical care of this group and dependent on the study site was undertaken by the PI, 
infectious diseases fellows or nurses responsible for in-patient management. Research samples 
were taken at the same time (during the same blood draw), after routine clinical samples. Post-
phlebotomy site bleeding was managed as per standard protocols.  
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Weight 
Samples at 
recruitment (R) 
Serial samples (S) daily 
Convalescent samples 
14, 30 days 
Total volumes of blood 
taken 
>40kg 
4mls EDTA blood 
5mls blood in 
serum(clotted) tube 
4mls Citrated tube 
3mls blood in blood 
RNA tube 
10ml Urine 
4mls EDTA blood 
5mls blood in serum(clotted) 
tube 
4ml citrated tube 
10 mls Urine 
4mls EDTA blood 
5mls blood in 
serum(clotted) tube 
10 mls urine 
Maximum any day: 
16mls (0.38mls/kg) 
Maximum any 4 
weeks: 96mls 
(2.4mls/kg) 
Table 2.1 Study sampling schedule 
 
2.5 Laboratory development and sample processing  
Research laboratories were established in the Infectious Diseases departments of Ondokus 
Mayis University Hospital and Tokat State Hospital. Ultra-low freezers (-800C), temperature-
controlled bucket centrifuges (Thermo Scientific Sorvall ST 16R, ClikSeal lids) and Class I and 
Class II Biological Safety Cabinets were sourced for each laboratory. Laboratory protocols were 
developed in conjunction with RIPL PHE and training undertaken by the PI of one ID specialist at 
each site. Samples were processed in Turkey, stored at -800C and then shipped to the CL-4 
laboratory at PHE Porton on dry ice by World Courier as Category A samples. Permission from 
the Health and Safety Executive in the UK was obtained prior to importation.  
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Figure 2.3 Research Laboratory OMU 
 
 
Figure 2.4 Research Laboratory Tokat State Hospital  
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Figure 2.5 One study day’s samples in Class I Biological Safety Cabinet (17 participants) 
 
 
 
Figure 2.6 Samples in ClikSeal Buckets in Sorvall 16R centrifuge.  
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Figure 2.7 Mobile follow-up of participants at 1 year after acute infection. The top-left picture 
shows a participant’s house in a remote rural village in Tokat where communities continue to 
live above their livestock.  
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2.6 Project safety and Infection prevention and control precautions 
Safety of the research project was given the highest priority in full recognition that CCHFV is a 
Hazard Group/Category 4 Pathogen. Study team and participant safety was given the highest 
priority from the point of sample collection at the bedside through to laboratory processing and 
analysis at OMUH/Tokat and then at PHE Porton. 
Well-established hospital protocols were used to collect specimens and strict adherence to 
collection protocols, biosafety and adequate personal protective equipment (PPE) were 
maintained. Biosafety procedures were as per local policy/guidance (WHO standard for Viral 
Haemorrhagic Fever) and were applied to the collection, transport, storage and laboratory 
handling of research samples. It was ensured that there was adequate equipment to complete 
the task safely and adherence to universal precautions and WHO best practices for phlebotomy 
at all times 179. The study team underwent training and mentorship by the Study PI to ensure 
safety was maintained at all time. Any new safety issues identified were brought to the 
attention of the Study PI.  
All samples collected were labelled as per standard procedure with appropriate identification 
and hazard labelling. All samples sent to external laboratories were anonymized with unique 
coded identifiers to protect the identity of the patient at the point of enrolment. International 
guidance (IATA) was adhered to for the transport of samples to PHE Porton (World Courier Ltd). 
The Health and Safety Executive in the UK provided advance approval for importation of 
samples to PHE Porton. 
2.7 Data management and analysis plan 
Prospective data on patient demographics, co-morbid conditions, medications, clinical features, 
clinical laboratory test results and treatment were collected on a standardised proforma 
developed by the PI. The case record form (CRF) is an adaptation of the ISARIC/WHO viral 
haemorrhagic fever CRF and was piloted in July 2014 at OMU. Data was then entered into the 
ISARIC electronic database, with subsequent quality assurance data checking against original 
CRFs subsequently.  
All participants had CCHF severity assessment undertaken by Swanepoel criteria, severity 
grading score (SGS) (9) and severity scoring index (SSI) scoring systems (Table 1.6). Participants 
presenting more than 5 days after onset of illness had an SSI score undertaken at admission. 
They were categorized as ‘mild’ if they had none of the Swanepoel parameters, were graded as 
mild by SSI and low risk by SGS. The ‘moderate/severe group’ included all patients graded as 
moderate/severe (SSI) or intermediate/high risk (SGS) or with Swanepoel criteria. Missing 
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laboratory variables scored as zero in scoring systems. Participants diagnosis was through PCR 
routinely performed within 24 hours at the Public Health Laboratory in Samsun.  
Sample size calculations were based on proposed differences in viral load and pro-inflammatory 
cytokines (Il-12) between patients in mild/moderate and severe/fatal groups. Published viral 
load and cytokine data were used. Based on prior observational research at OMU Hospital, a 
recruitment rate of >90% was anticipated with a total study sample size of 100 patients.  
Based on the severity scoring system and data published by Saksida et al 97, and assuming a 
60:40 split between the ‘mild/moderate’ and ‘severe/fatal` groups: 
1. Mean (SD) log10 (viral load) levels in the “mild/moderate” and “severe/fatal” groups 
were estimated to be 5.654 (1.603) and 7.903 (1.510) respectively; the proposed sample size 
would detect a difference of this magnitude or greater with >95% power. 
2. Mean (SD) log10 (IL-12) levels in the “mild/moderate” and “severe/fatal” groups would 
be 1.541 (0.220) and 1.301 (0.505) respectively; the proposed sample size would detect a 
difference of this magnitude or greater with 79.1% power. 
3. Sample size would have 90% power to detect a correlation of 0.316 (R²≈10%) or greater 
between log10(viral load) levels and log10 (IL-12) levels. 
4. All of these calculations assumed conventional two-sided significance levels of 5% and 
utilised Gpower version 3.1. 
Descriptive analyses are reported as frequencies (proportions) for categorical variables and 
means (standard deviation or 95% confidence interval (CI)) or medians (ranges) as appropriate 
for continuous variables. Categorical variables were compared between sub-groups with the 
Fisher exact test. Continuous variables measured at admission were compared using Student t-
tests or the Mann-Whitney U-test/Kruskal-Wallis test as appropriate. Bonferroni correction was 
applied to counteract risk of Type 1 errors through multiple comparison. Hypothesis testing of 
cytokines were grouped by severity/low platelets with subsequent analysis at p<0.025. 
Continuous variables measured longitudinally were compared using linear regression models 
with robust standard errors and adjustment for clustering of measures within patients when 
required. Correlation between variables was measured by Pearson correlation coefficient. No 
imputation for missing data was made due to small sample sizes. Hypothesis tests were two-
tailed (p<0·05) and analyses were performed using the SPSS (version 24), Stata (version 14) and 
GraphPad Prism (version 7.03) computer packages.   
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Fellowship time frame Pre- First 
year 
Second  
year 
Third  
year 
Post- 
Site visit and submission ethics committees 
(PI and OMU Supervisor) 
                            
Study preparation 
              
Main study period (Aims 1-4) 
1st cohort recruitment, investigation and 
follow-up.  
(PI and project team at OMU/TOKAT) 
                            
Second study period (Aims 1-4) 
Recruitment, investigation and follow-up (inc 
12 month follow up 1st cohort) 
(PI and project team at OMU) 
                            
Laboratory analysis (Aims 1-4) 
Quantitative Viral load analysis 
Serological profiling 
Luminex flow cytometry 
(PI and team at PHE Porton)  
                            
Data Analysis 
Preparation for presentation, publication, 
PhD 
                            
 
Figure 2.8 Fellowship timetable 
2.8 Role of the Chief Investigator/Wellcome Trust Fellow 
I was fully responsible for study conception/design and submission for ethical approval in the 
UK and Turkey. I trained and mentoring all study teams in Turkey and established two new CCHF 
research laboratories with guidance and SOPs developed in conjunction with PHE Porton. I 
supervised recruitment and consent of participants at study sites and undertook >50% of 
participants daily blood sampling. I processed and separated >90% of urine and blood samples 
in Turkey and was responsible for storage and sample transfer to PHE Porton. I undertook all 
ROTEM laboratory analysis in Turkey and worked with the laboratory team in PHE Porton on 
PCR, ELISA and luminex assays for 10-15% of samples. I supervised CRF data entry at all study 
sites and inputted all data to the study’s electronic database, undertaking all quality assurance 
checks. I undertook all data analysis and interpretation with support from supervisors, and 
guidance from medical statisticians at LSTM and UoL.    
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Chapter 3: Demographics and descriptive clinical data 
3.1 Study participants 
One hundred and forty-four participants with suspected CCHF were recruited into the study at 
the three study sites. One hundred and four were found to be CCHFV PCR positive at the Public 
Health Reference laboratory in Samsun and continued in the study. Two participants 
subsequently withdrew consent for continued sampling and follow-up. 
Sixty-six of 104 (63.5%) participants included in the study were male and the mean age was 50.0 
(SD 15.9) years. A history of tick bite was reported by 73/104 (70.2%) and 87/104 (83.7%) were 
admitted directly to the study site, with 17/104 (16.3%) being transferred from another 
healthcare facility. The median time from onset of symptoms until hospital admission was 4 
days (range 1-11 days), and in those with a history of tick bite, the median time from bite until 
onset of symptoms was 3 days (range 1-13 days). The median length of hospital admission was 
8 days (range 2-16), with 3/104 fatal outcomes (CFR 2.9%) (Table 3.1).  
The majority of participants (91/100) resided in rural CCHF endemic areas, with 93/99 having 
visited the countryside in the 2 weeks prior to onset of symptoms (including 9 participants that 
did not reside in rural areas). The majority of participants reported a history of close animal 
contact (81/99), and 47/97 reported direct contact with animal blood or tissue. 3/97 
participants reported a history contact with sick individuals in the 2 weeks prior to onset of 
symptoms, but none of these individuals were admitted with confirmed CCHF. Most patients 
had no significant past medical history: Diabetes mellitus (11/100); cardiovascular disease 
(10/100); and pulmonary (5/100) disease were the most commonly reported chronic conditions 
(Table 3.2).   
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 N (%) (n=104) 
Gender (%):  
- Male 
- Female  
 
66 (63.5) 
38 (36.5) 
Age (years)  
- Mean (SD) 
 
50 (15.9) 
Tick bite (%): 
- Yes 
- No  
- Unknown 
 
73 (70.2) 
30 (28.8) 
1 (1.0) 
Mode of admission (%): 
- Direct 
- Hospital transfer 
 
87 (83.7) 
17 (16.3) 
Time from symptom onset to admission (days) 
- Median (range) 
 
4 (1-11) 
Time from tick bite onset symptoms (days) 
- Median (range)  
 
3 (1-13) 
Length of admission (days) 
- Median (range) 
 
8 (2-16) 
Risk factors (%):  
- Live rural area 
- Visit the countryside last 2 weeks 
- Contact animal blood/tissue 
- Close contact animal  
- Contact with sick individuals last 2/52  
 
91/100 (91) 
93/99 (93.9) 
47/97 (48.5) 
81/99 (81.8) 
3/97 (3.1) 
CCHF severity score (%):    
- Mild/low  
- Moderate/severe 
 
63 (60.6) 
41 (39.4) 
Highest qSOFA score during admission  
<2  
>2 
 
61 (59.2) 
43 (40.8) 
Fatal outcome (%): 
- Yes 
- No 
 
3 (2.9) 
101 (97.1) 
 
Table 3.1 Demographic characteristics of CCHFV PCR positive participants  
53 
 
Past medical history Total n (%) 
Cardiovascular disease 10/100 (10.0) 
Pulmonary disease 5/100 (5.0) 
Renal disease 3/100 (3.0) 
Liver disease 1/100 (1.0) 
Cerebrovascular disease 0/100 (0.0) 
Diabetes 11/100 (11.0) 
Obesity 2/100 (2.0) 
Rheumatology  3/100 (3.0) 
Dementia  1/97 (1.0) 
HIV /Lymphoma/cancer 0/100 (0.0) 
 
Table 3.2 Past medical history of CCHFV positive participants 
3.2 Clinical and Laboratory features of CCHF participants 
At admission the combined CCHF severity scoring systems demonstrated that 63/104 (60.6%) 
were classified as mild, and 41/104 (39.4%) were classified moderate/severe  severity. Of the 41 
participants classified as moderate/severe, 19/41 were graded as moderate/high risk by all 3 
scoring systems, 8/41 by 2 scoring systems and 14 by one scoring system (Table 3.3, Figure 
3.1).This overlap and variation in scoring systems is demonstrated by the Figure 3.1, showing 
the severity allocations of the 41 participants in the moderate/severe group be each scoring 
system. 
There was no significant difference in age between severity groups (mild 51.8 years (SD 16.6) vs 
moderate/severe 47.2 years (SD 14.3, p= 0.14). The lowest platelet count recorded by patients 
during admission is another pragmatic disease severity indicator (a count of <50 x 109/L level), 
utilised in Turkey as a threshold for transfer to tertiary CCHF centres. Fifty-six participants 
(53.8%) had a platelet count of <50 x 109/L during admission with 22/104 (21.2%) having 
platelets measured at <20 x 109/L. In the moderate/severe group 35/41 participants had a 
platelet count of <50 x 109/L, with 22/63 in the mild group having a platelet count of <50 x 109/L 
(p<0.001).  
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CCHF Severity Score Total n=104 
Severity grading score (SGS): 
- Low risk SGS ≤ 4 
- Intermediate risk SGS 5-8 
- High risk SGS ≥ 9 
 
83 (79.8) 
19 (18.3) 
2 (1.9) 
Severity scoring index (SSI): 
- Mild 0-2 
- Moderate 3-9 
- Severe 10-13 
 
65 (62.5) 
39 (37.5) 
0 (0.0) 
Swanepoel criteria:  
- Non-severe 
- Severe/poor prognosis 
 
77 (74.0) 
27 (26.0) 
Combined CCHF severity score:   
- Mild or low risk 
- Moderate/severe or intermediate/high risk  
 
63 (60.6) 
41 (39.4) 
Lowest platelet count: 
- <50 x 109/L 
- <20 x 109/L 
 
56 (53.8) 
22 (21.0) 
 Table 3.3 CCHF severity scores of CCHF positive participants  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Venn diagram of severity scores for 41 participants in moderate/severe group 
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3.2.1 Clinical and laboratory features at admission 
At admission to hospital the most common complaints were of fever (88.2%), headache 
(75.7%), fatigue (74.8%), nausea (74.5%) and myalgia (72.3%). Anorexia was also common 
(63.3%), with vomiting reported by 52.4% and diarrhoea by 33% of participants. Bleeding at the 
time of admission was reported by 14/103 (13.6%) participants (Figure 3.2,Table 3.4). On 
comparison of clinical features at admission between severity groups, anorexia was more 
common in severe/moderate severity group (29/37 vs 33/61, p=0.02) as was petechiae (6/40 vs 
0/62, p=0.003), bruising (4/40 vs 0/61, p=0.02), splenomegaly (4/28 vs 0/49, p=0.02) and 
bleeding (14/40 vs 0/63, p<0.001).  
The admission mean temperature was 37.5OC (SD 0.83). Only 38/104 (36.5%) of participants 
had a temperature recorded of ≥38 0C at admission, with 50/104 (48.1%) a temperature 
recorded of ≥37.50C. Mean pulse, systolic and diastolic blood pressure were within normal 
limits, with mean respiratory rate elevated at 21.2 (SD 2.4). Diastolic and systolic blood pressure 
was lower in severe/moderate disease (p=0.07, p=0.04) , with temperature lower in 
severe/moderate disease compared to mild disease (37.2 (0.8) vs 37.6 (SD 0.8), p=0.02). 
Although NEWS score was higher (median 2, range 0-8 vs median 1, range 0-5) in the 
moderate/severe group, this was not statistically significant (p=0.66).  
Admission blood results are demonstrated in Table 3.5. Blood urea nitrogen (BUN) levels were 
elevated (median 22 mg d/L) on admission, but creatinine was within normal limits (median 
0.81 mg/dL). Glucose levels were also elevated (median 110 mg/dL) as was alanine 
transaminase (median 44 U/L) and aspartate transaminase levels (median 79 U/L). Creatine 
kinase(CK) levels and lactate dehydrogenase (LDH) levels were elevated (CK median 298 U/L, 
LDH (n=37) median 553 U/L), whilst amylase and bilirubin were within normal limits.    
Haematology laboratory results demonstrated that thrombocytopenia (platelet count <150 x 
109/L) was not universal at admission with 20/103 participants having platelets counts >150 x 
109/L. Median platelet count was reduced at 104 x 109/L with a range of 6 – 231 x 109/L. White 
blood cell count was also reduced (median 2.7 x 109/L), as was haemoglobin (13.5g/dL). 
Activated partial thromboplastin time (APTT) was mildly elevated (mean 37.8s, SD 19.4), but 
mean prothrombin time (PT) and international normalised ration (INR) were within normal 
limits (PT 13.6s SD 3.4, INR 1.12, SD 0.35). Comparison of blood biochemistry, haematology and 
clotting results between mild and moderate/severe groups demonstrated significant difference 
in a number of variables. Haemoglobin, haematocrit, white blood cell count and platelet count 
were significantly lower in the moderate/severe group than in comparison to the mild severity 
group. APTT, INR, AST, ALT, CK and LDH were significantly higher in the moderate/severity 
group (Table 3.5, Figures 3.3, 3.4).   
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Figure 3.2 Bar chart showing frequency (%) of clinical features at admission  
of CCHFV PCR positive participants  
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Table 3.4 Clinical features of CCHFV PCR positive participants at admission, stratified by disease 
severity.  Categorical data analysed by Fisher’s exact test and means compared by t-tests. 
Statistically significant results (p<0.05) highlighted in bold.    
Clinical Features at 
admission 
Total (%)  Mild  Moderate/severe  p-value 
Fever  
Fatigue  
Headache  
Myalgia  
Anorexia  
Swallowing Difficulties 
Nausea 
Vomiting 
Diarrhoea 
Abdominal pain 
Hiccups 
Shortness of breath 
Chest pain 
Sore throat 
Conjunctivitis 
Skin rash 
Cough 
Confusion 
Abdominal tenderness 
Hepatomegaly 
Splenomegaly 
Petechiae 
Bruising 
Bleeding 
 
90/103 (87.4) 
77/104 (74.0) 
79/104 (76.0) 
74/102 (72.5) 
63/99 (63.6) 
23/103 (22.3) 
76/103 (73.8) 
55/104 (52.9) 
35/104 (33.7) 
23/102 (22.5) 
1/94 (1.1) 
8/100 (8.0) 
10/101 (9.9) 
12/101 (11.9) 
25/101 (24.8) 
5/102 (4.9) 
18/101 (17.8) 
31/102 (30.4) 
13/101 (12.9) 
2/78 (25.6) 
4/78 (5.1) 
6/103 (5.8) 
5/101 (5.0) 
14/104 (13.5) 
56/63 (88.8) 
51/63 (81.0) 
49/63 (77.80 
44/61 (72.1) 
33/61 (54.1) 
13/62 (21.0) 
47/63 (74.6) 
32/63 (50.8) 
20/63 (31.7) 
12/61 (19.7) 
1/56 (1.8) 
5/59 (8.5) 
5/60 (8.3) 
6/60 (10.0) 
18/60 (30.0) 
2/61 (3.3) 
11/61 (18.0) 
22/61 (36.1) 
11/61 (18.0) 
0/48 (0) 
0/49 (0) 
0/62 (0) 
0/61 (0) 
0/63 (0) 
34/40 (85.0) 
26/41 (63.4) 
30/41 (73.2) 
30/41 (73.2) 
30/38 (79.5) 
10/41 (24.4) 
29/40 (72.5) 
23/41 (56.1) 
15/41 (36.6) 
11/41 (26.8) 
0/38 (0) 
3/41 (7.3) 
5/41 (12.2) 
6/41 (14.6) 
7/41 (17.1) 
3/41 (7.3) 
7/40 (17.5) 
9/41 (22.0) 
2/40 (5.0) 
2/30 (6.7) 
4/29 (13.8) 
6/41 (14.6) 
5/41 (12.2) 
14/41 (34.1) 
0.56 
0.066 
0.643 
1.0 
0.018 
0.637 
0.822 
0.689 
0.673 
0.471 
1.0 
1.0 
0.522 
0.540 
0.164 
0.389 
1.0 
0.187 
0.071 
0.171 
0.02 
0.003 
0.009 
<0.001 
 
Vital signs at admission 
Pulse -mean (SD) n=100 
Systolic BP - mean (SD) 
Diastolic BP – mean (SD) 
Temp – mean (SD) 
Respiratory rate – mean 
(SD) n=98 
 
81 (8.3) 
113 (13.3) 
69 (8.6) 
37.5 (0.85) 
21.2 (2.4) 
 
80.8 (6.5) 
115.1 (14.1) 
70.4 (7.9) 
37.6 (0.8) 
21.0 (2.1) 
 
 
81.9 (10.5) 
110.5 (11.4) 
67.7 (10.5) 
37.3 (0.9) 
21.6 (2.7) 
 
0.521 
0.079 
0.132 
0.035 
0.246 
NEWS score at admission 
Median (SD) (98) 
 
 
2 (0-8) 
 
1 (0-5) 
 
2 (0-8) 
 
0.565 
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Table 3.5 Biochemistry, haematology and coagulation laboratory results at admission. Data are 
mean (SD), or median (range). Means were compared by t-tests and medians by Mann-Whitney 
U Test. Statistically significant results (p<0.05) highlighted in bold.  APTT= activated partial 
thromboplastin time, PT= prothrombin time,  INR= international normalised ratio, ALT = alanine 
transaminase, AST= aspartate transaminase, LDH= lactate dehydrogenase.  
Blood results  Total Mild  Moderate/ 
severe  
p-value 
Sodium (136-145 mmol/L) 
n=98 
137.4 (3.6) 137.8 (2.9) 136.7(4.4) 0.121 
Potassium (3.5-5.1 mmol/L) 
n=98 
4.08 (0.44) 4.15 (0.36) 40. (0.53) 0.056 
Blood urea nitrogen (BUN) (6-
20mg/dL ) median n= 94 
22 (0.49 – 94) 23.5 (0.49-
64.7) 
17.6 (4.7-94.4) 0.021 
Creatinine (0.7-1.2 mg/dL) 
median n=99 
0.81 (0.4-4.6) 0.89 (0.4-2.6) 0.79 (0.41-4.6) 0.302 
Glucose (74-109mg/dL) 
median 
N=88  
110 (66-274) 112 (66-274) 107 (74-177) 0.290 
Haemoglobin (14-18g/dL) 
n=103 
13.5 (2.0) 13.9 (1.5) 13.0 (2.4) 0.036 
Haematocrit (36-44%) n=102 40.2 (5.6) 41.3 (4.4) 38.5(6.8) 0.014 
White blood cells (4-10 x 
109/L) 
median n=103 
2.74 (0.4-17.9) 2.85 (0.40-
9.47) 
1.8 (0.62-17.9) 0.009 
Platelets (130-400 x 109/L) 
median n= 103 
104 (6-231) 121 (36-231) 37 (6-119) <0.001 
APTT (25-37s) n=98 37.8 (19.4) 27.1 (9.3) 50.7 (24.5) <0.001 
PT (11-15s) n=96 13.6 (3.4) 13.2 (1.6) 14.2 (5.0) 0.167 
INR (0.8-1.2) n=99 1.12 (0.35) 1.07 (0.15) 1.21 (0.52) 0.045 
Amylase (28-100U/L) n=38 77.1 (36) 71.1 (34.4) 91.9 (36.9) 0.107 
Bilirubin (0.1-1.2 mg/L) 
median n=74 
0.39 (0.02-2.5) 0.36 (0.1-1.2) 0.44 (0.02-2.5) 0.106 
AST (5-40 U/L) median n=101 79 (14-2779) 5 (14-172) 283 (19-2779) <0.001 
ALT (5-41 U/L) median n=101 44 (10-1055) 259 (10-103) 115 (15-1055) <0.001 
Creatine kinase (20-200 U/L) 
median n=80 
298 (47-6355) 203 (47-3605) 413 (51-6355) 0.006 
Fibrinogen (200-400mg/dL) 
n=15 
291 (123) 333 (111) 245 (126) 0.179 
LDH (135 -214 U/L) n=37 553 (205-3568) 359 (205-1068) 1147 (249-
3568) 
0.001 
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Figure 3.3 Biochemistry laboratory results at admission by severity group. Scatter dot plots with 
median displayed and upper limit normal range (dotted line). p values are from Mann-Whitney 
U Tests. 
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Figure 3.4 Haematology and coagulation laboratory results at admission by severity group. 
Scatter dot plots with median/mean displayed and upper/lower limit normal range as 
appropriate. p values are from t tests (white blood count and platelets) and Mann-Whitney U 
Tests (all others). 
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3.2.2 Clinical features during hospitalisation 
During the course of hospital admission patients were assessed daily to characterise the natural 
history of confirmed CCHF disease. Bleeding occurred in 25/104 (24.0%) participants for a 
median of 2 days duration (IQR 2-5 days). Headache was reported by 72/104 (69.2%) 
participants for a median of 3 days duration (IQR 2-5 days). Myalgia was reported by 66/104 
(63.5%) participants for a median 3 days duration (IQR 2-5 days). Diarrhoea occurred in 41/104 
(39.4%) and vomiting in 70/103 (67.3%) participants, lasting a median 2 days (IQR 2-3 days) and 
2 days (IQR 1-3 days) respectively. Lethargy was reported by 75/104 (72.1%) lasting a median 5 
days (IQR 2-6 days).  
Vital signs (temperature, respiratory rate, heart rate, systolic and diastolic blood pressure) were 
recorded daily for a total of 749 patient days for 103 participants. For each vital sign, the most 
abnormal reading within that 24hr period was recorded. Fever (≥380C) occurred in 54/104 
participants during the course of hospital admission lasting for a median 2 days (IQR 1-10 days). 
The number of days of fever was significantly shorter in moderate/severe group than in the mild 
group (0 days (IQR 0-1 days) vs 1-day (IQR 0-2 days) p=0.005).   
Trends in vital signs during acute infection were analysed by simple linear regression analysis 
and stratified by CCHF severity. There was no significant trend for blood pressure (p=0.66) and 
respiratory rate (p=0.182), but significant slopes for temperature (p<0.0001) and heart rate 
(p=0.02), with both reducing as illness progressed. When blood pressure was stratified by 
disease severity, there was no difference in slopes, but lower elevations/intercepts in BP in 
moderate/severe disease (p=0.0003), compared to mild disease. Respiratory rate stratified by 
disease severity conversely had a higher elevation/intercept in moderate/severe disease 
(p<0.0001).  
Linear regression of temperature by severity demonstrated significant non-zero slopes for both 
mild (p<0.0001) and moderate/severe disease (p<0.0001), with unequal slopes (p=0.0003). 
Heart rate stratified by disease severity showed no significant trends (mild p=0.31, 
moderate/severe p=0.07), and no difference in slopes (p=0.17) or intercept/elevations (p=0.35) 
(Figure 3.5).  
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Figure 3.5 Longitudinal vital signs by day of illness. Mean and SD are plotted with linear 
regression lines. p-values indicate if slopes are significantly non-zero. When stratified by CCHF 
severity p-values indicated if slopes or intercepts/elevations are equal. 
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3.2.3 Laboratory results during hospitalisation  
During the study period participants had daily phlebotomy for both routine and research 
samples. Routine haematology, coagulation and clinical biochemistry samples were analysed in 
study site laboratories with individual clinicians deciding on the frequency of tests. The total 
number of tests in the CCHF PCR positive cohort (104 participants) were: Haematology 
parameters (WBC 782, Plts 779, HCT 782); Coagulation (APTT 494, PT 483), Biochemistry (CK 
454, Creatinine 431, AST 561, ALT 562). The serial daily blood results of these parameters are 
demonstrated in Figure 3.6.  
Alanine transaminase and aspartate transaminase (ALT/AST) reach peak levels at day 7/8 of 
illness. The lowest median white blood count was at day 4 with the median lowest platelet 
count occurring at day 6 of illness. There were only mild elevations of direct and indirect 
bilirubin. The highest median/peak of creatine kinase observed was at Day 4 whilst there was no 
clear patterns for creatinine, prothrombin time or haematocrit. Activated partial 
thromboplastin time was highest at day 4.  
Acute renal impairment occurred in 4/104 patients during the study period. By RIFLE criteria 1/4 
had RIFLE stage 1 (risk – creatinine 1.5 x upper limit normal (ULN)), that was present at 
admission and then improved during admission. One of the 4 patients had RIFLE stage 2 (Injury 
– 2 x creatinine ULN) that responded to fluids and improved, and 2 patients had RIFLE stage 3 
(Failure – 3 x creatinine ULN) that was associated with a fatal outcome within 24hrs, one of 
which received haemodialysis (Figure 3.8). At the time of the AKI stage 3 creatinine kinase levels 
were elevated at 688/685 U/L. 
Stratification of laboratory results by CCHF severity groups is shown in Figure 3.7. AST and ALT 
were higher in the moderate/severe group during acute illness until day 10/11. Conversely 
platelet count is lower in the moderate/severe group until day 11/12 with no clear differences 
shown in white blood cells, creatinine and creatine kinase during acute illness between severity 
groups. Median APTT is higher in the moderate/severe group until day 7/8 of illness, with PT 
higher in the first 0-2 days of illness in the severe/moderate groups. Median haematocrit levels 
were lower in the moderate/severe group during acute illness.   
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Figure 3.6 Longitudinal aligned dot plot of haematology, biochemistry and coagulation 
laboratory variables during acute admission by day of illness. Lines indicate median values.     
66 
 
 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
0
100
200
300
400
500
ALT by severity
Day
A
L
T
Mild
Moderate/severe
0 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4
0
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0
6 0 0
7 0 0
A S T  b y  s e v e r ity
D a y
A
S
T
 U
/L
M ild
M o d e ra te /s e v e re
0 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
5 0 0 0
6 0 0 0
7 0 0 0
8 0 0 0
W B C  b y  s e v e r ity
D a y
W
B
C
M ild
M o d e ra te /s e v e re
0 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
P la te le t c o u n t b y  s e v e rity
D a y
P
la
te
le
ts
 x
 1
0
9
/L
M ild
M o d e ra te /s e v e re
0 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4
0 .0
0 .5
1 .0
1 .5
C re a tin in e  b y  s e v e r ity
D a y
C
re
a
ti
n
in
e
 m
g
/d
L
M ild
M o d e ra te /s e v e re
0 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4
0
2 5 0
5 0 0
7 5 0
1 0 0 0
1 2 5 0
C K  b y  s e v e r ity
D a y
C
K
 U
/L
M ild
M o d e ra te /s e v e re
 
 
 
 
  
67 
 
 
Figure 3.7 Serial haematology, biochemistry and coagulation laboratory parameters during 
acute admission grouped by CCHF disease severity. Median and IQR displayed for mild and 
moderate/severe groups by day of illness. 
 
Figure 3.8 Serial creatinine levels by day of illness in participants with RIFLE stage 1&2 (n=2) and 
RIFLE stage 3 (n=2) acute kidney injury   
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3.3 Treatment received during hospitalisation 
All participants were admitted to a trial site/hospital during the study and all (104/104) had an 
intravenous catheter placed. Intravenous fluids were administered to 90/104 participants for a 
median 7 days (IQR 5-9 days). 2/104 patients were admitted critical care units with severe CCHF 
during hospitalisation and received ventilatory and vasopressor support for 1 day prior to death 
from multi-organ failure and septic shock. Oxygen supplementation was only administered to 
the 3 fatal cases. 
Blood components (platelet, fresh frozen plasma and packed red blood cells) were given to 
38/104 participants. In the mild group 11/63 (17.5%) of patients received blood products 
compared to 27/41(65.9%) in the moderate/severe group (p<0.0001). Platelets were the most 
frequent blood product utilised, received by 37/104 (35.6%)participants (mild 11/63 vs 
moderate/severe 26/41, p<0.0001). The median units of apheresed platelets received was 4 
units (IQR 2-7 units). Fresh frozen plasma (FFP) was administered to 25/104 (24.0%) participants 
(mild 5/63 vs moderate/severe 20/41, p<0.0001), with a median of 4 units given (IQR 2-11 
units). Packed red blood cells were less frequently administered, and 12/104 (11.5%) 
participants (mild 9/41 vs moderate/severe 3/63, p=0.01) received a median of 2 units (IQR 1-3 
units). Of the patients that received FFP, only 8/25 had either an APPT or PT >1.5 times the 
upper limit of normal. A further 8/25 had PT/APPT parameters less than this but had clinical 
evidence of bleeding and a 1/3 had neither bleeding or low PT/APTT levels. Platelet transfusion 
was administered to 37 participants of which 36/37 had a nadir platelet count <50 x 109/L and 
22/37 had a nadir platelet count <20 x 109/L. This represented 36/56 patients with platelet 
counts <50 x 109/L receiving platelet transfusion, with all patients with platelet counts <20 x 
109/L receiving platelet transfusion.  
3.3.1 Ribavirin treatment  
Ribavirin was administered to 36/104 participants, all of whom were managed at one study site 
after direct admission or hospital transfer. Ribavirin treatment was started a median of 4 days 
(IQR 2-5 days) after onset of symptoms. Ribavirin was administered orally for a median of 5 days 
(IQR 4-8 days), at standard dosing (2g loading day 1, 1g QDS days 1-4 and 0.5g QDS days 5-10). 
At the time that ribavirin was initiated 25/33 (3/36 no matching PCR sample) patients were still 
CCHFV positive, with 8/33 having already cleared CCHFV from blood. Ribavirin was administered 
for a total of 201 patient days in participants with matched daily CCHFV blood PCR results. For 
144 of the 201 days of ribavirin administration participants were CCHFV PCR negative. 
Comparison between treatment groups showed that 16/36 (44.4%) patients that received 
ribavirin were graded as moderate/severe compared to 25/68 (33.7%) graded moderate/severe 
in the non-ribavirin group.   
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3.4 Discussion  
The planned sample size of 100 PCR positive patients was achieved from the 3 study sites in 
Samsun and Tokat. During planning for the project, it was recognised that participants had to be 
recruited at the suspected CCHF stage to allow for early sampling for viral dynamics and host 
immune response investigation. There was also the chance that patients would rapidly 
deteriorate and lose the capacity for informed consent. During the course of recruitment only 4 
eligible patients refused consent to enter into the study and 2 subsequently refused further 
sampling and attendance at follow-up visits. CCHF PCR results were generally available 24-48hrs 
after admission and 104/144 patients recruited were PCR positive and continued in the study.  
The demographics of the cohort were similar to larger published epidemiological studies in 
Turkey, such as by Yilmaz et al that reported epidemiological data on 1820 patients from 2002-
2007 141. A slightly higher percentage of male patients were recruited (63.5%), and the median 
age was higher than expected (50 years, Yilmaz et al 141 44 years). There was only limited past 
medical history/comorbidities identified in the cohort, with diabetes and cardiovascular disease 
the most frequent. Comorbidity was not overrepresented in those with more severe CCHF.   
The majority of patients recruited had a history of tick bite (70%), consistent with data across 
Turkey 15, with symptoms developing a median of 3 days after the tick bite. Patients generally 
presented rapidly to hospital (median 3 days), with only 3 participants being admitted after 7 
days of illness. The vast majority of participants lived in CCHF endemic areas (91%) and 82% had 
close animal contact with around 50% also having direct contact with animal blood or tissue, 
both higher than Yilmaz’ report (32% animal contact and 10% blood or tissue contact). There 
was a low rate of contact with others with similar illnesses (3%), as reported by Yilmaz et al 141, 
and this provides further evidence that community based person to person transmission is rare. 
No contacts of any of the 104 were admitted or tested for CCHF during the study.  
There are three published CCHF severity scoring systems that utilise a combination of clinical 
and laboratory factors, although none include the crucial parameter of CCHF viral load. The 
oldest was developed by Swanepoel and relies on 5 parameters during the first 5 days of illness 
aimed at predicting mortality. Two further scoring systems have been developed and validated 
by investigators in Turkey. They both use a combination of clinical and laboratory parameters to 
group patients into low, intermediate and high risk (severity grading system) and mild, 
moderate and severe (severity scoring index).  
The SSI has the advantage of having only 5 parameters and is based on admission data but does 
include fibrinogen level which is not routinely available in many laboratories in endemic 
settings. Based upon a retrospective validation of the SSI in 281 patients, they report a case 
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fatality rate of >50% in severe cases (score >10), and that a high negative predictive value at 
admission demonstrated that mild cases (score 0-2) would not progress to death154. The SGS 
utilises 12 parameters in the first 5 days of illness but includes variables such as lactate 
dehydrogenase and separate parameters for INR and prothrombin time. Bakir et al153 
prospectively evaluated the SGS in multiple centres in Turkey in 2012 showing that all low risk 
(score 0-4) cases survived (n=323), those in the intermediate group (score 4-8) had a case 
fatality rate of 20% (14/70) and in the high risk group (score >9) all patients died (9/9).  
Although both the SSI and SGS scoring systems have been evaluated in large cohorts in Turkey 
they are not in routine use in most specialist CCHF centres. The ability to predict mortality is 
useful for healthcare workers, especially in endemic setting when managing large cohorts, but 
better predictive value is required for other key outcomes such as blood product requirements, 
critical care interventions and length of stay. Severity scoring systems would also be useful if 
they were able to also predict the risk of viral shedding/nosocomial infection and as such level 
of personal protective equipment required. Above all they need to be simple and based on 
widely available clinical and laboratory factors if they are to be in routine use. Currently in 
Turkey the most frequently used parameter to guide patient treatment and whether they 
require transfer to specialist tertiary units is a platelet count <50 x 109 /L. Other factors such as 
age, bleeding and somnolence are also recognised as risk factors and influence patient 
management and disposal 180.  
In this cohort we decided to score all participants utilising all 3 scoring systems at 
admission/first 5 days of illness and then categorize them as ‘mild’ if they had none of the 
Swanepoel parameters, and were graded as mild and low risk by SSI and SGS respectively. The 
‘moderate/severe group’ included all patients graded as moderate/severe (SSI), 
intermediate/high risk (SGS) or with Swanepoel criteria. The SSI system categorised the majority 
of participants in the moderate/severe group (39/41), with the SGS conversely recording more 
patients as mild. Of note all three fatal case were recorded as moderate by SSI, had Swanepoel 
criteria and by SGS 2/3 were intermediate risk and 1/3 graded high risk. A newer simpler CCHF 
severity score is required, probably incorporating CCHF viral load and other simple parameters 
such as platelet count and bleeding.  
The clinical features of the participants at admission is also consistent with larger data sets, 
although bleeding was less frequent (14%) than that reported by Yilmaz et al141 (23%) and Bakir 
et al152 (18%), and this probably reflects the higher proportion of patients were directly 
recruited from Tokat State hospital, with early/mild disease. There is limited data on vital signs 
at admission in patients with CCHF. The vast majority were normal at admission, with median 
NEWS scores of 2 and 1 in moderate/severe and mild disease groups respectively. Interestingly 
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although a history of fever is reported by 90% of patients with CCHF the mean temperature was 
37.50C. Although arbitrary temperature cut offs are frequently used in case definitions for 
surveillance and screening, only 37% of this cohort had a temperature of ≥38 0C, and 48% a 
temperature of ≥37.5 0C at admission. This is a key translational finding of the study with 
clear policy implications and is consistent with data on Lassa fever from Nigeria 94 and from 
the Ebola virus disease outbreak in West Africa 181.  
Clinical and laboratory features at admission are important for diagnosis, surveillance and 
incorporating into severity scores, but limited data exists on the natural history/evolution 
of CCHF and other viral haemorrhagic fevers. We collected daily routine laboratory 
variables, and also the clinical features of CCHF in the cohort through a standardised case 
record form. The most frequent symptoms reported were headache, myalgia, lethargy and 
vomiting, all occurring in approximately 70% of patients for 2-3 days. In total 23% of the 
cohort had an episode of bleeding, that lasted for a median 2 days. During the course of 
admission fever above 380C was only recorded in 50% of patients, and the duration of fever 
was surprisingly shorter in the moderate/severe group compared to the mild group, with 
different slopes demonstrated in linear analysis. Heart rate also reduced during the course of 
illness, and as might be expected the moderate/severe group had a lower systolic blood 
pressure and higher respiratory rate elevation/intercepts. Review of the vital sign data for the 
cohort demonstrates that in the majority of cases, a significant systemic inflammatory/sepsis 
response is not evident. It is also important to highlight that whilst approximately 25% of 
patients had bleeding, most patients did not demonstrate evidence of disseminated 
intravascular coagulation or multiorgan failure. This is in contrast to what has been observed in 
patients with EVD 182,183, and also Lassa Fever 94,168,184 where haemorrhage occurs late and is a 
poor prognostic marker.  
Some of the serial laboratory data showed clear patterns. The peak elevations of liver enzymes 
occurred later in the disease course than that observed for CK and APTT. The lowest white cell 
counts were observed 2 days earlier than the lowest platelet counts on days 5-6. This provides 
insights into disease pathogenesis, and whilst leucopenia is common in many acute viral 
infections, this may highlight CCHFV potentially disrupting cells in the bone marrow resulting in 
decreased production of leucocyte precursors, direct infection and bystander apoptosis86,185,186.  
The rise in liver enzymes probably represent dissemination of infection and then viral 
replication within hepatocytes, that have been demonstrated in animal models 88 and suggests 
the liver may have a significant role in amplifying CCHFV. Marked histopathological changes 
have also been reported showing a cytopathic effect, with hepatocellular necrosis varying from 
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mild to severe, with focal area marked by haemorrhage and associated with the eosinophilic 
change of hepatocytes and Councilman bodies. The degree of necrosis has also been shown to 
correlate with the degree of elevation of liver enzymes 187, and although not seen in this study 
fatal cases of liver failure occurring in CCHF have been reported 157,188. In this study both ALT 
and AST were higher in the moderate/severe group as might be expected. However, 10% of the 
mild group went on to develop AST levels greater 500IU/L during the course of admission, 
illustrating the difficulties of categorisation at admission.  
Thrombocytopenia is a consistent feature reported in CCHF, and has been shown to be a simple 
predictor of mortality 150,151,189,190. A number of mechanisms that lead to the thrombocytopenia 
seen in CCHF have been suggested including due to decreased production due to bone marrow 
hypoplasia, endothelial damage stimulating platelet aggregation and finally increased platelet 
consumption as a result of DIC 90,191,192. However previous hypotheses in CCHF, and viral 
haemorrhagic fevers in general have been based on traditional views that the cellular activities 
of platelets are restricted to rapid pro-coagulant responses that lead to platelet aggregation and 
granule secretion. However, as well as their key roles in maintaining haemostasis, platelets are 
now increasingly recognised as major inflammatory cells with roles in both the innate and 
adaptive immune systems 193. Platelets have been shown to express surface receptors able to 
mediate binding and entry of a range of viruses 194,195 and it is now known that they express 
various pattern recognition receptors (PRR) that respond to a range of infecting microorganisms 
including viruses. Although they do not have nuclei, they have all the molecular machinery that 
may enable RNA viruses to synthesize proteins such as cytokines 193.  
Dengue infection is the commonest viral haemorrhagic fever that has a spectrum of clinical 
illness and thrombocytopenia has been shown to correspond to disease severity. Whilst the 
pathophysiology of severe dengue syndromes is not fully understood, a pro-inflammatory 
response, similar to that reported in CCHF, and platelet activation have been associated with 
disease severity 196,197. The viral genome of dengue virus (a Flavivirus) and endocytosed dengue 
virus like particles have also been detected in circulating platelets from infected patients 198,199 . 
There is also evidence of viral replication and translation of the viral genome , but whether 
infectious virus is generated is unclear 200. 
In dengue infection it remains unknown whether viral attachment or internalisation is required 
for platelet activation 193. This may then contribute to platelet loss by mediating platelet 
deposition in microvascular bed and through clearance of activated platelets by inflammatory 
monocytes 200. Interestingly, it has also been demonstrated that platelet activation is maximal 
when virus particles are no longer circulating , indicating that additional mechanism such as pro-
inflammatory mediators drive platelet activation after clearance of viraemia 185,201, consistent 
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with maximal thrombocytopenia being seen later in CCHF. Increased platelet apoptosis is also 
thought to contribute to the thrombocytopenia in dengue, due to activation of an intrinsic 
death program involving apoptotic caspases, that has also been linked to disease severity 185,201.  
Renal dysfunction was not commonly seen in this cohort of CCHF with only 4/104 having acute 
kidney injury by RIFLE criteria. There are two cases of acute renal failure in the study, that has 
been reported previously in CCHF 139,159 although the mechanism of action remains unclear. 
Although creatine kinase levels are elevated in the patients with acute renal failure, suggesting 
a degree of viral myositis/rhabdomyolysis they are not at the levels that would be associated 
with significant renal impairment. A case report of a patient in Iran with suspected thrombotic 
microangiopathy and acute renal failure, that was subsequently confirmed to have CCHF, had a 
renal biopsy that revealed normal looking glomeruli and renal vasculature. Intrarenal 
hemodynamic dysregulation secondary to cytokines and endothelial dysfunction mediated by 
cytokines or virus were suggested as possible explanations 159. In a study of 44 children in 
Turkey with CCHF with normal renal function, proteinuria was found in 60% and increased 
uNGAL levels, an early and sensitive marker of AKI, found in severe patients 202. Although rare, 
the aetiology of renal dysfunction requires further evaluation to understand how much is a 
result of either direct viral renal damage, renal hypovolemia due to sepsis or as a consequence 
of DIC. 
Supportive care of patients during the study was guided by infectious diseases physicians in the 
different sites, with the vast majority (>98%) receiving ward level care. Intravenous fluid 
supplementation was administered to the majority of participants, for the entirety of their 
medical admission: this established practice was not generally guided by fluid losses or evidence 
of hypovolaemia/renal dysfunction. Only 2 patients received additional critical care support, 
both in the final stages of illness and lasting less than 24 hours. This further demonstrates the 
high percentage of ‘mild’ CCHF seen in Turkey and recruited in the study that is different to 
anecdotal clinical experience in Kosovo or South Africa. 
Blood product replacement is a key intervention in CCHF, aimed at managing the coagulopathy 
and preventing haemorrhage. Receiving blood products was clearly linked with the severity 
grouping for all blood components, although this has not been reported before when the 
scoring systems were independently validated. However, bloods products were utilised in 
patients that were graded as mild/low risk by all severity systems, recognising limitations of 
severity scores to predict the need for transfusion. More important was the decision making 
around use of blood products by clinicians and whether this could be rationalised and 
protocolised. Of the patients that received FFP, only 1/3 had either an APPT or PT >1.5 times the 
upper limit of normal. A further 1/3 had PT/APPT parameters less than this but bleeding and a 
74 
 
1/3 had neither bleeding or elevated PT/APTT levels. Platelet transfusion was generally 
administered according to absolute platelet count, with 36/37 receiving transfusion having 
platelet counts <50 x 109/L and all patients with platelet counts <20 x 109/L receiving platelet 
transfusion. 
The main limitations in the clinical and laboratory description of the natural history of CCHF are 
that a smaller number of fatal and severe disease were recruited than planned. This limits the 
ability to improve understanding of the more complicated spectrum of CCHF disease, but unlike 
other reports does describe a large cohort of ‘mild’ disease for comparison. The other main 
limitation was inconsistent or missing laboratory data due to daily laboratory tests being 
determined by individual clinicians. At the design stage of the study this practice was evaluated 
and the case record form piloted in one centre (OMUH) that undertook most biochemistry, 
coagulation and haematology assays daily, in line with recently published recommendations 160. 
As the study extended to other sites, regular assessment of coagulation and biochemistry 
parameters became less frequent and was guided by the clinical picture, which whilst clinically 
appropriate provided less data to inform understanding of the natural history of disease. A 
detailed schedule of the minimum frequency of laboratory analysis would have mitigated this, 
but it must also be recognised that this would have sent additional samples containing CCHFV to 
standard laboratories, for research as opposed to direct patient care need.  
In summary, the epidemiological, clinical and laboratory data is broadly consistent with 
published data sets in Turkey, apart from a significant proportion of ‘mild’ disease severity being 
recruited. This is evidenced by the low mortality, severity scoring approach and lower rates of 
key outcomes such as bleeding and critical care admission. The first description of the use of 
early warning scores further demonstrates this and provides the first evidence that the pattern 
and aetiology of most bleeding that is seen is not due multi-organ failure/DIC , supported by 
normal observations and other laboratory parameters at the time. As has been shown in other 
VHFs, only a third of patients at admission have temperatures >380C, that has important 
implications for case definitions and surveillance. Simultaneous evaluation of the scoring 
systems in parallel has further demonstrated that additional variables, and simplification for 
routine use is required.  
Longitudinal data highlighting the natural history of CCHF is lacking and this data set provides 
detailed clinical and laboratory data highlighting the difference by disease severity and over 
time. Thrombocytopenia is the key laboratory variable that in practice guides patient disposal 
and management in the Turkey, but the pathogenesis remains poorly understood and may be 
multifactorial like suggested in dengue infection. Case management in Turkey is known to be of 
a high standard, but improved utilisation of blood component therapy, potentially supported by 
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novel platforms such as ROTEM as discussed later may rationalise and improve this approach. 
Ribavirin therapy was utilised in a third of participants, generally relatively early in disease 
course (median day 4), and in more severe disease groups. In most cases in Turkey it is 
administered orally, with reduced bioavailability 203 that may limit its effect. Its relationship to 
CCHF viral load is evaluated further in the next chapter.   
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Chapter 4 CCHF Viral Load  
4.1 Introduction  
The viral load, when measured in diagnostic blood samples at admission has been shown to be 
an important prognostic indicator in Ebola Virus Disease 93,204 and Lassa Fever 94. A similar 
correlation between viral load at presentation and disease severity/outcome in CCHF has also 
been demonstrated in a number of studies. The first CCHF VL data were published by Cevik et al 
95 in 36 patients from Turkey and Duh et al 96 from 24 patients in Kosovo in 2007, demonstrating 
that CCHF viral loads were higher in fatal than surviving cases. In both studies a VL greater than 
1 x 109 copies/ml was indicative of a fatal outcome.  
This has been confirmed by a number of further studies 97–99, some of which also found 
associations between viral load and higher disease severity scores. A number of studies also 
investigated viral loads serially with daily sampling, the largest of which by Bodur et al 100, 
measured viral loads daily in 50 patients. By day 3 of admission 50% of patients had cleared 
virus, with only 1 /42 having a positive PCR on day 6. This is consistent with Cevik et al’s 95 first 
report and more recent data 101 demonstrating that virtually all patients had cleared viraemia 
within 6 days of admission, with patients being admitted 3-5 days after onset of symptoms. 
There are limited data on the viral dynamics of CCHFV in urine. This could have important 
diagnostic implications if CCHFV is detectable in urine after clearance from the blood and 
potential transmission risks. Prolonged viraemia in urine (>30 days post disease onset) has 
been demonstrated in one report from Kosovo 103, but this hasn’t been evaluated in other large 
cohorts.  
4.2 Methods 
Patients with suspected CCHF were admitted to the study hospitals and had blood samples sent 
to the Regional PH reference laboratory in Samsun for CCHF PCR. After recruitment into the 
study patients had daily blood sampling during acute admission. EDTA blood samples were 
centrifuged, plasma aliquoted in a Class 1 BSC and stored at -700C in the study laboratories in 
Samsun and Tokat. Urine samples were also collected daily and stored at -700C. Urine and 
plasma samples were then transferred on dry ice with temperature monitoring to PHE Porton 
for CCHF PCR. Serum samples were analysed by ELISA for CCHF IgM/IgG at PHE Porton. Data 
was analysed according to statistical methods described in chapter 2.  
PHE Porton RNA extraction and PCR  
1. One hundred forty microliters of supernatant were added to 560 μL AVL buffer for RNA 
extraction in sealable deep 96-well plates for removal from the CL4 laboratory.  
2. Extraction of RNA was performed using the MagnaPure 96 small volume RNA kit 
(Roche, Burgess Hill, UK), a magnetic bead-based method of RNA separation.  
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3. Samples were vessel transferred from plates taken from containment level 4 (CL4) into 
MagnaPure plates at CL3 prior to loading onto the MagnaPure 96 automated extraction 
robot and RNA eluted in 60 μL nuclease-free water.  
4. Target amplification was performed using an internal PHE assay with primers to the 
Crimean-Congo haemorrhagic fever glycoprotein as described in Atkinson et al 2012 205 
using the Fast Virus qRT-PCR Kit (Qiagen, Manchester, UK). The assay is designed based 
on an untranslated region of the CCHF S segment between pan-handle loop structures 
and has been validated for diagnostic use by the Rare & Imported Pathogens 
Laboratory, Public Health England. 
5. Analysis was performed using the ABi 7500 (Applied Biosystems, Paisley, UK) under the 
following cycling conditions: 50 °C for 10 min, 95 °C for 30 s followed by 40 cycles of 95 
°C for 15 s and 60 °C for 3 s; temperature cycling was set to the maximum ramp speed, 
and data were acquired and analysed using the ABi 7500 on-board software version 
2.0.6 (Applied Biosystems, Paisley, UK) with a threshold set to 0.05.  
6. Cycle threshold (Ct) values from the PCR assay were used to give a consistent reading of 
the amount of RNA levels in the samples. To calculate patient viral load Ct values were 
compared with a standard curve of synthetically produced RNA fragments (GeneArt) 
encoding the target region in the S segment of CCHFV. 
4.3 Results 
Of the 144 participants recruited with suspected CCHF, 818 plasma samples were collected and 
analysed for CCHFV by PCR. 569 acute samples taken during hospital admission were analysed 
from the 104 participants with PCR confirmed CCHF infection (at Samsun PH reference 
laboratory), of which 144/569 were CCHFV PCR positive in PHE Porton.  
In total 56/104 participants that tested PCR positive in Turkey, had samples taken that were also 
PCR positive in PHE Porton. Participants with discrepant PCR result (i.e. positive PCR result in 
MoH Ref lab and negative PCR result in PHE Porton) had samples analysed in Turkey a median 2 
days earlier in disease course than samples analysed in PHE Porton. All participants that were 
CCHF PCR positive in Turkey were IgM/IgG positive when subsequently tested by ELISA in PHE 
(results detailed in chapter 5). No participants that were PCR negative in Turkey were found to 
be PCR positive in PHE Porton. Three participants that were PCR negative in Turkey and PHE, 
were subsequently found to be IgM/IgG positive by ELISA in PHE and are not included in data 
analysis. Table 4.1 demonstrates the rates of sample PCR positivity by day of illness. It includes 
the sample timing of the diagnostic PCR results from Turkey to include the 48 participants that 
tested positive in Turkey and then negative by PCR in PHE Porton.  
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Day of 
illness 
Combined (Turkey MoH 
and PHE) PCR result 
positive (%)  
PHE Porton PCR result 
positive (569 acute samples)  
0 3/3 (100) n/a 
1 11/13 (84.6) 5/7 (71.4) 
2 17/25 (68) 8/17 (47.1) 
3 31/44 (70.5) 26/37 (70.3) 
4 45/71 (63.4) 33/59 (55.9) 
5 30/76 (39.5) 27/73 (37.0) 
6 22/81 (27.2) 19/79 (24.1) 
    7 14/76 (18.4) 13/75 (17.3) 
8 5/72 (6.9) 5/72 (6.9) 
9 5/61 (8.2) 5/61 (8.2) 
10 2/44 (4.5) 2/44 (4.5) 
11 1/25 (4.0) 1/25 (4.0) 
12 0/12 (0.0) 0/12 (0.0) 
13 0/8 (0.0) 0/8 (0.0) 
14 1/67 (1.5) 1/67 (1.5) 
30 0/53 (0.0) 53/53 (0.0) 
 
Table 4.1 Blood samples PCR positive for CCHFV by day of illness in 104 participants.  
4.3.1 Viral load at admission  
Viral load data at recruitment, shortly after admission was available on the 56/104 participants 
that tested positive in PHE Porton. The mean viral load at admission was 5.8 log 10 copies/ml 
(SD 1.17, range 3.2-8.4). The mean viral load was significantly different between the mild 
severity group (5.52 log 10 copies/ml (SD 1.02, n=35)) and the moderate/severe group (6.30 log 
10 copies/ml (SD 1.26, n=21) p=0.022). When patients were stratified by lowest platelet count, 
the mean log 10 viral load at admission of patients whose platelet count remained greater than 
50 x 109/L was significantly lower than those that had platelet counts less than 50 x 109/L (5.28 
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(SD 1.01) n=18 vs 6.06 (SD 1.16) n=38, p=0.018). The viral load in fatal patients (n=2, log10 8.26 
copies/ml, log 10 7.53 copies/ml) was significantly higher than in patients that survived 
(p=0.012) (Figure 4.1). There was no significant difference in admission CCHF viral load in 
patients with bleeding (p=0.61). 
  
 
Figure 4.1 CCHF viral load at admission grouped by severity, platelet count, outcome and 
bleeding. Boxplots with whisker represent min to max values. p values are from t tests.  
4.3.2 Correlations with admission CCHF viral load 
There were no significant correlations between admission viral load (log10 copies/ml) and 
length of stay (p=0.316) or age (p=0.628). There were no significant correlations shown 
between admission viral load and admission observation/vital signs (temperature p= 0.240, 
heart rate p=0.57, respiratory rate p=0.32) but viral load was significantly negatively correlated 
with systolic blood pressure (p=0.014). No correlation was shown between admission viral load 
and national early warning score (NEWS p=0.167). 
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Significant positive correlations with standard laboratory parameters were shown for white 
blood count (p=0.0003), APTT (p=0.009), PT (P=0.0001), creatinine (p=0.043), LDH (p=0.0002), 
fibrinogen (p=0.043), and CK (p=0.048). No significant correlations were seen between 
admission viral load and sodium (p=0.961), potassium (p=0.276), BUN (p=0.708), haemoglobin 
(p=0.586), haematocrit (p=0.67), AST (p=0.067), ALT (p=0.067) or glucose (p=0.59). Platelet 
count at admission also did not correlate with viral load at the <0.05 level (p= 0.083), but the 
platelet count on day 1 and 2 of admission did negatively correlate (p=0.018, p=0.006 
respectively).  
There were no significant correlations with admission viral load and the CCHF severity scoring 
index (p=0.11), or with CCHF severity grading system score (p=0.48). There were strong 
correlations at admission between viral load and the duration of clinical features during 
hospitalisation (headache p=0.01, myalgia p=0.001, vomiting p=0.008, lethargy p=0.03, fever 
>380C p=0.02). A correlation between admission viral load and days of bleeding during 
hospitalisation was also significant (p=0.001). Participants with a CCHF viral load greater than 6 
log 10 copies/ml at admission were significantly more likely to receive blood products during the 
course of their admission than those <6 log 10 copies/ml (p=0.005) but no differences in 
whether they developed bleeding during hospitalisation were shown (p=0.772). Participants 
that that were CCHF PCR positive in PHE porton, were more likely to receive blood products 
(p=0.002) and have an episode of bleeding (p=0.037). 
4.3.3 Serial viral load 
Serial CCHFV viral load for all patients is shown on a scatter dot plot with mean and SD in Figure 
4.2. Serial mean viral load by day of illness stratified by severity and lowest platelet count is 
shown in Figure 4.3. Scatter dot plots of serial viral load stratified by severity, lowest platelet 
and count and the presence of bleeding is also shown in Figure 4.4.  
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Figure 4.2 Scatter dot plot of CCHFV viral load (Log 10 copies/ml) by day of illness. Mean and SD 
error bars are shown in red. A line demonstrates 2 log 10 copies/ml L as the limit of detection.  
 
Figure 4.3 Mean CCHF viral load by day of illness stratified by disease severity and lowest 
platelet count.   
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Figure 4.4 Scatter dot plots of serial CCHF viral load by day of illness grouped by severity, lowest 
platelet count and bleeding. Mean and SD error bars are shown in red. A line demonstrates the 
2 log 10 copies/ml limit of detection. 
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4.3.4 Linear regression analysis viral load 
Serial viral load reduction was analysed by linear regression comparing slopes and 
intercepts/elevations stratified by severity, lowest platelet count and ribavirin use. There was a 
significant difference between the slopes by severity groups (p=0.0019) and lowest platelet 
count groups (p<0.0001). No significant difference in slopes (p=0.098) or intercepts/elevation 
was demonstrated when stratified by ribavirin groups.  
 
Figure 4.5 Serial CCHF viral load by severity , lowest platelet count and ribavirin use, with group 
means (SD) and linear regression lines. Slope p-values indicate if regression slopes are equal (a-
c). Intercept p-values indicate if the elevations or intercepts are equal.   
4.3.5 Viral Load clearance  
The clearance of CCHFV from blood (below limit of detection by PCR) by day of illness is shown 
in Figure 4.6. There was significant difference in rate of clearance of CCHFV by survival curves by 
severity (p=0.01) and lowest platelet count (p<0.0001). Median clearance of virus occurred at 
day 5 in mild and day 6 in moderate/severe groups. In participants that developed platelet 
counts <50 x 109/L they also cleared virus later at a median of 6 days, in comparison to day 4 in 
those maintained platelets >50 x 109/L.  
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In the mild group 38/58 (65.5%) of participants cleared virus by day 5 of illness compared to 
14/35 (40%) in the moderate severe group (p=0.02). In the platelet >50 x 109/L group 31/41 
(75.6%) cleared virus by day 5 compared to 19/52 (36.5%, p<0.0001). Duration of viraemia also 
positively correlated with a longer length of hospital stay (p=0.03) and number of platelet 
transfusions received (p=0.002). 
 
Figure 4.6 Clearance of CCHFV from blood by disease severity and lowest platelets plotted by 
survival curves. p-values indicate significance of different survival curves (Log-rank (Mantel-Cox) 
test).  
4.3.6 Ribavirin and CCHF VL  
Ribavirin was administered to 36/104 participants, all of whom were managed at one study site 
(Gaziosmanpasa University Hospital) after direct admission or hospital transfer. 16/36 (44.4%) 
patients that received ribavirin were graded as moderate/severe compared to 25/68 (33.7%) 
graded moderate/severe in the non-ribavirin group. Viral load at admission was log 5.69 (SD 
1.01) in the non-ribavirin group, compared to log 6.23 (SD 1.12) that received ribavirin (p=0.08). 
At the time that ribavirin was initiated, 25/33 participants were CCHFV positive (3/36 no 
matching PCR sample on the day of initiated as started prior to recruitment into the study) 
patients were CCHFV PCR positive, with 8/33 already clearing virus from blood. In total ribavirin 
therapy was administered for 201 admission days in patients with CCHFV blood PCR results, of 
which 144/201 were CCHFV PCR negative.  
Linear regression analysis showed no significant difference in viral load elimination slopes 
(p=0.098) between the group that received ribavirin and the group that did not. However, this 
binary classification of treatment groups risks introducing bias that may limit the potential 
effect of ribavirin on CHHF VL. This is due to 13/36 participants in the ‘ribavirin treatment 
group’ initially being admitted to Tokat State hospital (where ribavirin is not given), and then 
being transferred to the University Hospital where they received ribavirin. To limit this bias, the 
data was further analysed comparing the viral load kinetics by day with or without ribavirin 
administration, using nonlinear mixed effects, shown in Figure 4.7. Patients receiving ribavirin 
85 
 
according to this analysis had a typical elimination rate constant under treatment 56% greater 
than those that did not receive treatment (p<0.01).  
 
Figure 4.7 Viral load kinetics with or without ribavirin, using non-linear mixed effects model.  
 
4.3.7 CCHFV urine analysis 
Urine was collected daily from participants and at 14 and 30 day follow up visits. In total 679 
urine samples were processed for CCHF PCR from 104 plasma CCHFV PCR positive patients. This 
equated to 578 daily samples during the acute admission and 101 from subsequent visits (14 
days 54 samples, 30 days 47 samples).  
Eight acute CCHF samples were positive by PCR, the majority at Ct values greater than 35 (one 
sample Ct 30.5, 263,314 copies ml, log 5.5). These samples were all from different participants 
and were each preceded and followed by negative daily PCR results. Five of the 8 participants 
with a urine PCR positive result were graded as moderate/severe severity. Plasma was positive 
at the same time in 2/8 participants with positive urine samples. All convalescent urine samples 
were negative for CCHFV at 14 days and 30 days. 
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4.4 Discussion  
This is the largest study of CCHFV viral load undertaken to date, with the majority of previous 
studies evaluating CCHFV viral loads in small patient cohorts at baseline, with Hasanoglu et al 99 
in Ankara being the exception that recruited 126 patients for baseline analysis over 6 years. In 
accordance with this and data published in earlier smaller studies 95–97, we have demonstrated 
higher CCHF viral loads in fatal cases compared to survivors. We also demonstrated that there is 
a higher viral load in moderate/severe cases compared to mild cases using a composite severity 
scoring system. Saksida et al 97 has previously shown this but with different severe and 
moderate groups. A low platelet count is commonly used in Turkey as an indication to move 
patients from secondary to tertiary centres. We have shown for the first time that significantly 
higher CCHF viral loads at admission are associated with the development of platelet counts less 
than 50 x 109/L.  
We have demonstrated a correlation between CCHF viral load and bleeding during admission 
and also shown that viral load correlates with the use of blood products, that was more 
frequent than bleeding. The data shows a number of correlations between laboratory values 
and CCHF viral load at admission that include APTT, PT, LDH, CK and creatinine. These 
frequently form part of severity scoring systems and in practice are used by clinicians to gauge 
severity of illness and likelihood to require additional supportive care. The correlation with viral 
load provides further evidence that a simplified scoring system based on viral load could be 
evaluated. Interestingly there was no direct correlation between viral load and platelet count at 
the <0.05 level but there was with platelet count in the following days, that suggests a delay in 
maximal drop of platelets after peak viral load. This may be consistent with direct viral infection 
of the platelet and subsequent destruction or a delayed immune mediated mechanism resulting 
in thrombocytopenia. Hasanoglu et al 99 had previously showed a number of significant 
correlations between admission viral load and variables such as diarrhoea, bleeding, seizure, 
and requirement for haemodialysis. In this study, as might be expected, the admission viral load 
correlated with duration of fever. Although this has not been demonstrated previously it 
concurs with standard practice in the management of EVD and Lassa fever whereby the absence 
of fever for 48hrs during admission is utilised as a marker for recovery and an indication for PCR 
testing to allow discharge. Duration of myalgia also correlated with viral load, that is consistent 
with the CK/viral load correlation and indicates probable viral polymyositis that clinically (and by 
CK peak levels) was mild, and not at the levels associated with causing renal impairment.  
Longitudinal measurements of viral load of viral haemorrhagic fever cohorts have rarely been 
measured with hypotheses on viral dynamics in blood often crudely inferred from admission 
sampling at different time points. Only a few small studies have undertaken this in CCHF. The 
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largest study by Bodur et al 100 investigated VL dynamics in plasma in a case-control study in a 
cohort of 50 patients, 10 of which received ribavirin. Data is reported by day of admission and 
relation to ribavirin as opposed to day of illness, but it showed that patients rapidly cleared 
virus, with no effect of ribavirin demonstrated. This is the first study to show that there is clear 
differences in CCHF viral dynamics in plasma by disease severity, including the rarely studied 
‘mild cchf’ group and also by those who drop their platelets to less than 50 x 109/L, that is most 
frequently used cut off used in clinical practice to identify those with severe/complicated 
disease. The main limitation to the interpretation of disease severity viral load slopes is the 
potential confounding effect of ribavirin, that was more frequently given to the 
moderate/severe group.  
Overall half of patients cleared CCHFV from blood within 5-6 days of onset of symptoms. There 
were though significant differences in the time of viral clearance by disease severity. Clearance 
of virus by day 5 occurred in 65% of the mild and 75% of platelet >50 x 109/L groups, compared 
to only 40% in the severe group and 37% in the platelet <50 x 109/L groups. This has important 
infection prevention and control implications and is relevant when considering antiviral 
treatment and planning for future clinical trials, that may use CCHFV clearance as primary or 
secondary end-points. 
The study was not designed to investigate the potential effect of ribavirin on CCHFV, and when 
it was initially designed ribavirin was not utilised in the planned study sites. However, after 
extension to another tertiary specialist centre, one third of the cohort received ribavirin 
treatment. The use of ribavirin in CCHF has been controversial, with no strong 
recommendations for use given by WHO, CDC or ECDC. Published meta-analyses are limited by 
retrospective observational data sets, with the most recent evaluation by the Cochrane 
reporting that that there was insufficient evidence to show whether ribavirin is effective in 
treating CCHF, and recommending randomised clinical trials 174. Even allowing for uncertainty 
about the effectiveness of ribavirin, the inclusion of patients who received ribavirin has the 
potential to alter the natural history of disease and viral dynamics. It does however provide an 
opportunity to observationally evaluate ribavirin treatment, whilst recognising that although 
not statistically significant, those with moderate/severe disease were more likely to receive it 
due to the referral mechanisms in place in Tokat.  
There was no difference in viral elimination slopes between the group that received ribavirin 
and the group that did not using linear regression (Figure 4.5). However, this is a binary 
classification of the two groups, and fails to account for a significant percentage of patients 
being managed initially without ribavirin, and then it commenced on transfer to a tertiary 
facility. This has the potential to then underestimate the potential effect of ribavirin on CCHFV 
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slopes and may explain the difference in Figures 4.5 and 4.7. Figure 4.7 does show a difference 
between the typical patient model when the ribavirin data is evaluated by day of onset against 
the non-ribavirin typical patient. This has not been demonstrated before with the best previous 
study being by Bodur et al 100, who evaluated viral elimination dynamics in a observational study 
of 10 patients with ribavirin vs 40 control patients. One of the limitations of the ability to 
demonstrate a benefit of ribavirin therapy in Turkey has been the low case fatality rate which 
would require unfeasible numbers if powered on a mortality endpoint. Any future RCT is 
therefore likely to utilise different primary end-points such as viral clearance and elimination 
slope. This data supports this as a potentially useful strategy. 
This is the first practical observation of use of ribavirin in normal clinical practice in Turkey, with 
matched viral load data. We demonstrated that 25% of patients had cleared virus on the day 
that ribavirin was commenced, and patients were only PCR positive during 28% of the total 
number of days that they received ribavirin. This strongly suggests that greater use of CCHFV 
PCR monitoring, with rapid turnaround of results could improve this and limit the well-
recognised adverse sequelae of ribavirin. 
There are limited data on the viral dynamics of CCHFV in urine, but a previous report from a 
small cohort in Kosovo suggested evidence of prolonged viraemia in blood and urine 103. Urine 
was shown to be PCR positive in 5 patients that had samples sent to PHE Porton for evaluation. 
This included a case that was both serum and urine PCR positive at 36 days after onset of 
symptoms, and another positive on day 6 and 19 when serum was negative. Another case was 
shown to have variable expression in serum with an unusual pattern (PCR positive day 1,2,18,25 
and 34, whilst a negative PCR on sample on day 11). Urine PCR positivity was also variable in the 
same case with a positive result on day 25, but negative on days 4, 11, 15, 18, 34 and 40.  
Due to these results we undertook daily urine sample collection during hospital admission and 
again at days 14 and 30 when patients attended follow-up. In total 679 urines were processed 
from the 104 participants, that included 54 samples at day 14 and 47 samples at day 30. All 
convalescent samples were PCR negative, and only 8/578 acute admission urine samples were 
PCR positive, all from different participants, with only 2/8 samples PCR positive in blood at the 
same time. It is clear from these results that urine is rarely CCHFV PCR positive in acute infection 
and cannot be reliably utilised in convalescence to diagnose recent CCHF infection. The urine 
and plasma results are noticeably different from the results reported by Thomas et al from 
Kosovo 103 in 2012, who found prolonged PCR positivity in blood and urine. However, the total 
number of urines evaluated from confirmed patients is not reported and the samples were not 
taken as part of a prospective study. The pattern of CCHF clinical disease reported from 
colleagues in Kosovo is though different than that seen in Turkey (personal communication Salih 
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Ahmeti). They see a more severe spectrum of disease, with more haemorrhage and higher case 
fatality rates, and as such may have different viral dynamics. A future prospective study from 
Kosovo utilising the same RT-PCR, with matched serum results is required to try to re-produce 
these preliminary results, and to allow further investigation of the different results observed.  
In summary this intensive evaluation of CCHF viral load has shown as association with levels by 
markers of disease severity including platelet count and patient outcome. Viral load has been 
shown to correlate with clinical features such as bleeding and duration of fever and myalgia, 
and also with other laboratory variables such as APTT, LDH and CK, with a delayed correlation 
with platelet count observed. Longitudinal analysis of viral dynamics has again shown difference 
by CCHF disease severity, with earlier clearance observed in mild cases. For the first time a 
potential effect of ribavirin on plasma viral elimination slopes has been shown and that urine 
PCR for CCHFV is not a useful diagnostic test in acute infection or convalescence. Contrary to a 
previous report the presence of CCHFV in urine is rare occurring in less than 8% of cases and in 
less than 2% of total admission days.  
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Chapter 5: CCHFV ELISA  
5.1 Introduction 
Antibody production in CCHF has been suggested as an important early survival factor, with 
reduced antibody response demonstrated in fatal cases. The majority of the studies to date 
suggest that both IgG and IgM antibodies develop early in disease course with IgM becoming 
detectable from as early as 2-3, but more commonly around 6 days 101. Small previous studies 
have suggested that IgG does not become detectable in fatal cases if death occurs before 9 days 
97. No correlation with IgM titre and death or severity has been demonstrated. Previous studies 
have not undertaken serial daily ELISA but mainly focussed on analysis of diagnostic samples. 
5.2 Methods 
The detection of immunoglobulins M and G (IgM, IgG) to CCHFV in participant serum samples 
was undertaken in PHE and utilised a commercial diagnostic enzyme-linked immunosorbent 
assay (ELISA) kit, VectoCrimean-CHF-IgG/IgM (Vectorbest, Russia).  
ELISA is a plate-based assay technique that can be utilised to detect and quantify a range of 
substances such as antibodies and hormones. Detection is accomplished by assessing the 
conjugated enzyme activity via incubation with a substrate to produce a measurable product. 
The most crucial element of the detection strategy is a highly specific antibody-antigen 
interaction. An indirect ELISA is a two-step ELISA which involves two binding processes of 
primary antibody and labelled secondary antibody. 
1. CL4 laboratory: Samples were thawed and then heat inactivated at 56oC for 30 minutes, 
with mixing half-way through and then transferred to new tubes in the CL3 laboratory. 
2. Preparation of test samples: Test samples were diluted 10 times with the solution for 
preliminary serum dilution (SPSD), by adding 90ul of SPSD to plate wells and 10Uul of 
serum with thorough mixing.  
3. Washing solution was prepared by diluting the concentrated phosphate buffered saline 
with Tween (PBS-T) concentrate 25 times with distilled water. Conjugate and 
Tetramethylbenzidine (TMB) solution is ready to use.  
4. Sample addition: 100ul of negative and positive controls, and 10uL of diluted test 
serum with serum dilution buffer (SDB) was added to all other wells in duplicate. 
5. Incubation 1: The plates were sealed with the adhesive film and incubated in the 
thermostat for 60 minutes at 370C.  
6. Washing 1: Adhesive film was removed and the wells were washed 5 times with the 
prepared washing solution. 400ul of liquid was added to each well during every cycle 
with a I minute interval between filling and aspiration 
7. Adding conjugate: 100uL was added to each plate well. 
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8. Incubation 2: Plates were sealed with adhesive film and re-incubated for 90mins at 
370C.  
9. Washing 2: washing repeated as per Step 5. 
10. Adding TMB: 100uL of TMB solution was added to each well.  
11. Incubation 3: Plate protected from light for 25mins at 18-250C. 
12. Add stop solution: 100uL of stop solution was added to each well. 
13. The optical density (OD) was read on a Molecular Devices SpectraMax M3 absorbance 
reader and analysed with SoftMax Pro. ELISA background cut-offs were calculated as 
the mean of plate negative controls (taking highest individual plate value) plus 3 SDs 
from + 0.2 (ODCO=ODavC- + 3SD + 0.2). 
5.3 Results  
In total 763 serum samples from 102 participants were analysed for CCHFV IgM/IgG by ELISA. Of 
these 638 were acute samples taken during hospitalisation, 68 samples were taken at the day 
14 follow-up visit and 57 samples at day 30 follow-up. At admission 43/102 (42.2%) patients had 
a positive CCHFV IgM result, whilst at admission 51/102 (50.0%) had a positive CCHFV IgG. At 
admission 39/102 (38.2% )participants were IgM negative/IgG negative, 12/102 (11.8%) IgM 
positive/IgG negative, 20/102 (19.6%) IgM negative/IgG positive, and 31/102 (30.4%) IgM 
positive/IgG positive (Table 5.1). The proportion and percentage of samples that were positive 
at each day of acute illness and follow up visits is shown in Table 5.2.  
All samples tested after day 8 of clinical illness were IgM positive (149/149), and 96% of IgG 
samples (143/149) were positive after the same time point. All samples tested positive for IgG 
after day 11 of illness. All convalescent samples tested at 14 and 30 days after onset of 
symptoms were IgM and IgG positive. Participants became IgM positive at a median of day 5 
(IQR 4-6) of illness (n=100). There was no difference in median day of IgM seroconversion after 
excluding those that were: IgM positive at admission/first sampling (n=41) and; those without a 
negative preceding ELISA result 24hrs previously (n=4). Participants became IgG positive at 
median of day 5 (IQR 4-7) of illness (n=98), with no significant difference compared to the 
timing of IgM positivity (p=0.923) 
IgM titre rose during acute illness reaching a peak at days 9-11 (Figure 5.1). The IgM titre was 
significantly higher at 14 days in comparison to follow-up at 30 days (p=0.007) . After 8 days of 
clinical illness the majority of samples tested were positive for IgG (days 9-12 , 143/149, 96%). 
IgG titre continued to rise during acute infection, with the highest titres recorded on Day 12. 
Levels continued to rise in convalescence with day 30 having higher levels than day 14 
(p<0.0001). Of 39 participants recruited with suspected CCHF that tested PCR negative in Turkey 
and PHE, 3 participants were found to by IgM/IgG positive (one from each of the study sites), 
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and 6 participants IgM negative/IgG positive. The 3 participants that were IgM/IgG positive, but 
PCR negative have not been included in data analysis as after the negative PCR result in Turkey 
they did not continue with daily sampling.  
There was no significant difference in IgM/IgG titres at admission when stratified by CCHF 
disease severity (IgM p=0.08, IgG p=0.149), although a trend towards higher titres in the 
moderate/severe group was observed (Figure 5.4). No difference in IgM/IgG titres at admission 
was noted between fatal or surviving cases at admission. There was also no significant 
difference in IgM/IgG titres at 5 days (IgM p=0.81, IgG p=0.44), 14 days (IgM p 0.67, IgG p=0.18) 
or 30 days (IgM p=0.33, IgG p>0.99) when stratified by disease severity (Figure 5.4). 
There were 102 patients that had a matched viral load and ELISA results after recruitment, 53 of 
which had virus detected. In the cohort of patients with detectable VL and ELISA results (n=53) 
the VL across was significantly different between antibody groups (p=0.01). Viral load was 
significantly different if the 53 patients were divided into 3 groups (IgM / IgG neg (n=30) median 
6.03 Log10 copies/ml, IgM or IgG pos (n= 17) median 5.25 copies/ml and IgM/IgG pos (n=6) 
median 4.88 log 10 copies/ml, p=0.01) (Figure 5.5). CCHF viral load and both IgM and IgG had 
strong negative correlations at admission (IgM Pearson r = -0.5571 (95%CI -0.68 to -0.41), 
p=<0.0001, IgG Pearson r -0.326 (95%CI -0.49to -0.14) p=0.0009). In participants with matched 
viral load/ELISA data on the day of CCHFV clearance, 40/51 (78.4%) were IgM positive and 37/51 
(72.5%) were IgG positive.  
 IgM negative  IgM positive  Total  
IgG negative  39 (38.2%)  12 (11.8%) 51 (50%) 
IgG positive  20 (30.4%)  31 (30.4%) 51 (50%) 
Total  59 (57.8%) 43 (42.2%) 102 
 
Table 5.1 Vectorbest CCHFV IgM and IgG ELISA results at admission (n=102)  
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Table 5.2 Vectobest CCHFV ELISA IgM and IgG positive rates by day of illness 
 
 
  
Day of illness Proportion of samples IgM 
positive (%) 
Proportion of samples IgG positive 
(%) 
0 0 (0) 0 (0) 
1 1/9 (11.1) 2/9 (22.2) 
2 5/21 (23.8) 7/20 (35.0) 
3 10/37 (27.0) 16/37 (43.2) 
4 24/61 (39.3) 23/61 (37.7) 
5 48/70 (68.6) 43/70 (61.4) 
6 70/78 (89.7) 61/78 (78.2) 
    7 71/75 (94.7) 64/75 (85.3) 
8 65/69 (94.2) 64/69 (92.8) 
9 62/62 (100) 58/62 (93.5) 
10 45/45 (100) 45/45 (100) 
11 27/27 (100) 25/27 (92.6) 
12 15/15 (100) 15/15 (100) 
14 68/68 (100) 68/68 (100) 
30 57/57 (100) 57/57 (100) 
365 13/61 (21.3) (61/61) (100) 
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Figure 5.1 Longitudinal IgM ELISA graphs by day of illness. a= Median and IQR . b= Aligned dot 
plot with mean. y axis units are optical density reads with cut off values displayed. c= Serial IgM 
ELISA stratified by disease severity (survival curves).   
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Figure 5.2 Longitudinal IgG ELISA graphs. a= Median and IQR . b= Aligned dot plot with mean. y 
axis units are optical density reads with cut off values displayed. c= Serial IgG ELISA results 
stratified by disease severity (survival curves).   
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Figure 5.3. IgM and IgG levels in convalescence (IgM/IgG y axis units are optical density reads) 
Boxplots (whisker represent 10-90th centiles)  
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Figure 5.4. CCHFV IgM and IgG ELISA levels at admission, 14 days and 30 days by disease 
severity. y axis units are optical density reads. Boxplots (whiskers represent 10-90th centiles) 
 
 
 
 
98 
 
 
I g
M
 /
 I
g
G
 n
e
g
I g
M
 p
o
s
 o
r
 I
g
G
 p
o
s
I g
M
 /
 I
g
G
 p
o
s
0
2
4
6
8
1 0
C C H F  V i r a l  l o a d  a t  a d m i s s i o n  b y  a n t i b o d y  s t a t u s  ( n = 5 3 )
L
o
g
 
1
0
 
c
o
p
i
e
s
/
m
l
p = 0 . 0 1
I g
M
 /
 I
g
G
 n
e
g
I g
M
 p
o
s
 o
r
 I
g
G
 p
o
s
I g
M
 /
 I
g
G
 p
o
s
0
2
4
6
8
1 0
C C H F  V i r a l  l o a d  a t  a d m i s s i o n  b y  a n t i b o d y  s t a t u s  ( n = 1 0 2 )
L
o
g
 
1
0
 
c
o
p
i
e
s
/
m
l
p < 0 . 0 0 0 1
 
Figure 5.5 CCHF viral load at admission by CCHFV antibody groups. n=53 participants with a 
matched positive PCR result. n=102 includes participants that were negative by PCR (limit of 
detection log 2) at study admission sampling. Boxplots (whiskers represent min to max values).  
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Follow up at 1 year after onset disease 
At 1 year follow up (+/-1 month) 61/86 (71%) eligible participants attended or were reviewed in 
the community with blood sampling. 18/104 were not eligible due to fatal outcome during 
admission (n=3), location (n=1) being outside the 1 year (+/- 1 month) follow up period (n=14). 
All participants (61/61) were CCHFV IgG positive at the upper limit of OD, consistent with 30 
days results. 13/61 participants were also CCHFV IgM positive at 1 year.   
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Figure 5.6 CCHFV IgM and IgG ELISA levels at follow-up. Boxplots (whiskers represent min to 
max values). y axis units are optical density (OD) reads with dotted line as positive result OD cut-
off.   
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 5.4 Discussion 
The adaptive immune responses to CCHFV have not previously been well characterised. 
Improved data on the antibody responses to infection is critical for understanding the natural 
history of infection and has implications for both current diagnosis and the future development 
of diagnostics and vaccines. CCHF serological responses have previously been evaluated in 
Turkey during large population seroprevalence studies. In 2009 a large study using the same 
Vectorbest ELISA kit evaluated 3557 adults, the majority of which were farmers in the CCHF 
endemic region in Turkey, and showed that 10% overall were positive for CCHF IgG136. Our data 
is the largest and most complete study of IgM and IgG antibody responses to acute infection 
with CCHFV to date, both in terms of sample size and the total number of samples analysed due 
to serial daily sampling. It is also the first time that antibody profiles in a cohort of patients with 
acute CCHF has been followed up at 14, 30 and 365 days.  
In total, over 750 samples from 102 participants with PCR confirmed CCHF were analysed for 
CCHFV IgM/IgG by a commercial ELISA, VectoCrimean-CHF-IgM/IgM produced by Vectorbest. At 
admission 40.2% of patients had a positive IgM result, with 29.4% of patients being both IgM 
and IgG positive. Participants became IgM positive after a median 5 days of illness, although as 
some patients presented with positive IgM results, one would expect the actual median time 
from that calculated to be shorter. All samples tested after 8 days of clinical illness were shown 
to be positive for IgM, with levels increasing until days 9-11 (Figure 5.1). IgM remained positive 
in all convalescent samples tested, although it was significantly lower at 30 days in comparison 
to 14 days.  
At admission 50% of participants had a positive CCHFV IgG result, with the median time for IgG 
seroconversion again being 5 days. After 8 days of clinical illness the majority of acute samples 
tested were also positive for IgG (96%). However, unlike IgM titres that began to drop in at the 
end of acute infection, as might be expected the IgG titre continued to rise until the last 
sampling point at day 12. Consistent with this and conversely to the IgM pattern, IgG titres were 
significantly higher at day 30 in comparison to day 14.  
These finding are broadly similar to other published data sets, which overall indicate an early 
and similar IgM/IgG response. Early studies in in South Africa demonstrated CCHF IgG and IgM 
developing on day 7-9 of illness 26,143. Later in Kosovo, Saksida et al 97 evaluated the serological 
response in a cohort of 46 patients with CCHF, of which 15 were fatal cases. Samples were 
evaluated retrospectively from diagnostic samples a median 6 days (IQR 4-8 days) after onset of 
symptoms. IgG positivity was only detected in 5/46 patients (all survivors), and IgM in 24/46 of 
all patients. Further analysis of data showed that the median time of sampling for those with a 
negative IgM (determined in 15/22) was 5 days (IQR 3-6 days).  
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More recently Ergunay et al 101 et al, evaluated serological response in Turkey in 20 patients 
with serial sampling although used a different assay. Although limited clinical data is reported 
the cohort is similar with only 1/20 fatal cases and a similar duration of viraemia. They found 
differences with nucleocapsid (N) IgM antibodies becoming positive earlier than glycoprotein 
precursor IgM antibodies (N-IgM median of 2–3 days after disease onset, GPC-IgM 4–6 days). 
GPC-IgM and GPC-IgG had a median time to detection of 5 and 6 days respectively. No 
information is publicly available on the nature of the antigen or CCHFV strain used in the Vector-
Best ELISAs, but it is expected to have been validated from strains from south-west Russia. 
During our study only participants that were shown to be CCHFV PCR positive in Turkey 
continued with daily sampling (n=104). Of the participants recruited with suspected CCHF that 
tested PCR negative in Turkey and PHE, 3/39 participants that were tested by ELISA in PHE were 
found to be CCHFV IgM/IgG positive, with 6/39 participants CCHFV IgM negative/IgG positive. 
The aetiology of disease in the 36/39 participants that were CCHFV PCR and IgM negative was 
not further investigated as part of this study, but in line with previous reports included a range 
of infective and non-infective causes 206,207. 
There was no significant difference in IgM/IgG titres at admission or convalescence when 
stratified by CCHF disease severity although a trend towards higher titres in the 
moderate/severe group was observed at admission (Figure 5.4). There was also no difference in 
IgM/IgG titres at admission between fatal or surviving cases. Saksida et al’s 97 cohort included 
more severe/fatal disease cases, but also demonstrated no relationship between IgM positivity 
or titre with clinical classification or outcome; only a few IgG positive results generated. Duh et 
al 96 investigated antibody profiles in 24 patients in Kosovo, including 9 fatal cases and also did 
not show any correlation with IgM with outcome or CCHF viral load; no patients had detectable 
IgG in the first 7 days of illness.  
Additional previous small studies have also evaluated the relationship between CCHF viral load 
and antibody response. Wolfel et al 105 demonstrated significant differences in CCHF viral load 
between those who were IgG positive and negative in 43 samples. Saksida et al 97 also detected 
a significant inverse correlation of viral load with antibody response with viral load, with RNA 
levels highest in patients with no detectable antibodies (7.44 log 10 copies per ml) and lowest in 
patients with detectable IgM and IgG antibodies (4.01 log 10 copies ml – p=0.033). Duh et al 
also showed that IgG levels after 7 days inversely correlate with VL.  
The distribution of viral load across different antibody groups was significantly different. 
Limiting analysis to only patients with detectable viral loads, participants with the highest viral 
loads were IgM/IgG negative and those with the lowest in IgM/IgG positive groups (Figure 5.5). 
This was more significant when all patients with PCR and ELISA results were included (n=102), 
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with undetectable viral load level inputted at the limit of detection. In accordance with these 
results strong negative correlations at admission were demonstrated between viral load and 
both IgM and IgG. There was persistent IgG responses at 1 year that were not significantly 
different from IgG levels at 30 days, however 20% of participants were IgM positive at 1 year. 
This is the first long term data on CCHFV antibody responses following acute infection. It shows 
IgG persistence at 1 year but also that IgM responses may be maintained for long periods in a 
sub-set of patients. Although IgM has traditionally been considered as a source of transient 
immunity prior to the development of IgG, recent studies have suggested that it may contribute 
to natural immunity through specialised subset of B-1 cells 208. Persistent IgM (> than 1 year) 
has also been demonstrated in patients that have had Lassa or West Nile virus infection and 
after yellow fever vaccination 209–211. Whilst this has important diagnostic implications, the 
aetiology remains unclear, although it has been hypothesized to occur as a result of strong 
initial stimulation of the immune system that results in long-term antibody memory 212. 
There is limited indirect evidence or knowledge about antibody responses in other viral 
haemorrhagic fevers to compare with CCHF. In Lassa fever little is known about the immune 
control of acute infection and recovery has not been shown to correlate with IgG production 213, 
with neutralizing antibodies only detected after clinical recovery 214. This is consistent with 
animal model data such as a study of Lassa fever in cynomolgus macaques by Baize at al 215, that 
failed to detect neutralising antibodies in up to month after infection in survivors. They did 
however notice that LV-specific IgM and IgG appeared at earlier stage in survivors.  
In EVD data is also limited but IgM antibodies have been shown to appear as early as 2 days 
after the onset of symptoms, with variable results up to day 9, that then last for up to 30-168 
days. IgG antibodies have been shown to develop between day 6-18 and persist for several 
years 216,217. Baize et al 218 compared the immune responses of fatal and survivor cases of EVD 
from two outbreaks in 1996 in Gabon. In survivors, early and increasing titres of IgG, directed 
mainly against the nucleoprotein and the 40-kDa viral protein, were followed by clearance of 
circulating viral antigen and activation of cytotoxic T cells. In contrast, fatal infection was 
characterized by impaired humoral responses, with absent specific IgG and barely detectable 
IgM.  
In dengue, IgM also shown to persist for prolonged period of time 219, that may be useful for 
serological surveillance as the viremia is short lived. In practice if patients present after 7 days, 
confirmation relies on serodiagnostic tests. ELISAs are widely available and frequently utilised; 
however, a single positive dengue IgM result is only considered to indicate a probable case, with 
seroconversion of IgM or a fourfold increase in IgG antibody titres in paired acute and 
convalescent serum specimens is required for confirmation. Blacksell et al 220 conducted a meta-
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analysis of 11 studies evaluating dengue IgM. The sensitivity and specificity of samples taken up 
7 days were shown to be 73% and 88% respectively, compared to later samples (7-10 days) with 
sensitivity 96% and specificity of 90%. 
In summary this data is in accordance with previous data sets reported but has evaluated CCHF 
antibody responses in much greater depth. It is broadly similar to that reported in EVD with 
early IgG responses, and persistence of IgM response seen in dengue. The evaluation of the 
antibody responses in CCHF utilising the Vectorbest kit, is the most detailed and complete 
undertaken to date and provides important insights into timing and progression of IgM/IgG 
responses to CCHFV. This will provide important data to the WHO CCHF R&D Blueprint that has 
identified the qualification of commercial IgM and IgG serological tests using panels of well- 
characterised clinical samples by 2020 as landmark goal.  
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Chapter 6 ROTEM Thromboelastography. 
6.1 Introduction 
Haemorrhage frequently occurs in CCHF and early severity scoring systems 27 reported that 
platelet counts <20 x 109/L, activated partial thromboplastin time (APTT) of greater than 60s or 
fibrinogen <1.1g/L in the first 5 days of illness were >90% predictive of a fatal outcome 143. Later 
scoring systems also incorporated haematological markers and clinical parameters of bleeding 
152,154. In severe disease haemorrhage typically develops after 3-6 days of illness 142 and rates of 
haemorrhage in Turkey are around 20% 152. Petechiae, ecchymoses, epistaxis and bleeding from 
the gastrointestinal, genitourinary and respiratory tracts are the most common haemorrhagic 
manifestations 180 and have been shown to be associated with a poor clinical outcome 147,148. 
The evolution and pathogenesis of coagulopathy of viral haemorrhagic fevers are poorly 
understood and there are few data about the coagulopathy of CCHF. Protein S and protein C 
levels, activated protein C resistance and D-dimer levels were not associated with mortality in 
one study of 83 patients with CCHF 190. Thrombocytopenia and platelet dysfunction have been 
demonstrated in Lassa fever 168,184,221 and in Ebola virus disease 204.  
Traditional screening coagulation tests such as APTT were first developed whilst discovering the 
coagulation cascade 222, and provide information about coagulation factor deficiencies, but not 
about the full haemostatic capacity of clot formation, thrombin generation, platelet number 
and function, or fibrinolytic activation. They also have a laboratory turnaround time that can 
delay therapeutic interventions. Rotational thromboelastometry (ROTEM) is a near-patient 
assay giving a global haemostatic picture, in that it can give information on all haemostatic 
parameters. It is derived from a technique that was first developed in the 1940’s, and analyses 
three phases of coagulation (initiation, amplification, and propagation), reflecting the 
interactions of the cellular and plasma components of coagulation and the activity of the 
fibrinolytic system 223. A whole blood sample is placed in a cuvette and a cylindrical pin 
immersed, maintaining a gap bridged by the blood. The pin is rotated and, as the blood begins 
to clot, its movement is restricted and the changes in mechanical kinetics that result can be 
plotted to generate typical curves (TEMogram) and numerical parameters (Figure 6.1).  
ROTEM values have been used to detect and manage coagulopathy in haemorrhagic disorders 
including trauma, post-partum haemorrhage, intensive care, and surgery including liver 
transplantation. The National Institute of Clinical Excellence (NICE) in the UK has recommended 
its use during cardiac surgery as it has been associated with improved clinical outcomes 
222,224,225. ROTEM analysis of a cohort of 53 patients with dengue demonstrated significant 
impairment in thromboelastometry values 226. A similar technique, thromboelastography (TEG) 
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was undertaken on two cases of Ebola virus disease in the UK 227, showing evidence of a 
coagulopathy, followed by hypercoagulability on recovery.  
 
Aim  
The aim of this study was to undertake ROTEM analysis alongside conventional coagulation 
testing in a cohort of patients with CCHF to increase understanding of the coagulopathy. 
 
Figure 6.1  ROTEM® thromboelastometry parameters and scaling (from www.rotem.de)  
6.2 Methods  
Study Design 
Prospective observational cohort study. Demographic, clinical and laboratory data were 
collected from patients consecutively admitted with confirmed CCHF in hospitals in Samsun and 
Tokat, Turkey, between May and August 2015. Blood samples for ROTEM analysis were drawn 
during the course of hospital admission, and in convalescence (day 14-30). As previously 
described all participants had CCHF severity assessment undertaken by Swanepoel criteria 143, 
severity grading score (SGS) 152 and severity scoring index (SSI) scoring systems 154(Table 1.6). 
Patients were given blood products according to clinician assessment and recorded daily. 
Blood sampling 
Routine haematology variables were analysed using automated analysers in local ISO / IEC 
17025 and ISO 15189 standard accredited laboratories. The normal ranges for Prothrombin time 
(PT) and APTT were 11-15 and 27-45 seconds respectively. Standard ROTEM analysis was 
performed on 3.2% citrated whole blood using a ROTEM delta point of care analyser (Tem 
International, Germany) according to the manufacturer’s instructions, less than 2 hours after 
106 
 
blood draw. Single use EXTEM S and FIBTEM S assay reagents were used with an automated 
pipette for standardised volumes. Analysis was performed inside a Class 2a BSC, with the 
operator wearing personal protective equipment. EXTEM S screening was used which gives 
information on clot formation particularly through the extrinsic pathway and FIBTEM S which 
isolates coagulation and provides information on the contribution of fibrinogen to clot firmness. 
The following EXTEM (S) variables were recorded (normal range): Clotting time (CT, time from 
start of the measurement until initiation of clotting - 38-79 seconds); Clot formation time (CFT, 
time from initiation of clotting until a clot firmness of 20 mm is detected- 34-159 seconds); 
Amplitude at 10 minutes after CT (A10, clot firmness 10 mins after clot initiation - 43-65mm); 
Maximum clot firmness (MCF, clot firmness/ overall clot stability - 50-72mm); Maximum lysis 
(ML, >15% at 1 hour). The following FIBTEM S variables were recorded: A10 (7-23mm); and MCF 
(9-25mm).  
Statistical Analysis 
Descriptive analyses are reported as frequencies (proportions) for categorical variables and 
means (standard deviation or 95% confidence interval (CI)) or medians (ranges) as appropriate 
for continuous variables. Categorical variables were compared between sub-groups with the 
Fisher exact test. Continuous variables measured at admission were compared using Student t-
tests or the Mann-Whitney U-test/Kruskal-Wallis test as appropriate. Continuous variables 
measured longitudinally were compared using linear regression models with robust standard 
errors and adjustment for clustering of measures within patients. No imputation for missing 
data was made due to small sample sizes. Hypothesis tests were two-tailed (p<0·05) and 
analyses were performed using the SPSS (version 24) and Stata (version 14) computer packages. 
6.3 Results  
6.3.1 Demographics and sampling  
During the study period 65 patients with confirmed CCHF were recruited, with 49/65 (75%) 
graded mild illness severity and 2/65 (3.1%, 95%CI 0.4% - 10.7%) cases having a fatal outcome. 
Demographic information is detailed in Table 6.1. In total, 212 ROTEM analyses (EXTEM S n= 
107, FIBTEM S n= 105) were performed. In 45/65 participants, baseline ROTEM analysis was 
undertaken within 48 hours of admission, of whom 31/45 (69%) were graded mild illness 
severity. Of the remaining 20/65, 14/20 had ROTEM analysis after this time point (48hrs) during 
acute admission and 6/20 only at follow-up during convalescence. In total 110 blood samples 
were analysed and grouped by day of illness: day 0-3 (n=27); day 4-6 (n=46): day 7-10 (n= 25); 
and convalescence (n=12, median 21 days after onset of illness, IQR 17-30 days).  
6.3.2 Clinical features and case management 
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Haemorrhage occurred in 13/65 (20%, 95%CI 11.1-31.8%) participants, who had a total of 25 
days of haemorrhage during 424 days of study observation. The site of bleeding was: oral 
(7/13); nasal (7/13); sputum (3/13); vomit (2/13); stool (2/13); intravenous puncture sites 
(2/13); vaginal (1/13); urine (1/13) and skin (1/13). Thirty-five participants developed platelet 
counts <50 x 109/L during admission (35/65, 54%), with 11/65 (17%) having a platelet count <20 
x 109/L.  
Fresh frozen plasma was administered to 15/65 (23%) participants, red cell concentrates to 
8/65 (12%) and platelet transfusion to 21/65 (32%) participants. Eleven of 13 (84.6%) patients 
who developed haemorrhage had received blood component therapy prior to the onset of 
bleeding. At the time of bleeding (25 patient admission days), median platelet count was 44 x 
109/L (range 4-152 x 109/L), median PT 13 seconds (range 11-38 s, 23/24 within normal limits) 
and median APTT was 48 seconds (range 22-85 s, 10/24 within normal limits). At the time of 
bleeding vital signs were within normal limits for 17/25 participants, with only one having a 
qSOFA score ≥2 and national early warning score (NEWS) >3 (0-4 no action). NEWS score of >3 
was utilised as oxygen saturations were not routinely available. Ribavirin treatment was given to 
35/65 (54%) participants at standard dosing. 
6.3.3 ROTEM at admission 
Haematological parameters on admission (n=45) are shown in Table 6.2. Those with 
moderate/severe disease had significantly lower platelet counts (p<0.001) and more prolonged 
APTT (p<0.001). ROTEM analysis at admission demonstrated significant differences in all EXTEM 
S parameters by disease severity, with CT, A10, CFT and MCF all having more abnormal values in 
the moderate/severe group when compared to the mild group (Table 6.2, Figure 6.2). There was 
no evidence of hyperfibrinolysis (EXTEM S LI60 >15%) at 60 minutes (0/44). There were 
significant correlations between maximal clot firmness, clot formation time and A10 with 
platelet count (p<0.0001). PT and APTT both correlated with clotting time (p<0.0001) (Figure 
6.4). Importantly for a disease thought to be associated with disseminated intravascular 
coagulation, there were no significant differences in FIBTEM S A10 or MCF between the disease 
severity groups. 
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 All  
(n=65) 
Mild   
(n=49) 
Moderate/ 
severe      
(n=16) 
 p-value 
Gender (%):                           
- Male 
- Female  
 
40 (61.5) 
25 (38.5) 
 
31 (63.3) 
18 (36.7) 
 
9 (56.3) 
7 (43.7) 
 
 
0.77 
Age (years)  
- Mean (SD) 
 
53 (15.6) 
 
53.9 (16.6) 
 
50.3 (11.8) 
 
0.43 
Tick bite (%): 
- Yes 
- No  
 
45 (69.2) 
20 (30.8) 
 
36 (73.5) 
13 (26.5) 
 
9 (56.3) 
7 (43.7) 
 
 
0.22 
Mode of admission (%): 
- Direct 
- Hospital transfer 
 
56 (86.2) 
9 (13.8) 
 
44 (90.0) 
5 (10.0) 
 
12 (75.0) 
4 (25.0) 
 
 
0.21 
Time from symptom onset 
to admission (days) 
- Median (range) 
 
2 (0-7) 
 
3 (1-8) 
 
4 (1-8) 
 
0.07 
Length of admission (days) 
- Median (range) 
 
8 (2-16) 
 
8 (3-16) 
 
8 (2-11) 
 
0.45 
Fatal outcome (%): 
- Yes 
- No 
 
2 (3.1) 
63 (96.9) 
 
0 (0) 
49 (100) 
 
2 (12.5) 
14 (87.5) 
 
 
0.06 
Haemorrhage during 
admission (%): 
- Yes 
- No 
 
 
13 (20.0) 
52 (7.0) 
 
 
7 (14.3) 
42 (85.7) 
 
 
6 (37.5) 
10 (62.5) 
 
 
 
0.07 
Blood product replacement 
(%): 
- Platelets 
- Fresh frozen 
plasma 
- Red Blood cells 
 
 
21 (32.3) 
15 (23.1) 
 
8 (12.3) 
 
 
13 (26.5) 
7 (14.3) 
 
3 (6.1) 
 
 
9 (56.3) 
9 (56.3) 
 
5 (31.3) 
 
 
0.03 
0.002 
 
0.02 
Ribavirin treatment (%): 
- Yes 
- No 
 
35 (53.8) 
30 (46.2) 
 
23 (47.0) 
26 (53.0) 
 
12 (75.0) 
4 (25.0) 
 
 
0.08 
 
Table 6.1 Demographics, clinical features and treatment characteristics of CCHF cases with 
ROTEM analysis  
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Table 6.2  Haematology and ROTEM data at admission(<48hrs) by severity (total n=45). * 
indicates 28 patients in mild and 13 patients in moderate/severe groups with admission 
PT/APTT results 
ROTEM parameter All                 
(n=45) 
Mild              
(n=31) 
Moderate/seve
re (n=14) 
P-value 
Platelets 
Median (range) 
 
73 (4-162) 
 
90 (46-166) 
 
46 (4-108) 
 
<0.001 
WBC 
Median (range) 
 
2400 (740-
28300) 
 
2350(740-5310) 
 
2450 (850-
28300) 
 
0.741 
Prothrombin time (s) 
Mean (SD) * 
 
14.0 (4.4) 
 
13.1 (2.1) 
 
15.8 (7.0) 
 
0.076 
APTT 
Mean (SD) * 
 
38.3 (13.8) 
 
32.8 (6.7) 
 
49.9 (17.8) 
 
<0.001 
Haemoglobin 
Mean (SD)  
 
13.5 (2.1) 
 
13.8 (1.8) 
 
12.7 (2.6) 
 
0.103 
EXTEM S CT (s) 
Median (range) 
38-79 (number) 
>79 (number) 
 
59 (42-164) 
42 
3 
 
56 (42-81) 
30 
1 
 
68.5 (48-164) 
12 
2 
 
0.01 
EXTEM S A10 (mm) 
Mean (SD) 
43-65 
<43 
 
41.6 (9.1) 
19 
26 
 
45.1 (7.0) 
17 
14 
 
33.9 (8.6) 
2 
12 
 
<0.001 
EXTEM S CFT (s) 
Median (range) 
34 - 159 (normal range) 
160 - 220 (usually unimpaired 
haemostasis with reduced reserve) 
221 - 300 (bleeding risk) 
300 - 400 (high bleeding risk) 
>400 (usually no effective 
haemostasis) 
 
165 (72-418) 
20 
17 
 
6 
0 
2 
 
147 (72-255) 
16 
13 
 
2 
0 
0 
 
197 (98-418) 
4 
4 
 
4 
0 
2 
 
0.006 
EXTEM S MCF (mm) 
Mean (SD) 
>50 (normal range) 
46-49 (usually unimpaired 
haemostasis with reduced reserve) 
40-45 (bleeding risk) 
30-40 (high bleeding risk) 
<30 (usually no effective 
haemostasis) 
 
51.5 (10.1) 
24 
12 
 
6 
2 
1 
 
54.4 (7.2) 
21 
7 
 
3 
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Figure 6.2 Box and whisker plots of haematology, coagulation and ROTEM findings at admission 
(n=45) stratified by CCHF disease severity. Boxes represent median, 25th and 75th centiles. 
Whiskers represent maximum and minimum values. Dotted lines represent upper (PT, APTT, CT, 
CFT) and lower limits (platelets, A10, MCF) of normal.   
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Among the patients with EXTEM S CFT measurements that demonstrated increased bleeding 
risk (CFT >221s), 16/25 (64%) had platelet counts >20 x 109/L and 5/25 (20%) had counts >50 x 
109/L. Of the patients with EXTEM S MCF measurements demonstrating bleeding risk (MCF < 
40mm), 15/24 (62.5%) had platelet counts >20 x 109/L and 3/25 (12%) had counts >50 x 109/L,  
again suggesting that the platelet count was not the determining factor of bleeding risk.   
6.3.4 ROTEM changes according to day of illness  
There was no significant difference in CT by day of illness (p=0.68). EXTEM S A10 and MCF 
analysis was different by day of illness, with lowest values occurring on days 4-6 (p=0.090 and 
p=0.024 respectively). There was no significant difference in EXTEM S LI60 by day of illness, with 
no abnormal results. FIBTEM S A10 showed significant differences by day of illness in acute 
samples with Days 0-3 and 4-6 having lowest values (p=0.003), but only 1/93 FIBTEM values was 
lower than normal (<7s). FIBTEM S MCF was also lowest on days 0-3 and 4-6 (p=0.082). All 
EXTEM S and FIBTEM S parameters were within normal ranges in convalescence (n=12). There 
were significant differences between EXTEM S acute and convalescent CT (p=0.013), A10 
(p<0.001), CFT (p<0.001) and MCF (p<0.001) values but no significant differences in FIBTEM S 
between acute and convalescent samples (Table 6.3).  
A typical case of CCHF with ROTEM data, standard haematology/coagulation parameters and 
TEMOGRAMs is displayed in Figure 6.3. Two fatal cases of CCHF were included in the study. The 
first case was a 69-year old male who had no episodes of bleeding, normal ROTEM parameters 
and died due to a hospital acquired infection. The second case was a 52-year old female who 
presented on day 4 of illness and then rapidly developed septic shock with minor bleeding from 
the oral mucosa, nose and intravenous access sites. Bloods results at admission were: aPTT 
=120 secs; PT= 40 secs; platelets = 28 x 109/L. ROTEM values at admission were grossly 
abnormal: EXTEM S CT 164 secs; A10 = 33 mm; CFT=240 secs; MCF 46mm; LI60 <15% (no 
evidence of hyperfibrinolysis); FIBTEM A10 = 7mm; and MCF = 7mm. She progressed to multi-
organ failure, dying within 36 hours of admission, despite ribavirin treatment. She received 2 
units of platelets and 6 units of FFP on each days of admission 
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Figure 6.3  Illustrative case with serial ROTEM analysis: Case history: 30-year old male admitted 
3 days after a tick bite with a 1-day history of fever, lethargy, headache and anorexia. He 
developed gingival bleeding on day 7 and 8 of illness and was discharged on day 11 of illness. He 
did not receive any blood products during admission. a) Haematology and coagulation 
parameters. b) ROTEM EXTEM S parameters by day of illness c) EXTEM S TEMOGRAM at day 6 
of illness. d) ROTEM EXTEM S TEMOGRAM at day 10 of illness. 
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Figure 6.4  ROTEM and conventional coagulation testing correlations (all ROTEM timepoint 
measurements). P value from Pearson correlation.    
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6.4 Discussion  
Crimean-Congo haemorrhagic fever is major emerging infectious threat and, although ribavirin 
is frequently utilised, the mainstay of case management is supportive care. Haemorrhage 
frequently occurs in severe disease and traditional laboratory tests (PT/APTT) do not show 
dramatic changes. This suggests that the coagulopathy seen in patients with CCHF is not due to 
disseminated intravascular coagulation (DIC) but may lie in areas not measured by conventional 
coagulation testing, such as a defect in platelets or fibrinolysis. This study is the first to 
investigate the use of a global haemostasis test, ROTEM, alongside conventional coagulation 
testing in CCHF, demonstrating that using ROTEM is feasible and can provide safe, rapid point of 
care results. 
The analysis of this large cohort of patients in Turkey gives new insights into the aetiology and 
natural history of the coagulopathy in CCHF. Patients presented after a median of two days 
illness had a median platelet count of 73 x 109/L, with mean PT and APTT of 14 s and 38.3 s 
respectively, i.e. both coagulation tests were within the normal range of values, yet patients had 
a bleeding tendency. On admission most patients (42/45) had normal EXTEM S clotting times 
(CT), showing that initiation of clotting, thrombin formation and the start of clot polymerisation 
was not significantly abnormal in most cases at this point. In contrast, EXTEM S CFTs were 
abnormal in most cases at admission. CFT represents the time from initiation of clotting until a 
clot firmness of 20 mm is detected and elevated results indicate problems with fibrin 
polymerisation and stabilisation of the clot with Factor XIII and platelets. In the face of normal 
or slightly deranged APTT/PT, this points to a platelet and/or Factor XIII defect. 
In keeping with the CFT results the MCF was abnormal in 21/45 patients on admission and was 
very deranged in 9/45. MCF represents the firmness of the clot, with abnormal values indicating 
reduced stabilisation of the clot by the polymerised fibrin, platelets and Factor XIII. Activation of 
fibrinolysis can be discounted as there was no significant reduction in MCF/clot lysis. In FIBTEM 
S, coagulation is activated as in EXTEM S but the addition of cytochalasin D, an antiplatelet 
agent, blocks the effects of platelets. The resulting clot formation therefore depends only on 
fibrin formation and fibrin polymerisation and this mainly relates to fibrinogen levels. The 
results show that the vast majority of patients at admission had normal FIBTEM S A10 (42/43) 
and MCF (41/43), indicating normal fibrinogen levels. In DIC there is consumption of coagulation 
factors with the formation of small thrombi throughout the vasculature leading to end organ 
failure. A key finding in DIC is the presence of hypofibrinogenaemia. The absence of significantly 
low fibrinogen levels or of activation of fibrinolysis are not in keeping with DIC.  
A reversible coagulopathy was discovered in those who survived CCHF. Combined data from 
acute samples showed significant differences in all EXTEM S fields compared to those in 
116 
 
convalescent samples taken post discharge in a subset of survivors, which showed ROTEM 
results within normal ranges. When acute samples were stratified by day of illness, days 4-6 had 
the most abnormal values, indicating that this is the major coagulopathic period in CCHF with 
respect to a patient’s ability to generate stable clots. Although there was no significant 
difference in median CT values, the highest percentage of abnormal CT results was also found in 
days 4-6. This is consistent with previous reports and consensus that patients with severe CCHF 
begin to haemorrhage in days 3-6. 
In summary, these studies have demonstrated that a coagulopathy develops during CCHF 
infection, that is not associated with a major coagulation defect, as evidenced by only minor 
changes in PT, APTT, and ROTEM clotting time and FIBTEM. Importantly, ROTEM has shown no 
evidence of hyperfibrinolysis. Such a defect could be due to either Factor XIII deficiency or a 
platelet dysfunction, to account for the bleeding and the defect in clot firmness. Factor XIII 
merits further investigation but is unlikely to be the cause of the bleeding defect. The clinical 
pattern of bleeding is also in keeping with a platelet defect, as bleeding was predominantly 
from mucous membranes. This was not simply due to thrombocytopenia either, as most 
patients had platelet counts greater than 50 x 109/L and such counts are not usually associated 
with spontaneous bleeding.  
Platelet dysfunction has been demonstrated in other viral haemorrhagic fevers, particularly by 
Cummins et al, who found a clear platelet function defect using platelet aggregometry in both 
Lassa and Argentinian HFs 184,228. They may have similar pathogenic pathways as acute severe 
viral infections that produce similar patterns of bleeding. There is a small possibility that the 
platelet defect is due to a change in von Willebrand factor, possibly through loss of large 
molecular weight forms. This is unlikely, as this is usually either due to high shear stresses or an 
antibody against von Willebrand factor and has never been seen associated with a viral disease. 
This study excludes DIC as the cause of the bleeding defect in all patients at presentation with 
CCHF. In DIC there is a consumptive coagulopathy associated with low platelet counts (which 
were found), low FIBTEM values and prolonged PT and APTT, with prolongation of CT, all 
reflecting low coagulation factors: these were not found in this study. However, as highlighted 
by the second fatal case of CCHF described, DIC can occur in fatal cases of CCHF with multi-
organ failure. 
A limitation of the study is that less patients with severe/fatal disease were recruited than 
expected, but it demonstrated that the coagulopathy occurred in those graded with mild 
disease. The clinical and laboratory data are consistent with larger cohorts in Turkey in which PT 
prolongation occurred in only 14/404 patients and APTT >70 seconds was found in 15/404 
patients 152. CCHF severity scores were developed to predict mortality and have been validated 
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in Turkish healthcare settings where there is access to good supportive care and blood 
transfusion. In this study some participants had data missing at admission for severity score 
calculation and this potentially risked underscoring some participants. However, imputation in 
with maximum/minimum scores did not change the severity grouping of most participants or 
alter the significance of the results. Prognostic scoring at baseline is challenging and existing 
scoring systems require laboratory variables which are not routinely available in all settings. In 
routine practice, simple parameters such as a platelet count <50 x 109/L is used as the trigger 
for referral to tertiary centres, indicating more severe disease, increased likelihood of 
haemorrhage and the possible need for intervention with blood transfusion 160.   
Although prospective, given the observational nature of the study it is not appropriate to 
analyse data stratified by subsequent ribavirin use. For similar reasons it is not possible to 
analyse the data on blood component therapy use in relation to ROTEM parameters in this 
study. The decision to use blood components was up to the treating clinicians with resulting 
variability in practice. ROTEM analysis was also not routinely undertaken at specific time points 
after transfusion to allow evaluation of effect on haemostasis, and this should be evaluated in 
future studies. A limitation of ROTEM is that it does not reflect what happens in the blood 
vessels due to its lack of being able to reproduce the endothelium. Serial daily ROTEM analysis 
of all cases would provide more complete data, but this study was limited by the practical 
challenges of time required for analysis, high caseloads and safety considerations. Earlier 
recruitment of patients during the illness course would have provided more data on the 
progression of the coagulopathy, but was constrained by delays in patient presentation and the 
time required for participant recruitment/informed consent.  
The management of CCHF is challenging due to limited therapeutics available and its 
appreciable mortality. This ROTEM and conventional coagulation analysis has demonstrated 
that CCHF-related coagulopathy is predominantly related to clot development/stabilisation that 
is most marked during days 4-6 of the illness and in severe disease. In the context of 
normal/only slightly deranged coagulation screens and FIBTEM results, and combined with the 
absence of hyperfibrinolysis, this study provides the first evidence that the initial coagulopathy 
in CCHF probably relates to platelet dysfunction. Further studies are required to confirm these 
findings and look at possible mechanism(s). 
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Chapter 7: Cytokine changes in CCHF  
7.1 Introduction    
Following CCHFV infection the innate immune system comprising cellular and humoral 
responses act ‘quasi-automatically’ to generate an inflammatory response 70,71,229. The key cells 
involved are monocytes/macrophages, neutrophils, eosinophils, basophils and natural killer 
cells. These leucocytes are activated by binding of pathogen-associated molecular patterns 
(PAMPs) molecules from CCHFV, or damage -associated molecular patterns (DAMPs) from 
necrotic cells, to pattern recognition receptors (PRRs). PRRs include Toll-like receptors (TLRs)s, 
nucleotide-binding oligomerization domain-like (NOD-like) receptors, retinoic acid-inducible 
gene-I-like receptors (RIG-I-like) and C-type lectin receptors 70. TLRs are the best studied and 
trigger a cascade of activation generating release of inflammatory cytokines.  
7.1.1 Cytokine pathogenesis 
Cytokines are a broad category of small proteins involved in cell signalling, that have a broad 
range of functions including immunomodulatory roles. They can be divided into several 
categories: interleukins; chemokines; interferons; tumour necrosis factor; and growth factors 
70,111. A tightly regulated cytokine network is crucial for elimination of invading pathogens and 
restricting excessive tissue damage 112,113, and sepsis has been shown to develop when this 
initial host response becomes amplified and deregulated 114–117. Release of inflammatory 
cytokines induces new cytokine production and release, and this ‘cytokine storm ‘ or ‘cytokine 
cascade’ is likely to be responsible for the many diverse and local effects of the ‘sepsis 
syndrome’ 70. This has been demonstrated in a range of viral and bacterial infections, and was 
recently emphasised in the context of avian influenza 118. Numerous pro-inflammatory cytokines 
have been identified during sepsis with IL-1β, IL-6, IL-12, and IL-17 being of crucial importance. 
However despite significant progress in the research of sepsis utilising the ‘omics’ (genomic, 
proteomic, metabolomic and transcriptomic approaches), therapeutic clinical trials targeting 
cytokines and the immune response in sepsis have failed 70. The failure of immunomodulatory 
trials and the current lack of clear understanding about the organisation of host response 
reflects the fact that patients with sepsis are not a homogeneous group. Patients have different 
pathogens, presentations and levels of severity that make direct comparisons of 
pathophysiology and clinical trials focussed on immune response modification challenging.  
7.1.2 Cytokines in viral haemorrhagic fevers/CCHF 
A common pathogenic feature of VHFs is the ability of the virus to disable the host immune 
response by attacking and manipulating macrophages and dendritic cells. In severe cases of 
CCHF, it has been suggested that this, combined with the deregulation and excessive pro-
inflammatory cytokine release, leads to toxic endothelium effects, increased vascular 
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permeability, multi-organ failure and shock 87. A significant number of studies have evaluated 
the role of cytokines in CCHF, most frequently through analysis of baseline admission samples 
and direct comparison of severity groups or fatal/non-fatal disease. The majority of the 18 
studies are from Turkey (14/18), with the largest study including 80 patients. Few have 
presented longitudinal data; one study of 31 patients evaluated a panel of 4 cytokines daily for 
7 days, demonstrating that IL-6 and TNF-α were consistently higher in fatal cases. Another 
recent study of 52 patients evaluated a panel of cytokines every 3 days (119 samples in total), 
demonstrating that IL-6, IL-8, IL-10, IL-10/ 12, IFN-γ, MCP-1, and MIP-1β were higher in patients 
with CCHF than controls, and that IL-6 and IL-8 were higher in the first 5 days of illness in fatal 
cases. Evaluation of the data from these studies broadly demonstrates the that high serum 
levels of pro-inflammatory cytokines, particularly IL-6 and TNF-α, have been implicated as 
negative prognostic factors in CCHF and other VHFs 97,98,119,121–124. IL-10 is an anti-inflammatory 
cytokine that has also been shown to be higher is severe/fatal disease in some CCHF studies 
119,123,125, but this was not reproduced in other studies 120,126. IL-12 production has demonstrated 
a mixed picture when assessing CCHF severity and comparing patients versus controls 97,121,126. 
Other studies investigating endothelial adhesion mediators have shown VCAM-1 and sICAM-1 
to be higher in severe cases 127,128, and other markers of endothelial dysfunction to be higher in 
haemorrhagic cases 129.  
Overall the ability to draw prognostic inferences from these studies is usually limited by 
retrospective design, incomplete data sampling, small study numbers and the evaluation of 
cytokines at only one time point. Patients with CCHF present at different stages of illness and 
whilst baseline evaluation of cytokines may be useful to guide incorporation of these variables 
into prognostic severity scores, larger longitudinal studies are required to provide greater 
insights into the dynamic host immune response over time. Sample integrity for cytokine 
measurement is also important, and benefits from early processing and storage in ultra-low 
freezers. Repeated freeze-thaw cycles of legacy samples taken in different outbreaks may affect 
cytokine results and the ability to draw clear and valid conclusions. The ability to us multiplex 
assays in extremely beneficial due to the number of potential cytokines involved, the ability to 
use multiplex assays is extremely beneficial, but in common with other assays is technically 
difficult due to the highly pathogenic nature of VHFs.  
Aims of cytokine analysis  
1. Investigate the host immune response to clinical infection through serial measurement of 
cytokine/chemokine levels and quantitative serological response, related to disease severity 
and clinical outcomes. 
120 
 
2. Test the hypothesis that severe/fatal CCHF is associated with a deregulated cytokine network 
characterised by an exaggerated pro-inflammatory cytokine response (IL-1β, IL-6, IL-8 and 
tumour necrosis factor alpha [TNF-α], and reduced IL-12 
7.2 Methods  
After participant recruitment blood samples for multiplex cytokine analysis were taken daily 
from patients with confirmed CCHF, during their acute admission and at 14 and 30 days after 
onset of clinical disease. Blood was drawn into serum gel tubes, centrifuged and then serum 
removed and aliquoted into cryovials before storage at -700C. Priority for sample processing 
was given to serum samples and the time period from daily blood draw to freezing of serum 
was less than 4 hours. Samples were then transferred to PHE Porton at -700C. A commercial 
human 19-plex luminex kit was used and the assay was performed according to the 
manufacturer's instructions (Millipore,Watford, UK). All samples were run in duplicate. 
Luminex staining  
1. The wells of the 1.2-μmfilter membrane 96-well microtiter plates were pre-wetted with 
assay buffer. 
3. 25 μl of sample, standard and quality control preparations were added to the relevant 
wells and incubated with pre-mixed microbeads for 2h on an orbital plate shaker at 
room temperature. 
4. The plates were washed twice with assay wash buffer and 25 μl biotinylated detector 
antibody added per well.  
5. Samples were incubated for 1h at room temperature on the plate shaker. Without 
washing, 25 μl/well streptavidin–phycoerythrin solution was added, and plates 
incubated for a further 30min at room temperature on a plate shaker, protected from 
direct light. 
Microbead fixation and analysis of results  
1. After completion of staining, the microbeads were washed twice with assay wash 
buffer. 
2.  Beads were then left overnight (17h) with 100 μl/well of 10% formalin. 10% formalin 
was made by diluting 100% formalin (40% w/v formaldehyde solution) (Scientific 
Laboratory Supplies, Nottingham, England) 1:10 with PBS. 
3. Before analysing, microbeads were washed twice in assay wash buffer and 
resuspended in 100 μl/well of luminex sheath fluid. 
Analysis of results 
1. The luminex assay was acquired on a luminex-200™ instrument using Exponent 
software (Invitrogen, Paisley, England).  
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2. An acquisition gate of between 8000 and 13,500 was set to discriminate against any 
doublet events and ensure that only single microbeads were measured. 
3.  50 events per region were collected and the median fluorescence intensity (MFI) 
measured. 
4.  MFI were converted to concentrations using results from a standard cytokine 
preparation.  
5. The cytokine standard was diluted 1:4 with a starting concentration of 10,000 pg/ml, 
giving a lower limit of detection of 3.2 pg/ml. 
 
7.3 Results - analysis and stratification of cytokine results  
Cytokines were analysed at admission, daily across the course of acute admission and during 
follow-up in convalescence. Means (standard deviation or 95% confidence interval (CI)) or 
medians (interquartile ranges) were utilised as appropriate for continuous variables, with 
distribution tested for normality by the Kolmogorov-Smirnov and Shapiro-Wilk Tests. 
Continuous variables measured longitudinally were compared using linear regression models.  
Log-transformed viral load data and cytokines levels were compared by Pearson correlation 
analysis. Heatmaps were generated using Morpheus software 
(https://software.broadinstitute.org/morpheus/). No imputation for missing data was made 
due to small sample sizes. Hypothesis tests were two-tailed (p<0·05) and analyses were 
performed using the SPSS (version 24). CCHF cases were stratified for cytokine comparison 
according to disease severity at baseline, lowest platelet count during admission (plts <50 x 
109/L or >50 x 109/L), haemorrhage during admission and outcome.  
 
1. Cytokines at admission vs 30-day cytokine levels  
2. Cytokines at admission by severity (mild vs moderate/severe disease) 
3. Cytokines at admission by lowest platelet count (platelet count <50 x 109/L or >50 x 
109/L) 
4. Cytokines at admission by outcome 
5. Serial cytokines : all; severity (mild vs moderate/severe); platelet count (plts <50 x 109/L 
vs > 50x 109/L); and haemorrhage. 
6. Linear regression: all; severity (mild vs moderate/severe); platelet count (plts <50 x 
109/L vs >50 x 109/L); and fatal/survived 
7. Correlation cytokines and CCHF log viral load. 
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No.  Cytokine  Produced by Function 
Pro-Inflammatory  
1. IL-6 
Interleukin-6  
T cells 
Macrophages 
ICAM/VCAM upregulated on endothelial cells 
Upregulates M-CSF receptor expression 
Can increase Il-10 expression 
Inhibits TNF-α and IL-1 
2. IL-1Β  
Interleukin-1b 
(catabolin) 
Macrophages 
Monocytes 
Endothelial cells  
Induces synthesis of IL-6, IL8. MCP-1 
 
3. TNF-α  
Tumour necrosis 
factor alpha  
Macrophages mainly  
T and B Cells 
Monocytes 
Mast cells 
NK cells 
Endothelial cells 
Induces synthesis of IL-1, IL-6 
Stimulate acute phase proteins 
Activates endothelial cells and neutrophils 
4. IFN-γ 
Inteferon-gamma 
T cells 
NK cells  
Activates macrophages, cytotoxic t cells and NK 
cells 
Increase differentiation of Th1 lymphocytes  
Increase class 1 and II MHCs 
Regulated by IL-12/IL-18 
Inhibited by IL-4/IL-10 
5. IFN- α2 
Interferon- a2  
 Activates NK cells 
Induces anti-viral state 
6. IL-17A Th2 cells  Induces synthesis of IL-6, GM-CSF, IL-B, TNF, IL-8, 
MCP-1 
7. IL-5 Th2 cells B-lymphocytes – proliferation and differentiation 
Eosinophils – proliferation and activation  
8. IL-2 T-cells Promotes clonal expansion of T and B lymphocytes  
NK cells proliferation and activation 
 
9. IL-12/p70 Dendritic cells 
Macrophages 
T-cell Stimulating factor  
stimulates IFN-γ and TNF-α release from T-cells  
Induces Th1 differentiation from naive T-cells 
Reduces IL-4 
Activates NK cells 
Also has anti-inflammatory /regulatory functions 
10.  IL-15  Similar to IL-2 
- Proliferation of T and B lymphocytes and 
NK cells   
11. G-CSF  
Granulocyte 
colony stimulating 
factor 
Endothelium  
macrophages 
Growth and differentiation of neutrophils 
12. GM-CSF 
Granulocyte 
macrophage 
Th- cells Growth and differentiation of monocytes and 
dendritic cells 
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Table 7.1 Cytokines/chemokines evaluated in the 19 plex panel 
  
colony stimulating 
factor 
Regulatory/anti-inflammatory cytokines  
13. IL-10  Th2 cells 
Macrophages 
Mast cells  
Cytotoxic t cells  
Key immuno-regulatory /anti-inflammatory 
cytokine  
Human cytokine inhibitory factor 
Inhibit synthesis of IFN-γ, IL-2, IL-3, IL-6, TNF-α, 
GM-CSF, Il-12and  IL-17 
14. IL-4  Macrophages 
Th2 cells 
Regulatory/ant-inflammatory  
Promotes proliferation of B and T cells  
Stimulates development and growth of 
differentiated Th2 cells from naïve Th cells 
Suppresses production of TH1 cells 
Increases expression of VCAM-1 and decreases E-
selectin 
Chemokines (pro-inflammatory) 
15 IL-8 /CXCL8 
chemokine 
Macrophages 
Endothelial cells 
Neutrophil chemotactic factor – promotes 
chemotaxis and degranulation  
 
16 IP-10/CXCL10 
Interferon-gamma-
inducible protein 
10  
Monocytes/macrophages, 
plus endothelial cells and 
fibroblasts 
Chemoattraction macrophages, T cells and NK 
cells 
17 MCP-1/CCL2 Monocytes/macrophages 
plus endothelial cells, and 
fibroblasts   
Monocyte chemoattractant protein  
Attracts monocytes, memory T-cells and dendritic 
cells 
 
18 MIP-1α/CCL3 
Macrocyte 
inflammatory 
protein alpha 
/chemokine ligand 
3 
Macrophages  Induce synthesis of IL-5, IL-6 and TNF-α,  
Pyrogen  
19 MIP-1β/CCL4 
Macrocyte 
inflammatory 
protein 
alpha/Chemokine  
ligand 4 
Lymphocytes  Chemoattraction of NK cells, monocytes  
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7.3.1 Cytokines at admission vs 30 days 
At admission 102/104 participants had cytokines levels measured and 60/104 participants 
attended follow-up at 30 days. There was no significant difference in age, sex or severity ratio of 
the 60 participants that attended follow-up in comparison to the 102 participants at admission. 
The distribution of all of the cytokine levels was significantly higher at admission compared to 
30 days part from in IL-17A, IL-1β, IL-2 and IL-5.  
 
Cytokine  
(pg/ml) 
Admission (n=102) 30 days (n=60) p-value 
G-CSF 83.3 (37.1-144.9) 21.2 (3.2-94.8) <0.0001 
GM-CSF 8.5 (4.8-15.5) 3.2 (3.2-8.6) 0.002 
IFN- α2 53.0 (18.0-133.0) 3.2 (3.2-3.3) <0.0001 
IFN-γ 17.5 (9.5-31.7) 6.7 (3.2-18.7) <0.0001 
IL-10 118.7 (38.7-288.9) 3.2 (3.2-4.6) <0.0001 
IL-12 3.2 (3.2-8.2) 3.2 (3.2-13.2) <0.0001 
IL-15 8.8 (4.1-20.1) 3.2 (3.2-3.2) <0.0001 
IL-17A 4.0 (3.2-9.5) 3.2 (3.2-15.8) 0.90 
IL-1β 3.2 (3.2-3.2) 3.2 (3.2-3.9) 0.42 
IL-2 3.2 (3.2-3.2) 3.2 (3.2-3.2) 0.87 
IL-4 3.2 (3.2-6.3) 3.2 (3.2-3.2) 0.004 
IL-5 3.2 (3.2-3.2) 3.2 (3.2-3.2) 0.39 
IL-6 9.6 (3.2-26.9) 3.2 (3.2-4.8) <0.0001 
IL-8 34.9 (21.3-73.0) 19.4 (7.0-29.5) <0.0001 
IP-10 8426.0 (4777.6-13835.0) 495.6 (273.2-741.4) <0.0001 
MCP-1 1435.1 (799.6-2688.7) 555.2 (429.4-756.0) <0.0001 
MIP-1α 18.5 (9.3-28.0) 7.6 (3.2-20.0) 0.0004 
MIP-1β 35.2 (25.4-58.4) 23.5 (12.8-39.2) <0.0001 
TNF-α,  24.5 (17.0-46.2) 9.1 (6.4-13.8) <0.0001 
 
Table 7.2 Cytokine levels (median/IQR) at admission and at 30 days after onset of symptoms. P-
values calculated by Mann-Whitney U Test with statistically significant results (p<0.05) 
highlighted in bold.   
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Figure 7.1 Cytokine levels at admission compared to 30 days after onset of symptoms. (Y axis 
pg/ml) Boxplots (whiskers 10-90th centile) with outliers. P-values calculated by Mann-Whitney 
U Tests.   
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7.3.2 Cytokines levels at admission by disease severity  
At admission cytokines were measured in 102/104 of participants at a median of 4 days (IQR 3-6 
days) after onset of symptoms. There were significant differences in the distribution of cytokine 
levels between mild and moderate/severe groups in GM-CSF (p=0.024), IL-10 (P<0.0001), IL-12 
(p=0.022), IL-17A (p=0.013), IL-8 (p=0.009) and IP-10 (p=0.015), with moderate/severe group 
demonstrating higher cytokine levels (Table 7.3, Figure 7.2).   
 
Cytokine 
(pg/ml) 
All 
(n=102) 
Mild 
(n=62) 
Moderate 
/severe 
(n=40) 
p-value 
G-CSF 83.3 (37.1-144.9) 82.1 (37.1-140.7) 90.1 (36.3-156.3) 0.542 
GM-CSF 8.5 (4.8-15.5) 7.1 (4.0-11.9) 11.7 (5.3-25.3)  0.024 
IFN-α2 53.0 (18.0-133.0) 57.4 (19.2-161.5) 42.3 (17.9-127.4) 0.548 
IFN-γ 17.5 (9.5-31.7) 13.6 (9.1-26.4) 20.6 (12.6-40.6)  0.044 
IL-10 118.7 (38.7-288.9) 77.4 (32.5-178.7) 280.7 (94.5-
843.7)  
<0.0001 
IL-12 3.2 (3.2-8.2) 3.2 (3.2-6.1) 4.8 (3.2-14.1) 0.022 
IL-15 8.8 (4.1-20.1) 8.4 (3.7-17.6) 9.9 (4.6-28.3) 0.376 
IL-17A 4.0 (3.2-9.5) 3.2 (3.2-5.9) 6.0 (3.2-15.0) 0.013 
IL-1β 3.2 (3.2-3.2) 3.2 (3.2-3.2) 3.2 (3.2-3.3) 0.877 
IL-2 3.2 (3.2-3.2) 3.2 (3.2-3.2) 3.2 (3.2-4.1) 0.112 
IL-4 3.2 (3.2-6.3) 3.2 (3.2-3.2) 3.2 (3.2-14.0) 0.031 
IL-5 3.2 (3.2-3.2) 3.2 (3.2-3.2) 3.2 (3.2-3.2) 0.313 
IL-6 9.6 (3.2-26.9) 8.3 (3.2-21.1) 9.8 (4.7-34.6) 0.113 
IL-8 34.9 (21.3-73.0) 31.3 (20.9-53.0) 54.2 (24.9-131.6) 0.009 
IP10 8426.0 (4777.6-
13835.0) 
7320.3 (4395.5-
11443.3) 
10000.0 (5875.9-
18215.0) 
0.015 
MCP1 1435.1 (799.6-2688.7) 1356.4 (870.4-2290.6) 1587.2 (674.7-
3543.7) 
0.661 
MIP-1α 18.5 (9.3-28.0) 16.0 (9.3-25.0) 20.9 (9.2-37.2) 0.088 
MIP-1β 35.2 (25.4-58.4) 34.6 (23.1-58.4) 37.1 (25.9-61.2) 0.810 
TNF-α,  24.5 (17.0-46.2) 21.0 (16.8-35.6) 35.2 (17.1-52.3) 0.067 
 
Table 7.3 Cytokines levels (median, IQR) at admission by grouped disease severity. p-values 
calculated by Mann-Whitney U Test with statistically significant results (p<0.05) highlighted in 
bold 
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Figure 7.2 Cytokines at admission by severity (y axis pg/ml). Boxplots (whiskers 10-90th centile) 
with outliers. p-values calculated by Mann-Whitney U Test 
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7.3.3 Cytokines levels at admission by lowest platelet count (plts <50 x 109/L or >50 x 109/L) 
There were significant differences in distribution of cytokines at admission when groups were 
stratified by lowest platelet count recorded during the course of admission (platelet count <50 x 
109/L or >50 x 109/L). Higher median levels of G-CSF (p=0.02), GM-CSF (p=0.01), IFN-Α2 (p=0.01), 
IL-10 (p=0.02), IL-15 (p=0.001), IL-6 (p=0.001), IL-8 (p<0.0001), IP-10 (p=<0.0001), MCP-1 
(p=0.001), MIP-1α (p=0.001), MIP-1β (p=0.006) and TNF-α, (p=0.002) observed in the group that 
had developed a platelet count of <50 x 109/L. 
Cytokine All  
(n=102)  
Plts >50 x 109/L 
(n=47) 
Plts <50 x 109/L 
(n=55) 
p-value 
G-CSF 83.3 (37.1-144.9) 55.3 (34.4-139.4) 96.1 (50.5-156.7) 0.02 
GM-CSF 8.5 (4.8-15.5) 6.2 (4.0-12.1) 11.1 (6.4-20.6) 0.01 
IFN-α2 53.0 (18.0-133.0) 39.9 (9.4-102.2) 86.5 (32.2-265.6) 0.01 
IFN-γ 17.5 (9.5-31.7) 13.4 (8.7-30.9) 18.7 (10.3-36.1) 0.13 
IL-10 118.7 (38.7-288.9) 82.3 (29.5-225.8) 145.2 (50.6-436.5) 0.02 
IL-12 3.2 (3.2-8.2) 3.2 (3.2-6.4) 3.2 (3.2-16.0) 0.137 
IL-15 8.8 (4.1-20.1) 5.8 (3.2-12.9)  15..0 (6.8-27.4) 0.001 
IL-17A 4.0 (3.2-9.5) 3.2 (3.2-3.2) 4.7 (3.2-9.5) 0.39 
IL-1β 3.2 (3.2-3.2) 3.2 (3.2-3.2) 3.2 (3.2-3.2) 0.57 
IL-2 3.2 (3.2-3.2) 3.2 (3.2-3.2)  3.2 (3.2-3.4) 0.39 
IL-4 3.2 (3.2-6.3) 3.2 (3.2-3.2) 3.2 (3.2-10.7) 0.20 
IL-5 3.2 (3.2-3.2) 3.2 (3.2-3.2)  3.2 (3.2-3.2) 0.59 
IL-6 9.6 (3.2-26.9) 4.9 (3.2-13.4) 16.8 (5.3-40.4) 0.0001 
IL-8 34.9 (21.3-73.0) 28.1 (18.1-47.1) 55.3 (29.9-113.4) <0.0001 
IP-10 8426.0 (4777.6-
13835.0) 
5260.5 (3223.9-
7779.9) 
10000.0 (6722.0-
16593.0) 
<0.0001 
MCP-1 1435.1 (799.6-
2688.7) 
993.54 (663.4-
1825.0) 
1860.6 (1043.0-
3722.0)  
0.001 
MIP-1α 18.5 (9.3-28.0) 12.5 (7.8-20.9) 24.3 (14.9-37.3) 0.001 
MIP-1β 35.2 (25.4-58.4) 31.4 (21.8-41.1) 43.4 (28.5-67.3) 0.006 
TNF-α  24.5 (17.0-46.2) 19.8 (16.4-30.6) 37.6 (20.2-66.4) 0.002 
 
Table 7.4 Cytokines levels (median, IQR) at admission grouped by lowest platelet count. P-
values calculated by Mann-Whitney U Test with statistically significant results (p<0.05) 
highlighted in bold. 
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Figure 7.3 Cytokine levels at admission by lowest platelet count (x 109/L) (y axis pg/ml). Boxplots 
(whiskers 10-90th centile) with outliers. p-values calculated by Mann-Whitney U Tests.  
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7.3.4 Cytokines levels at admission by outcome 
There were significant differences in distribution of cytokines at admission when groups were 
stratified by outcome into those that died of CCHF (fatal/survived). Higher levels of IL-10 
(p=0.029), IL-15 (p=0.044), IL-6 (p=0.017), IL-8 (p=0.004), MCP-1 (p=0.01), and TNF-α (p=0.017) 
were observed in the fatal cases. Other cytokines including GM-CSF (p=0.078), IL-17 (p=0.072) 
and MIP-1α (p=0.052) were also elevated in the fatal group but not at a significant level 
(p<0.05). 
7.3.5 Daily serial cytokines levels  
Serial cytokines were measured daily in 102 participants for a median 5 days (IQR 4-7 days) 
during the course of acute admission (day 1-13), for a total of 580 CCHF patient days. The 
number of samples analysed by day of illness is shown in Table 7.5. After hospital discharge 
cytokine profiles were analysed in 76 of 100 eligible patients attending out-patient follow up. 60 
participants attended at 14 (+2) days and 60 participants (including 46/60 from the day 14 
group) at 30 (+/-2) days.  
 
 
 
Figure 7.5 Number of different patients’ samples analysed by the 19 plex cytokine panel at each 
day of illness.  
7.3.6 Linear Regression  
Simple linear regression between cytokine levels and day of illness is shown in Figure 7.6 for the 
individual cytokines. There was a significant non-zero regression slope demonstrated with a 
decreasing slope from onset of disease for IFN-Α2 (P<0.0001), IL-5 (p=0.007), IL-10 (p=0.03), IL-
15 (p<0.0001), MCP-1 (p=0.009), MIP-1α (p<0.0001), MIP-1β (p<0.0001) and TNF-α (p<0.0001).  
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Figure 7.6 Linear regression of cytokines by day of illness. IL-5 is displayed with split y axis, to 
demonstrate slope and outliers (y axis pg/ml). Median and IQR are shown for each day. Il-5 is 
represented by an aligned dot plot.  
7.3.7 Serial cytokines by severity and outcome 
Linear regression analysis was then undertaken stratified by severity of illness (mild vs 
moderate/severe) and outcome (survived or fatal) (Figure 7.7) demonstrating 2 patterns of 
significant differences in cytokine expression during acute infection.  
1. Cytokine slope differences  
Disease severity: G-CSF (p=0.04); IL-5 (p<0.0001); IL-8 (p=0.02), MIP-1α (p=0.001) 
Outcome: G-CSF (p=0.001); IL-6 (p<0.0001); IL-10 (p<0.0001); MIP-1β (p=0.043) 
 
2. Higher cytokine slope elevations/intercepts 
Disease severity: IFN-γ (p=0.001); IL-10 (p<0.0001); IL-17A (p=0.004); IP-10 (p=0.029); 
and TNF-α (p=0.007). 
Outcome: IL-8 (p<0.0001); IL-15 (p=0.001; and TNF-α (p=0.007)  
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Figure 7.7 Linear regression of cytokines by day of illness stratified by disease severity and 
outcome (y axis pg/ml). Median (IQR) cytokine levels are shown for each day. p-values indicate 
if slopes are significantly non-zero, and if slopes or intercepts/elevations are equal. 
7.3.8 Cytokine level correlations with Log10 CCHF viral load 
There were 149 matched daily cytokine and viral load samples, with a quantifiable CCHFV result. 
Significant positive correlations between individual cytokine and log10 viral load were shown 
with IFN-α2, IL-8, IL-10, IL-15, IP-10, MIP-1α, MIP-1β and TNF-α (Figure 7.8). The most marked 
correlations (r=0.3-0.5) occurred with IFN- α2, IL-8, IL15, MIP-1α, MIP-1β and TNF-α, . 
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Figure 7.8 Scatter plots of cytokine levels correlated with Log10 CCHF viral load (n=149) r= 
Pearson’s correlation coefficient. Best fit lines included in significant (p<0.05) results (y axis 
pg/ml, x axis Log10 copies/ml).  
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Cytokine 
 
Admission vs 
convalescence  
p-value 
Admission 
by  
severity   
 p-value 
Admission  
by 
Plt count 
p-value 
Admission 
by  
outcome  
p-value  
Admission 
correlation 
Viral load 
p-value 
Linear 
regression 
slopes 
p-value 
G-CSF <0.0001 0.54 0.02 0.23 0.33 0.14 
GM-CSF 0.002 0.024 0.01 0.078 0.53 0.06 
IFN-Α2 <0.0001 0.55 0.01 0.15 <0.0001 <0.0001 
IFN-γ <0.0001 0.044 0.13 0.62 0.33 0.73 
IL-10 <0.0001 <0.0001 0.02 0.029 0.259 0.03 
IL-12 <0.0001 0.022 0.137 0.17 0.19 0.68 
IL-15 <0.0001 0.38 0.001 0.044 <0.0001 <0.001 
IL-17A 0.90 0.013 0.39 0.072 0.26 0.99 
IL-1β 0.42 0.88 0.57 0.43 0.69 0.37 
IL-2 0.87 0.11 0.39 0.59 0.36 0.29 
IL-4 0.004 0.031 0.20 0.63 0.64 0.32 
IL-5 0.39 0.31 0.59 0.67 0.87 0.007 
IL-6 <0.0001 0.11 0.0001 0.017 0.03 0.25 
IL-8 <0.0001 0.009 <0.0001 0.004 0.0002 0.17 
IP-10 <0.0001 0.015 <0.0001 0.28 0.85 0.31 
MCP-1 <0.0001 0.66 0.001 0.01 0.074 0.009 
MIP-1α 0.0004 0.088 0.001 0.052 0.051 <0.0001 
MIP-1β <0.0001 0.81 0.006 0.20 <0.0001 <0.0001 
TNF-α,  <0.0001 0.067 0.002 0.017 <0.0001 <0.0001 
 
Table 7.5 Summary of cytokine results   
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7.4 Discussion 
Cytokines are key proteins involved in the host immune response, and through cell signalling 
mechanism have both pro-inflammatory and immunomodulatory roles. Regulation of the 
cytokine network maintains the equilibrium of adequate detection and response to pathogens 
whilst limiting excessive tissue damage. Sepsis and related organ dysfunction are frequently 
attributed to excessive release of pro-inflammatory cytokine with a resultant ‘cytokine storm’. 
Immunomodulation of the host immune response in sepsis has to date not been shown to be 
beneficial in sepsis clinical trials, but results may be the heterogenous nature of the sepsis 
syndrome. 
This study aimed to evaluate the dynamic cytokine response in patients with CCHF 
longitudinally during their acute illness. This involved intensive daily sampling and analysis 
utilising a comprehensive 19 plex human cytokine panel that resulted in 580 cytokine results for 
each of the cytokines, in 102 participants with confirmed CCHF. Samples were also rapidly 
processed and frozen to prevent degradation, with no freeze thaw cycles and were measured in 
duplicate. 
Baseline or admission cytokine levels in CCHF have been the focus of the majority of studies 
reported, often stratifying patient groups by severity or outcome. They provide useful 
preliminary information with potential prognostic benefit, but do not reveal the longitudinal 
trend of cytokine expression in acute illness and hence a deeper understanding of this 
component of the immune response. This research also includes a previously unstudied ‘mild’ 
severity CCHF cohort, and data on 30-day cytokine levels that should provide valuable 
comparator arms if deregulated cytokines are associated with CCHF infection, severe and fatal 
disease. 
The first evaluation of the cytokines compared the 19 plex panel values at admission against 
values obtained in convalescence at 30 days post onset of symptoms. As might be expected 
from the panel selected, the levels were elevated at admission in the vast majority (15/19) of 
the cytokines, generally with highly statistically significant differences. The four cytokines that 
had no difference were IL-1β, IL-2, IL-5 and IL-17A that are all characterised as predominantly 
pro-inflammatory, with levels remaining low and at the limit of detection. No difference was 
also noted in these cytokines at admission when stratified by disease severity or outcome, 
suggesting that they are not playing a key role in CCHF pathogenesis.  
Previous studies in CCHF that have demonstrated positive results for IL-2 and IL-5, include 
Ozsurekci et al 126 who showed levels to be higher in fatal cases in a small study of 33 survivors 
vs 3 fatal cases; there were no differences compared to controls. Parlak et al 122 conversely 
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found IL-2 levels to be higher in patients than controls, but no difference by disease outcome. 
IL-1Β might be expected to demonstrate more significant results as an important pro-
inflammatory cytokine and it was hypothesised to be associated with severe disease. Papa et al 
123 found it to be raised in fatal cases and previous studies in animal and human bacterial sepsis 
suggest it is a powerful pro-inflammatory cytokine released predominantly from activated 
macrophages with a pyrogenic effect. IL-17A is a pro-inflammatory cytokine produced by Th2 
cells that may have more of important role in inducing a pro-inflammatory response to 
extracellular pathogens. It has previously been investigated in autoimmune disease, 
inflammatory bowel disease and psoriasis 230,231. Our results are consistent with a previous 
evaluation in CCHF when no difference in levels were found in adults or children compared to 
controls126, although it was elevated in severe cases in our study.  
The elevated levels of the remaining 15 cytokines/chemokines analysed, compared to 
convalescence levels suggest a role in the complex immune response to CCHFV infection. The 
potential to assess cytokine profiles stratified by markers of disease severity is also important. 
The low case fatality rates in Turkey makes it difficult to adequately compare cytokine profiles 
between fatal and survivor cases. Whilst acknowledging the limitations of existing scoring 
systems, cytokine levels were evaluated in severity groups and the pragmatic Turkish grouping 
of patients with a platelet count <50 x 109/L. 
There was a difference in cytokine levels at admission between disease severity/platelet count 
groups (Table 7.3). Our demonstration of higher levels of cytokines IL-10, IP-10 in severe vs non-
severe cases at the p<0.025 level is consistent with previous studies. However, for the first time 
GM-CSF, IL-12 and IL-8 have been shown to be higher in moderate/severe cases and when 
severity is gauged by platelet count, MIP-1α, MIP-1β, MCP-1, Il-6, IL-15, TNF-α, INFA2 and G-CSF 
were also elevated in patients who have platelet counts <50x 109/L. Many of the previous small 
cytokine studies focussed on the evaluation of small panels at admission in surviving or fatal 
cases. The most consistently elevated cytokines in fatal cases in previous studies (n=4-5) are IL-
10, IL-6 and TNF-α (Table 1.5). Even though this cohort had a limited number of CCHF deaths we 
also found significant associations between fatality and elevations in IL-10, IL-6 and TNF-α. We 
also found significant associations with mortality and higher levels of IL-15, IL-8 and MCP-1.  
Intensive longitudinal analysis of large cytokine profiles during sepsis is rarely undertaken and 
no large comparative data sets exist. Previously in CCHF sampling has been intermittent during 
acute infection and limited panels of cytokines evaluated. This data demonstrates a linear 
relationship for a number of pro-inflammatory cytokines including IFN-Α2, IL-15, MCP-1, MIP-
1α, MIP-1β and TNF-α. However, all linear regression slopes were accompanied by low R-
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squared values highlighting that whilst a relationship/trend exists there is significant data 
variability around regression lines. This is expected with regression analysis of noisy, high 
variability cytokine data, in a cohort with a broad spectrum of clinical illness and other 
contributing predictor variables that will affect response. Analysis of longitudinal cytokine 
responses by disease severity and outcome highlights exaggerated and persistent pro-
inflammatory immune responses during infection associated with severe disease and death. 
This is demonstrated through significantly different slopes or slope elevations in G-CSF, IL-6, IL-
8, IL-15, MCP-1, MIP-1α, MIP-1β and TNF-α. IL-10 is a key anti-inflammatory cytokine, that also 
showed different trends during illness course with elevated levels in moderate/severe disease, 
and increasing levels during illness with a fatal outcome.  
Looking at all the individual cytokines, there are clear patterns of a relationship between certain 
cytokines and severity, independent of the method utilised for stratifying groups for 
comparison. These include IL-10, IL-15, IL-6, IL-8, IP-10, MIP-1α and TNF-α (Figure 7.4). TNF-α is 
one of the most studied pro-inflammatory cytokines in VHF and sepsis more generally, and is 
sometimes referred to as the master regulator of inflammatory cytokine production 232. It has 
also been implicated in a number of non-infectious diseases such as rheumatoid arthritis 233 and 
atherosclerosis 234. It is mainly derived from macrophages shortly after they are activated and 
after release acts via specific receptors, activating other immune cells and release of other 
immunoregulatory mediators (IL-6,IL-8) 113. The ratio between TNF-α and its receptors, has also 
been shown to be important in patients with sepsis 235, whilst injection of TNF-α into animals 
and humans 236–238 results in a sepsis-like syndrome also generating fever. It has many of its 
direct effects on macrophages, enhancing their production, activation, differentiation and 
survival that further promotes a pro-inflammatory response 113. TNF-α also induces expression 
of tissue factor that can initiate the coagulation cascade 196. In this study TNF-α levels were 
higher in acute samples, more severe disease and in fatal cases. Longitudinal analysis showed 
that survivors had different expression patterns to fatal cases, with a linear reduction in TNF-α 
during illness course in survivors. By disease severity the slopes were similar but elevated in the 
moderate/severe group.  
IL-6 is another important pro-inflammatory cytokine that has a broad range of immune effects 
as a including as a mediator of the acute phase response 239,240, and a role in the activation of B 
and T lymphocytes. Unlike TNF-α, the injection of IL-6 has not been shown to result in a sepsis 
clinical picture in animals 241, but has been implicated in causing myocardial depression in 
meningococcal disease 242. It also has important anti-inflammatory responses, including 
inhibition of TNF-α and the release and increased production of IL-10 243. Whilst IL-6 has been 
shown to be elevated in acute, more severe and fatal cases in this study there was no clear 
153 
 
linear trend identified. This may support its mixed anti and pro-inflammatory response in 
contrast to the heightened pro-inflammatory response observed in TNF-α earlier in disease 
course.  
IL-15 is increasingly recognised as an important cytokine in sepsis and septic shock, due to its 
role maintaining the homeostasis of natural killer (NK) and memory CD8 T lymphocytes 244, that 
have been shown to promote the pathophysiology of sepsis 245,246. IL-15 has been shown to 
result in increased production of IFN-γ, and also prevent apoptosis through up-regulation of 
anti-apoptotic proteins 247. IL-15 knockout mice show resistance against sepsis 244,248 and 
elevated levels of IL-15 have been demonstrated in patients with severe sepsis 249,250. In a large 
cohort of patients with Stevens-Johnson syndrome IL-15 (and IL-6, IL-8 and TNF-α) was 
upregulated, and was the only factor to correlate with disease severity and mortality 251: IL-15 
has also been shown to correlate with invasive fungal infection in battlefield trauma patients 
252. There is ample evidence to indicate that the innate immune system including NK cells are 
also activated early during the course of primary and secondary DENV infection. The ability of 
NK cells to secrete cytolytic granules has long been recognized, and they are considered a 
crucial first line of defence in eliminating DENV-infected cells (221). Flow cytometry has also 
shown that the frequencies of activated NK cells are higher in patients with DHF compared to 
those with DF 253. 
In this study IL-15 has been shown to be significantly elevated in acute infection, fatal cases and 
those who developed low platelet count counts. It also showed a clear correlation with CCHF 
viral load and markedly reduced during the course of acute illness/infection. The fatal cases had 
evidence of septic shock that would be consistent with previous reports of elevated IL-15, but 
the other mild and moderate/severe cases did not develop severe sepsis/septic shock, 
consistent with the lack of difference in IL-15 levels between disease severity groups. Yilmaz et 
al 254 reported that there more peripheral blood NK cells in severe-risk CCHF patients than in 
non-severe risk group CCHF patients, and found a positive correlation between NK cell count 
and aspartate transferase (AST), alanine transferase (ALT) and activated partial thromboplastin 
times (aPTT). Another report by Akinci et al 110 did not demonstrate any correlation with NK 
cells and fatal disease. It is clear from these data that IL-15 plays a dynamic role in the host 
immune response to CCHFV aligned with its pro-inflammatory response in maintaining NK cell 
integrity and function. There is an early heightened IL-15 response in acute infection, that fails 
to reduce and is increased in fatal disease.  
A number of pro-inflammatory chemokines demonstrated elevated levels in more severe and 
fatal disease, with clear trends and correlations with CCHF viral load observed for the first time. 
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The three with the most consistent statistically significant elevated results are IP-10 (CXCL10), 
IL-8 (CXCL8) and MIP-1α. Chemokine signalling elicited from infected cells contributes to both 
innate and adaptive immune responses that control growth of the invading pathogen 255. 
Elevated IP-10 levels have been shown to occur in broad range of infections, and in particular 
has been shown to have a strong correlation with HIV viral load 256, and to be elevated in 
children with sepsis 257 and patients with severe malaria and multi-organ dysfunction 258. IP-10 is 
a potent pro-inflammatory chemokine that chemoattracts CXCR3-positive cells, including 
macrophages, dendritic cells, NK cells and activated T lymphocytes (CD4+ Th cells, CD8+ Tc cells) 
towards infected sites. Its powerful chemotactic action on activated lymphocytes allows it to 
modulate both innate and adaptive immunity, whilst also having an important role inducing 
apoptosis 259. In 2 small previous retrospective studies (total 55 patients) by Papa et al 107,123, IP-
10 was elevated in patients compared to controls and also in severe/fatal cases. In this study IP-
10 levels were elevated in acute infection and severe disease, and correlated with CCHF viral 
load during hospitalisation. They were not associated with fatal outcome, and the ongoing 
expression during acute infection may indicate its role in the adaptive immune response. 
IL-8 (CXCL8) is a pro-inflammatory chemokine that is produced by macrophages and endothelial 
cells and predominantly promotes chemotaxis and degranulation of neutrophils. It has been 
suggested as an early biomarker for the diagnosis of neonatal sepsis and sepsis occurring in 
burns patients (228,229). It has also been evaluated in one previous CCHF study in Turkey, that 
showed it was higher in cases versus controls and in fatal cases 124. Our data showed that IL-8 
was elevated in acute infection, more severe disease, fatal outcome and also significantly 
correlated with CCHF viral load. There was no clear trend of expression during acute infection 
by linear regression, consistent with the previous limited evaluation in CCHF. The endothelium 
plays a pivotal role in the host response in sepsis and these elevations provide further evidence 
of endothelial cell activation in CCHF. MIP-1α/CCL3 (Macrocyte inflammatory protein alpha 
/chemokine ligand 3) is produced predominantly by macrophages and acts as a pro-
inflammatory cytokine, and with related CCH chemokines can mobilise a range of monocyte-
lineage cells and lymphocytes into inflammatory tissue. It can also induce synthesis of IL-5, IL-6 
and TNF-α, and has been shown with CCL4 (MIP1β), and CCL5 (RANTES) to inhibit the release of 
the pro-inflammatory cytokine IL-1β 260. We have demonstrated that elevated MIP-1α levels are 
associated with acute infection, outcome and viral load, with clear and marked reduced levels 
during the course of symptomatic infection. Similar trends were also observed for MIP-1β that 
also correlated with acute infection, low platelet counts and CCHF viral load.  
The opportunity to evaluate cytokine profiles with matched CCHF viral load data is rarely 
available, but has been done on for limited cytokine panels previously by Saksida et al 97 (n=46 
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patients at admission, IL-10, IL-12, IFN-γ, TNF-α), Papa et al 107(n= 35 patients at admission, IP-
10) and Kaya et al 98 (n=31 sequential samples, Il-6, TNF-α, , IL-10 and IFN-γ). As shown in Table 
1.5 correlations between CCHF viral load and cytokine levels have been demonstrated twice 
previously for TNF-α, , once for Il-6 and IP-10, with mixed results for IL-10 and IFN-γ. At 
admission we also demonstrated correlations between viral load and a range of 
cytokines/chemokines including TNF-α and IL-6, but not for IP-10, IL-10 or IFN-γ. However, when 
the data was expanded to evaluate the cytokine correlations in all CCHFV positive longitudinal 
samples IL-10 and IP-10 positive correlations were demonstrated. As we and others have 
already demonstrated there are significant associations between disease severity and CCHFV 
viral load. There is a clear relationship between the quantitative levels of both CCHFV blood and 
the expression of a range of cytokines and chemokines, that are contributing to eliminate virus 
and limit tissue damage. 
IL-12 is a pro-inflammatory cytokine that we had hypothesised would be reduced in severe 
disease. Its role in sepsis remains controversial 113, with lower levels in fatal cases of severe 
sepsis 261,262. It is produced predominantly by innate immune cells, including epithelial cells, 
dendritic cells, and macrophages. It plays a critical role in inducing Th1 responses 263 with 
enhanced mononuclear phagocyte responses 113, leading to the production of a number of 
cytotoxic cytokines, as well as interferon-gamma. In the study levels were significantly higher in 
acute infection compared to convalescence and in severe disease, but showed no clear trend on 
longitudinal sampling.  
 IL-10 is a key anti-inflammatory cytokine produced by Th2 cells, monocytes and B-cells that 
inhibits the expression of TH1 cytokines. It has been shown be elevated in levels of in patients 
with severe sepsis, sepsis scores and fatal outcome 264,265. Previous research in CCHF has 
demonstrated mixed results but higher levels have been predominantly associated with fatal 
outcome 119,122–124, apart from in one study 120. Our data clearly shows that it is an important 
cytokine in the host immune response to CCHFV infection. It was elevated in acute infection 
compared to convalescence and by all markers of increased severity and outcome. Its 
expression during the course of illness also demonstrated significantly different slopes in fatal 
and surviving cases.  
The cytokine profiles that we have identified in patients with CCHF represent a valuable tool for 
the characterisation of immunological response patterns. In the future they may also be 
combined with other prognostic indicators such as viral to aid identification of patient groups at 
risk for developing severe disease. However, whilst trying to make a direct link between 
cytokine concentrations and the severity of CCHF is appealing, the spectrum of CCHF severity 
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cannot solely be attributed to the actions of single or small combinations of cytokines. Our 
results may be highlighting a complex relationship between a range of cytokines, including 
some not analysed and other immunological and virological factors involved. Overall, the 
longitudinal serial measurement of cytokines/chemokines indicates a strong pro-inflammatory 
response early in the disease course, potentially focussed on activation and chemoattraction of 
NK cells, B cells and the stimulation of acute phase proteins. TNF-α is clearly an important 
cytokine and in combination with other pro-inflammatory cytokines remains 
elevated/dysregulated in fatal disease. Patterns of IL-10 expression are similar, demonstrating 
that the immune response to CCHF is not a simple model and that both pro- and anti-
inflammatory responses occur simultaneously, that may act to both eliminate CCHFV and limit 
excessive collateral tissue damage.  
This data has for the first time also shown the expression of different cytokines during the 
course of illness and clearance of CCHF, as well the correlations with CCHF viral load. Whilst the 
priority for future clinical research in CCHF should focus on evaluating and antiviral/immune 
based therapeutics, there may also be role in investigating opportunities to target specific steps 
of the interactive and dynamic process of the cytokine-based host immune response. 
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Chapter 8 Discussion  
CCHF is a major emerging infectious threat and although it is widely distributed and increasingly 
reported, the pathogenesis of disease is poorly understood. This is mainly due to the current 
necessity to perform research in advanced biosafety laboratories and the occurrence of 
infections in areas where research facilities are limited. Until recently there has also not been an 
established animal model, and the first reports of CCHFV disease in a non-human primate 
model need confirmation 266. The role of ribavirin antiviral therapy continues to be 
controversial, but an improved understanding of disease pathogenesis should inform new 
approaches to improving clinical outcomes. 
The specific aims of this research were to recruit a cohort of adults with PCR positive CCHF in 
Turkey to: 
1. Determine the viral load dynamics in serum and urine over the course of clinical 
infection. 
2. Investigate the hypothesis that: (1) initial viral load (day 1) and (2) rate of viral load 
reduction are correlated with disease severity and clinical outcome. 
3. Investigate the host immune response to clinical infection through serial measurement 
of cytokine/chemokine levels and quantitative serological response, related to disease 
severity and clinical outcomes. 
4. Test the hypothesis that severe/fatal CCHF is associated with a deregulated cytokine 
network characterised by an exaggerated pro-inflammatory cytokine response (IL-1β, 
IL-6, IL-8 and tumour necrosis factor alpha [TNF-αl], and reduced IL-12). 
 
In this study, three research sites and two laboratories were established in the CCHF 
hyperendemic region and one hundred and forty-four participants with suspected CCHF were 
recruited, of which one hundred and four were found to be CCHFV PCR positive. The 
demographics of the cohort were similar to larger published epidemiological studies in Turkey, 
although the median age was higher than was expected (50 years), but with a low frequency 
identified comorbidities. The majority of patients had a history of tick bite (70%), consistent 
with data across Turkey and presented rapidly to hospital, a median of 3 days after symptom 
onset. A high percentage had close animal contact (82%) with 50% having direct contact with 
animal blood or tissue. Tick bite remains the main transmission risk factor for CCHF, whilst in 
other CCHF endemic countries direct contact with animal blood and tissue may be more 
frequent. Differences in the mode of transmission between different endemic countries 
influence control measures, but may also have implications with respect to viral inoculum dose 
and the severity of clinical disease encountered.   
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8.1 Clinical and laboratory features 
The clinical features of the participants at admission is consistent with larger data sets, although 
bleeding was less frequent. This probably reflects recruitment of patients directly from Tokat 
State hospital, that as secondary level healthcare facility manages higher rates of early/mild 
disease, in contrast to the tertiary CCHF treatment centres where most research has been 
undertaken. There are limited data on vital signs at admission in patients with CCHF; in this 
study the vast majority were normal, with median NEWS scores of 2 and 1 in moderate/severe 
and mild disease groups respectively. A history of fever was reported by 90% of patients with 
CCHF with the mean temperature at admission 37.50C. This has important implications for case 
definition for surveillance and screening and is consistent with data on Lassa fever from Nigeria 
94 and from the Ebola virus disease outbreak in West Africa 181, that ‘high fever’ is not always 
present. 
 The ability to predict mortality in patients with CCHF, through utilisation of severity scoring 
systems would be extremely useful. This is especially relevant in endemic settings when 
managing large cohorts, but scoring systems are not in routine use in most specialist CCHF 
centres in Turkey. Whilst the SSI and SGS systems have been validated in cohorts in Turkey for 
this aim, improvement in their predictive value is required for other key outcomes such as blood 
product requirements, critical care interventions and length of stay. Severity scoring systems 
would also be useful if they were able to predict the risk of viral shedding/nosocomial infection 
and the consequent level of personal protective equipment required. Above all they need to be 
simple and based on widely available clinical and laboratory factors if they are to be used 
routinely. In this study patients were graded by all three severity systems, with the SSI system 
aligning best to the 39/41 in the moderate/severe group. The comparative mild severity group 
was identified by all three scoring systems designating the participant as mild/low risk.  
Clinical and laboratory features at admission are important for diagnosis, surveillance and 
incorporating into severity scores, but limited data exists on the natural history/evolution of 
CCHF and other viral haemorrhagic fevers. There were significant differences in a range of 
laboratory variables between the moderate/severe and mild groups. The median platelet count 
at admission for the cohort was 104 x 109/L, with median liver enzyme levels and CK only mildly 
elevated to 2 x the upper limit of normal. This study is unique in being able to describe the 
longitudinal clinical and laboratory features of CCHF collected through a standardised case 
record form. The most frequent symptoms reported were headache, myalgia, lethargy and 
vomiting, all occurring in most patients for 2-3 days. In total 23% of the cohort had an episode 
of bleeding, that lasted for a median 2 days.  
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Duration of fever was surprisingly shorter in the moderate/severe group than in the mild group, 
with different temperature slopes demonstrated in linear analysis. Heart rate also reduced 
during the course of illness, and as might be expected the moderate/severe group had a lower 
systolic blood pressure and higher respiratory rate elevation/intercepts. Overall review of the 
vital sign data for the cohort demonstrates that in the majority of cases, a significant systemic 
inflammatory/sepsis response is not evident. It is also important to highlight that whilst 
approximately 25% of patients had bleeding, this was not in conjunction with multi-organ 
failure or disseminated intravascular coagulation (DIC). Patients with haemorrhage had normal 
vital signs, probably highlighting why CCHF is regularly transmitted nosocomially to non-
infection specialists such as ENT surgeons whilst nasal packing for epistaxis. This robust 
evaluation of vital signs and severity is important as it provides the first clear evidence that a 
significant percentage of the CCHF managed in Turkey is ‘mild’ consistent with the lower-case 
fatality rates reported. It also provides the first indication and evidence that the bleeding 
pattern and coagulopathy observed is not simply due to DIC, subsequently further evaluated 
through ROTEM analysis. 
There were clear patterns in some laboratory variables. Thrombocytopenia is a consistent 
feature in CCHF and has been shown to be associated with mortality 180. A number of 
mechanisms that lead to the thrombocytopenia seen in CCHF have been suggested, and as well 
as their key roles in maintaining haemostasis, platelets are now increasingly recognised as major 
inflammatory cells with roles in both the innate and adaptive immune systems 193,194. The rise in 
liver enzymes is consistent with dissemination of infection and then viral replication within 
hepatocytes: fatal cases of fulminant liver failure occurring in CCHF have been reported 157,188. 
Renal dysfunction was not commonly seen in this cohort of CCHF with only 4/104 having acute 
kidney injury by RIFLE criteria. Although rare, the aetiology of renal dysfunction requires further 
evaluation to understand how much is a result of direct viral renal damage, renal hypovolemia 
due to sepsis or as a consequence of DIC. The main limitations in the clinical and laboratory 
description of the natural history of CCHF are that a smaller number of fatal and severe cases 
were recruited than planned. This limits the ability to improve understanding of the more 
complicated spectrum of CCHF disease, but unlike other reports does describe a large cohort of 
‘mild’ disease for comparison.  
8.2 Case management  
The case management of CCHF is largely supportive with a focus on the provision of blood 
component therapy to prevent bleeding and critical care support when it is required for severe 
cases. Supportive care of patients during the study was guided by infectious diseases physicians 
in the different sites, with the vast majority receiving ward level care. Only 2 patients received 
160 
 
additional critical care support, both in the final stages of illness and lasting less than 24 hours. 
This further confirms the high percentage of ‘mild’ CCHF seen in Turkey. 
Blood components were given to 37% of participants in the study and receipt of blood products 
was associated with disease severity. Although this would be expected this has not been 
reported previously when scoring systems were independently validated. Blood products were 
also utilised in patients that were graded as mild/low risk by all severity systems, demonstrating 
the limitations of severity scores at admission to be able to predict the need for transfusion. 
Platelet transfusion was generally administered according to absolute platelet count, with 
virtually all participants with counts <50 x 109/L and all patients with counts <20 x 109/L 
receiving platelet transfusion. The use of FFP was more variable and could be rationalised with 
more protocolised care.  
The evaluation of ribavirin in CCHF has mostly been in retrospective studies: the one 
randomised controlled trial failed to show any reduction in mortality. A subsequent metal-
analysis 173 did not demonstrate that ribavirin conferred any survival benefit or additional 
benefit such as shorter hospital stay, earlier improvement of laboratory values or decreased 
requirement for blood products. The utility of ribavirin in post-exposure prophylaxis (PEP) for 
healthcare workers that have a had a high risk CCHFV exposure such as a needle stick injury is 
much clearer 175. Ribavirin was administered to 35% of participants, all of whom were managed 
at Gaziosmanpasa University Hospital. It was started a median of 4 days after onset of 
symptoms and administered for a median 5 days. However matched viral load analysis showed 
that 25% of participants had already cleared CCHFV from blood when it was started. 
Participants had also cleared CCHFV from blood for 72% of the days on which it was 
administered. Ribavirin has an established dose-dependent side effect profile and although its 
benefit needs to be established in large randomised studies, improved access to PCR based 
CCHFV monitoring could reduce its use and side effects. 
8.3 Viral load (aim 1 &2) 
This is the largest study of CCHFV viral load undertaken to date, with most previous studies 
evaluating CCHFV viral loads in small patient cohorts at baseline, with the exception being 
Hasanoglu et al 99 who reported baseline viral loads on 126 patients over 6 years. Similarly to 
that and earlier smaller studies, we demonstrated higher CCHF viral loads in fatal cases 
compared to survivors. We also demonstrated for the first time that there is a higher viral load 
in moderate/severe cases compared to mild cases using a composite severity scoring system. 
In Turkey, a key variable that influences patient referral to CCHF specialist centres is platelet 
count. We have shown for the first time that participants that dropped their platelet counts to 
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less than 50 x 109/L had significantly higher CCHF viral loads at admission than those that did 
not. The laboratory parameters of APTT, PT, LDH, CK and creatinine also correlated with CCHF 
viral load, as did the duration of clinical features: fever; myalgia and vomiting. We have also 
demonstrated a correlation between CCHF viral load and bleeding during admission and also 
shown that viral load correlates with the use of blood products. 
Longitudinal viral loads of any viral haemorrhagic fever are rarely measured with hypotheses 
about viral dynamics in blood often crudely inferred from admission sampling at different time 
points. A few small studies have undertaken this in CCHF, the largest of which was by Bodur et 
al 100 that investigated VL dynamics in plasma in a case-control study in a cohort of 50 patients. 
This is the first study to show that there is clear differences in CCHF viral dynamics in plasma by 
disease severity, including in mild disease and in patients who develop platelet counts to less 
than 50 x 109/L. The majority of patients cleared CCHFV from blood within 5-6 days of onset of 
symptoms: this has important infection prevention and control implications and is relevant 
when considering antiviral treatment and planning for future clinical trials, that may use CCHFV 
clearance as primary or secondary end-points. 
The study was not designed to investigate the potential effect of ribavirin on CCHFV, and when 
it was initially designed ribavirin was not utilised by the study sites. However, after extension to 
another tertiary specialist centre, one third of the total cohort received ribavirin treatment. The 
use of ribavirin in CCHF has been a controversial issue, with no strong recommendations for use 
given by WHO, CDC or ECDC. Published meta-analyses are limited by retrospective 
observational data sets, with the most recent Cochrane evaluation reporting that that there was 
insufficient evidence to show whether it is effective in treating CCHF, and recommending 
randomised clinical trials 174. Even allowing for uncertainty about the effectiveness of ribavirin 
the inclusion of patients who received ribavirin has the potential to alter the natural history of 
disease and viral dynamics in this cohort. It does however provide an opportunity to 
observationally evaluate ribavirin treatment, whilst recognising that although not statistically 
significant, those with moderate/severe disease were more likely to receive it due to the 
referral mechanisms in place in Tokat.  
Viral elimination slopes were compared through linear regression for those that receiving 
ribavirin and those that did not (Figure 4.5). This is a binary classification of the two groups and 
fails to account for a significant percentage of patients who were initially managed without 
ribavirin, and then it received it on transfer to a tertiary facility. This has the potential to 
underestimate the effect of ribavirin on CCHFV slopes, and may explain the difference in figures 
4.5 and 4.7. Figure 4.7 does show a difference between the typical patient model when the 
ribavirin data is evaluated by day of onset against the non-ribavirin typical patient. One of the 
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limitations of the ability to demonstrate a benefit of ribavirin therapy has been the low case 
fatality rate in Turkey, that means that a future RCT would require study arms of 600 for 
adequate power. However utilising different primary end-points such as viral clearance and 
elimination slope would be more feasible, assuming ribavirin has a direct antiviral effect. Daily 
viral load analysis prior to and during ribavirin therapy does however provide the first practical 
evaluation of its use in normal clinical practice in Turkey.  
There is limited data on the viral dynamics of CCHFV in urine, but a previous report from a small 
cohort in Kosovo suggested evidence of prolonged viraemia in blood and urine 103. As these 
were interesting results daily urine sample collection was undertaken during admission and 
again at days 14 and 30 follow-up. In total, 679 urines were processed from the 104 
participants, including 54 samples at day 14 and 47 samples at day 30. All convalescent samples 
were PCR negative, and only 8/578 acute admission urine samples were PCR positive, all from 
different participants. It is clear from these results that urine is rarely CCHFV PCR positive in 
acute infection, and cannot be reliably utilised in convalescence to diagnose recent CCHF 
infection. The urine and plasma results are noticeably different from the results reported from 
Kosovo. However, the total number of urines evaluated from confirmed patients is not reported 
and the samples were not taken as part of a prospective study. The pattern of CCHF clinical 
disease reported from colleagues in Kosovo may also different than that seen in Turkey. A 
future prospective study from Kosovo utilising the same RT-PCR, with matched serum results is 
required to try to re-produce these preliminary results, and to allow further investigation of the 
different results observed.   
In summary, this intensive evaluation of CCHF viral load has shown higher levels by markers of 
disease severity including platelet count and patient outcome. Viral load has been shown to 
correlate with clinical features such as bleeding and duration of fever and myalgia, and also with 
other laboratory variables such as APTT, LDH and CK, with a delayed correlation with platelet 
count observed. Longitudinal analysis of viral dynamics has again shown difference by CCHF 
disease severity, with earlier clearance observed in mild cases. For the first time a potential 
effect of ribavirin on plasma viral elimination slopes has been shown. Contrary to a previous 
report the presence of CCHFV in urine is rare.  
8.4 ELISA antibody responses (aim 3)  
The adaptive immune responses to CCHFV have not been well characterised previously. 
Improved data on the antibody responses to infection is critical for understanding the natural 
history of infection and has implications for both current diagnosis and the future development 
of diagnostics and vaccines. Development and testing of commercial serology assays for 
detecting IgM and IgG antibodies to CCHFV for use in supplementary diagnostic tests, for 
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epidemiology and surveillance during outbreaks, and for evaluation of vaccine immunogenicity 
and durability have also been identified as a priority research area by WHO 267. 
This is the largest and most complete study of IgM and IgG antibody responses to acute 
infection with CCHFV to date , both in terms of sample size and the total number of samples 
analysed due to serial daily sampling. It is also the first time that antibody profiles in a cohort of 
patients with acute CCHF has been followed up at 14, 30 and 365 days. In total, over 750 
samples from the cohort of PCR confirmed CCHF were analysed for CCHFV IgM/IgG by a 
commercial ELISA, VectoCrimean-CHF-IgM/IgM produced by Vectorbest. At admission 40% of 
patients had a positive IgM result, with 30% of patients being both IgM and IgG positive. 
Participants became IgM positive a median of 5 days into illness and all samples tested after 8 
days of clinical illness were shown to positive for IgM. IgM remained positive in all convalescent 
samples tested, although titres were significantly lower at 30 days in comparison to 14 days. At 
admission just over 50% of participants had a positive CCHFV IgG result, with the median time 
for IgG seroconversion again being 5 days. After 8 days of clinical illness 96% of acute samples 
tested were also positive for IgG.  
There was no significant difference in IgM/IgG titres at admission or convalescence when 
stratified by CCHF disease severity, or fatal or surviving cases. The distribution of CCHF viral load 
by different antibody groups was significantly different. The aetiology of disease in CCHF PCR 
negative suspect patients is unclear with limited diagnostic ‘fever panels’ being utilised in this 
cohort. They may include patients with CCHF who have cleared CCHFV from blood and some 
units send serum for IgM testing at the time of their discharge. In this study the CCHF PCR 
negative participants underwent IgM/IgG analysis in PHE and 3/39 participants were found to 
be IgM and IgG positive, with 6/39 participants CCHFV IgM negative/IgG positive.  
There is limited indirect evidence or knowledge about antibody responses in other viral 
haemorrhagic fevers to compare with CCHF. In Lassa fever, little is known about the immune 
control of acute infection and recovery has not been shown to correlate with IgG/IgM 
production 213,268, with neutralizing antibodies only detected after clinical recovery 214. There is 
consistent with animal model data such as a study of Lassa fever in cynomolgus macaques by 
Baize at al 215, that failed to detect neutralising antibodies in up to month after infection in 
survivors. They did however notice that LV-specific IgM and IgG appeared at earlier stage in 
survivors.  
These data is in accordance with the previous data sets reported but has evaluated CCHF 
antibody responses in much greater depth. The ability to detect differences between fatal and 
surviving cases is probably due to a lack of statistical power as a result of the small number of 
fatal cases recruited. The data are broadly similar to those reported in EVD 216–218 with early IgG 
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responses, and persistence of IgM response also seen in dengue 219. In summary the evaluation 
of the antibody responses in CCHF utilising the Vectorbest kit, is the most detailed and complete 
undertaken to date. It provides important insights into timing and progression of IgM/IgG 
responses to CCHFV with important diagnostic implications and combined with the PCR data, 
further validates this commercial test for wider use, that is a landmark goal of the WHO R&D 
blueprint.  
8.5 ROTEM analysis 
This study is the first to investigate the use of a global haemostasis test, ROTEM, alongside 
conventional testing in CCHF, demonstrating that using ROTEM is feasible and can provide a 
safe rapid point of care capability. Haemorrhage frequently occurs in severe disease and 
traditional laboratory tests (PT/APTT) do not show dramatic changes 100,160,180. This suggests 
that the coagulopathy seen in patients with CCHF is not due to DIC but may lie in areas not 
measured by conventional coagulation testing, such as a defect in platelets or fibrinolysis.  
In this large cohort of patients in Turkey we demonstrate new insights into the aetiology and 
natural history of the coagulopathy in CCHF. Patients presented after a median of two days 
illness with a median platelet count of 73 x 109/L, and mean PT and APTT of 14 s and 38.3 s 
respectively, i.e. both coagulation tests within the normal range and yet patients had a bleeding 
tendency by ROTEM analysis. At admission, the majority of patients had normal EXTEM S 
clotting times (CT), showing that initiation of clotting, thrombin formation and the start of clot 
polymerisation was not significantly abnormal in most cases at this point. In contrast, EXTEM S 
CFTs were abnormal indicating problems with fibrin polymerisation and stabilisation of the clot 
with Factor XIII and platelets. In the face of normal or slightly deranged APTT/PT, this points to a 
platelet and/or Factor XIII defect. Activation of fibrinolysis can be discounted as there was no 
significant reduction in MCF/clot lysis.  
Our results show that the vast majority of patients at admission had normal FIBTEM results, 
indicating normal fibrinogen levels. A key finding in DIC is the presence of hypofibrinogenaemia 
and there is also consumption of coagulation factors with the formation of small thrombi 
throughout the vasculature leading to end organ failure. The absence of significantly low 
fibrinogen levels or of activation of fibrinolysis are not in keeping with DIC. We did detect a 
reversible coagulopathy in those who survived CCHF and when acute samples were stratified by 
day of illness, values were most abnormal on days 4-6, indicating that this is the major 
coagulopathic period in CCHF with respect to a patient’s ability to generate stable clots.  
In summary, we have shown a coagulopathy developed during CCHF infection, that was not 
associated with a major coagulation defect as evidenced by only minor changes in PT, APTT, and 
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ROTEM clotting time and FIBTEM. Importantly, ROTEM has shown no evidence of 
hyperfibrinolysis. Such a defect could be due to either Factor XIII deficiency or a platelet 
dysfunction, to account for the bleeding and the defect in clot firmness. We plan to investigate 
Factor XIII further but consider it unlikely to be the cause of the bleeding defect. The clinical 
pattern of bleeding is also in keeping with a platelet defect as bleeding was predominantly from 
mucous membranes.  
Platelet dysfunction has been shown in other viral haemorrhagic fevers, particularly by 
Cummins et al, who showed a clear platelet function defect on platelet aggregometry in both 
Lassa and Argentinian HFs 184,228. Our findings exclude DIC as the cause of the bleeding defect in 
all patients at presentation with CCHF. However we do recognise that DIC can occur in fatal 
cases of CCHF associated with multi-organ failure. The main limitation of the ROTEM analysis 
was that less patients with severe/fatal disease and with haemorrhage were recruited than 
expected, but we were able to demonstrate that the coagulopathy occurred in those graded 
with mild disease. ROTEM analysis was also not routinely undertaken at specific time points 
after transfusion of blood products to allow evaluation of effect on haemostasis, and we plan to 
evaluate this in future studies. We would have liked to evaluate the prognostic and predictive 
effect of ROTEM parameters for the development of bleeding and use of blood products, but 
due to the study design and individual clinician-based choice for utilisation of blood products 
this was not possible.  
In summary, ROTEM and conventional coagulation analysis has demonstrated that CCHF 
coagulopathy is predominantly related to clot development/stabilisation that is most marked 
during day 4-6 of the illness and in severe disease. In the context of normal/only slightly 
deranged coagulation screens and FIBTEM results, and combined with the absence of 
hyperfibrinolysis, this data provides the first evidence that the initial coagulopathy in CCHF 
probably relates to platelet dysfunction. 
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8.6 Cytokines/chemokines (aim 3&4) 
Cytokines are key proteins involved in the host immune response, that have both pro-
inflammatory and immunomodulatory roles. Regulation of the cytokine network maintains the 
equilibrium and sepsis and related organ dysfunction are frequently attributed to excessive 
release of pro-inflammatory cytokines. The majority of studies published to date investigating 
cytokine expression in CCHF have been based on admission samples and do not reveal the 
longitudinal trend of cytokine expression in acute illness. 
This study evaluated the dynamic cytokine response through intensive daily sampling and 
utilised a comprehensive 19 plex human cytokine panel in 102 participants with confirmed 
CCHF. Samples were also rapidly processed and frozen to prevent degradation, with no freeze-
thaw cycles prior to first analysis and were measured in duplicate. We also recruited a 
significant cohort ‘mild’ severity CCHF and followed participants to 30 days after onset of 
symptoms.  
Evaluation of the individual cytokines at admission clearly demonstrates that a number are 
statistically significant, independent of the method utilised for stratifying groups for 
comparison. These include IL-10, IL-15, IL-6, IL-8, IP-10, MIP-1α and TNF-α, . However, IL-1β, IL-
2, IL-5 and IL-17A had levels that remained low and at the limit of detection, with no difference 
in convalescence samples. No difference was also noted in these cytokines at admission when 
stratified by disease severity or outcome, suggesting that they are not playing a key role in CCHF 
pathogenesis. IL-1Β in particular was expected to demonstrate more significant results as it is 
considered an important pro-inflammatory cytokine. We had hypothesised that elevated levels 
would be associated with severe disease as Papa et al 123 had previously found it to be raised in 
fatal cases. The elevated levels of the remaining 15 cytokines/chemokines analysed, compared 
to convalescence levels suggest a role in the complex immune response to CCHFV infection. 
However, differences in cytokine profiles when they are stratified by markers of disease severity 
provides more interesting data.  
Consistent with previous reports, we have demonstrated that at admission the cytokines IL-10, 
IL-6, IP-10 MCP-1, TNF-α are significantly higher in moderate/severe vs mild cases. However, for 
the first time GM-CSF, IL-12, IL-4 and IL-8 have been shown to be higher in moderate/severe 
cases and furthermore when severity is gauged by platelet count, MIP-1α, MIP-1β IL-15, INFA2 
and G-CSF are also elevated in patients who have platelet counts <50 x 109/L. Stratification by 
outcome (fatal/survived) revealed differences in IL-10, IL-6 and TNF-α levels in line with 
published reports. We also found further significant associations between higher levels of IL-15, 
IL-8 and MCP-1 and mortality despite only a small number of fatal cases. 
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The opportunity to evaluate cytokine profiles with matched CCHF viral load data is rarely 
available. We demonstrated correlations between admission cytokines and viral load for a range 
of cytokines/chemokines including TNF-α and IL-6, but not for IP-10, IL-10 or IFN-γ. However, 
when the dataset was expanded to evaluate correlations in all CCHFV positive longitudinal 
samples IL-10 and IP-10 positive correlations were demonstrated. The other cytokines that 
correlated with viral load at admission were IFN-Α2, IL-15, IL-8 and MIP-1β. Longitudinal analysis 
of cytokine expression highlights linear trends during illness course with predominant increased 
pro-inflammatory immune responses associated with severe disease and death, particularly in 
G-CSF, IL-6, IL-8, IL-15, MCP-1, MIP-1α, MIP-1β and TNF-α. IL-10 is a key anti-inflammatory 
cytokine that remains elevated in severe and fatal disease.  
The cytokine profiles that we have identified in patients with CCHF represent a valuable tool for 
the characterisation of immunological response patterns. They highlight a complex relationship 
of feedback loops, with a range of cytokines, including some not analysed and other factors 
involved. The immune response to CCHF is not a simple model and our results suggest that both 
pro-inflammatory and anti-inflammatory responses correlate with the pathogenesis of sepsis in 
a combined relationship.  
These data has for the first time also shown the expression of different cytokines during the 
course of illness and clearance of CCHF. It has identified additional biomarkers for disease 
severity and due the comprehensive, has highlighted the key cytokines involved in the host 
immune response. Immunomodulation of this response has to date not been shown to be 
beneficial in sepsis clinical trials, but this is likely to reflect the heterogenous nature of the 
sepsis syndrome. Whilst the priority for future clinical research in CCHF should focus on 
evaluating and antiviral/immune based therapeutics, there may also be potential in targeting 
specific steps of the interactive and dynamic process of the cytokine expression to limit organ 
dysfunction.  
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8.7 Limitations of the study 
The main limitations of the study are the limited numbers of severe and fatal CCHF cases that 
were recruited, that was out with the control of the chief investigator. Due to informed consent 
procedures there was also an unavoidable delay in recruitment and sampling of participants. 
Due to quicker than predicted clearance of CCHFV from bloods, this had a direct effect on the 
number of participants with positive viral load data at entry of the study for comparison.  
Recruitment of ‘mild’ severity CCHF disease is important to improve understanding of host 
immune response and viral dynamics, and the study recruited from secondary and tertiary 
health care facilities. Seroprevalence studies in Turkey have though highlighted high rates of 
CCHFV IgG positivity in populations living in hyperendemic areas that is thought to represent an 
undiagnosed/asymptomatic infection. To fully investigate this group/spectrum of illness further 
a combination of prospective fever and longitudinal epidemiological studies are required. 
There is a potential effect of ribavirin use in one third of the cohort, that whilst providing 
important observational data, may have had a confounding effect on viral loads, particularly 
when analysed by disease severity. There were also different times to presentation and a small 
number of participants who were transferred to study sites from other facilities. The cohort 
recruited in Tokat and Samsun are broadly representative of the adult CCHF population in 
Turkey, but host and viral genetic factors in other endemic countries such as Iran, Kosovo and 
South Africa must be considered when considering the results in a broader context. Data was 
collected by trained study teams at each site, but it is possible that errors were made in CRF 
completion and sample labelling although great care was made to avoid this. Data was entered 
and independently checked, then verified.  
Whilst recognising these limitations it must also be recognised that undertaking an intensive 
clinical and laboratory study of this nature in a large cohort of patients with viral haemorrhagic 
fever, presents significant IP&C and safety challenges throughout that must be mitigated.  
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8.8 Conclusions and summary key points 
This comprehensive study of a large cohort of adults with confirmed CCHF in Turkey has 
described the clinical features and management, immune responses and viral dynamics 
providing new insights into disease pathogenesis. For the first time a large number of ‘mild’ 
severity CCHF cases have been included that provide an important group for comparison, 
particularly with respect to host immune response to CCHF infection. ROTEM analysis has been 
undertaken at scale for the first time in any viral haemorrhagic fever and combined with 
standard laboratory tests and clinical observation, highlighted a mechanism for the 
coagulopathy and pattern of bleeding seen.  
• A high percentage of patients admitted with confirmed CCHF in Turkey have mild 
severity disease (60%), with the majority recording vital signs within normal limits at 
admission and during hospitalisation.  
• Consistent with other VHFs, high fever is not characteristic of CCHF with important 
implications for case definitions utilised in surveillance and screening. 
• Thrombocytopenia and a hepatitis are consistent features of CCHF and associated with 
disease severity and higher CCHF viral loads. Renal dysfunction is not commonly seen in 
CCHF with only 4% having acute kidney injury by RIFLE criteria. 
• Bleeding occurred in 23% and blood component therapy was received by 37% of 
participants, associated with increased disease severity.  
• Ribavirin was administered to 35% of participants, a median of 4 days after onset of 
symptoms. 25% of participants were CCHF PCR negative when ribavirin was 
commenced and for 72% of the days it was administered. 
• Higher CCHF viral load is associated with increased disease severity (mild vs 
moderate/severe), lower platelet counts and fatal outcome. The laboratory parameters 
of APTT, PT, LDH, CK and creatinine correlated with CCHF viral load, as did the duration 
of clinical features: fever; myalgia and vomiting. 
• Most patients clear CCHFV from blood within 5-6 days of onset of symptoms, occurring 
more rapidly in patients with mild disease and higher platelet counts (65% CCHFV 
clearance at day 5 of illness vs 40% in moderate/severe group). Urine is rarely CCHFV 
PCR positive in acute infection (8/578 samples) and cannot be reliably utilised in 
convalescence to diagnose recent CCHF infection. 
• Duration of viraemia positively correlated with a longer length of hospital stay and 
number of platelet transfusions required. 
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• At admission, 42% of patients are IgM positive, with all patients IgM positive by day 8 of 
clinical illness continuing to 30 days. At admission, 50% of patients are IgG positive, 
with >95% positive by day 8 of illness.  
• ROTEM and conventional coagulation analysis has demonstrated that the coagulopathy 
in CCHF is reversible and predominantly related to clot development/stabilisation that 
is most marked during day 4-6 of the illness and in severe disease. In the context of 
normal/only slightly deranged coagulation screens and FIBTEM results, and combined 
with the absence of hyperfibrinolysis, this data provides the first evidence that the 
initial coagulopathy in CCHF probably relates to platelet dysfunction and not DIC. 
• In accordance with previous data, at admission the cytokines IL-10, IL-6, IP-10, MCP-1, 
TNF-α were significantly higher in moderate/severe vs mild cases. However, for the first 
time GM-CSF, IL-12, IL-4 and IL-8 were shown to elevated in moderate/severe disease.  
• Stratification by outcome (fatal/survived) also revealed differences in IL-10, IL-6 and 
TNF-α levels in line with published reports. We also found further significant 
associations with mortality and higher levels of IL-15, IL-8 and MCP-1 despite a small 
number of fatal cases.  
• Significant linear regression slopes during the course of illness were demonstrated by 
IFN-α2, IL-5, IL-10, IL-15, MCP-1, MIP-1α, MIP-1β and TNF-α. At admission we 
demonstrate previously reported correlations with TNF-α and IL-6 with CCHF viral load, 
and also with IFN-Α2, IL-15, IL-8 and MIP-1β. 
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Appendix 4 
Study: Pathogenesis of Crimean-Congo Haemorrhagic Fever (CCHF) - interaction of immune 
response, viral load and clinical course.  
INFORMATION SHEET FOR PARTICIPANTS -  
25th March 2015. Version 1.3 
 
We are undertaking a research study involving patients with suspected Crimean-Congo 
Haemorrhagic Fever (CCHF).  
You are invited to take part in this study. 
Before you decide to take part it is important for you to understand why the research is being 
done and what it would involve for you. Please take time to read this information carefully. One 
of our team will go through the information with you. Please ask us if there is anything that is 
not clear or if you would like more information and time to decide. Your decision is completely 
voluntary, you can withdraw at any time and the decision you make will not affect your care in 
any way. 
 
What is the study about? 
CCHF is an important infection in Turkey, where the most cases in the world are reported each 
year. Although it is quite common we still do not understand how the CCHF virus interacts with 
the human immune system. This research study will gain important information about this 
disease and may help people in the future. 
The main study investigator is Dr Tom Fletcher from the UK who is working with Professor 
Hakan Leblebicioglu at Ondokus Mayis University Hospital in Samsun. 
 
What will happen if I take part in this study? 
We will collect information and blood and urine samples which are in addition to normal 
medical care. As part of your standard medical care blood samples will be taken every day by 
the medical team. We would like to take up to 3 small blood tubes at the same time and also 
collect some urine samples. We would also take another blood and urine sample at around 30 
days and a blood sample 1 year from now. 
 
 
Figure 1: Phlebotomy and urine collection 
 
 
Will my taking part or not taking part affect my treatment? 
No. You should only participate if you want to; choosing not to take part will not 
disadvantage you in any way with regards to medical care. 
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What will happen to the samples and information? 
We will use the blood samples to look at how the body fights the infection and how the virus 
interacts with the body. Some of the tests will be done in the UK. 
All information about you will be handled in confidence and only the people responsible for 
your care and for this study will know that you were a part of the study. All information and 
samples will be labelled only with a number so that neither the samples or test results cannot 
be directly linked to you personally. Most of the laboratory tests will be completed in Turkey 
but some specialised tests will be take place in the UK. With your permission, we would also like 
to store your samples and use them for future ethically approved medical research.  
 
Are there any benefits to taking part in this study? 
No. The information gained from this study will not benefit you directly in the management of 
your illness. 
 
What are the risks of being in the study? 
Being a part of this study means that a few samples will be taken that are not needed for 
normal medical care. There is a small risk of pain or irritation when blood samples are taken but 
these samples will be planned to be taken at the same time as your routine daily samples.  
 
Can I request that I be withdrawn from the study at any point? 
Yes, you can withdraw at any time without giving a reason and without affecting your medical 
care at all . Any samples that have not already been analysed can be destroyed anytime you 
request it. 
 
Who is funding the research? 
The study is being funded by the Wellcome Trust and the UK Defence Medical services.  
 
What if I have any problems or would like further information about the study? 
Please contact the Chief Investigator Dr Tom Fletcher (local mobile, 
tomfletcher@doctors.org.uk) or the lead Supervisor Prof Hakan Leblebicioglu (unit Number). 
You can also discuss being involved in the study with an independent doctor who is not part of 
the research team (Prof Saban Esen tel: 0 362 312 1919 ext 2797). 
 
This study complies, and at all times will comply, with the Declaration of Helsinki [1] as adopted 
at the 64th WMA General Assemble at Fortaleza, Brazil in October 2013.  
_____________________________________ 
 
[1] World Medical Association Declaration of Helsinki [revised October 2013]. 
Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Studies. 
64th WMA General Assembly, Fortaleza (Brazil). 
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Appendix 5 
 
CONSENT FORM FOR PARTICIPANTS IN RESEARCH STUDIES 
 
Study: Pathogenesis of Crimean-Congo Haemorrhagic Fever (CCHF) - interaction of immune 
response, viral load and clinical course 
 
Ministry of Defence Research Ethics Committee Reference:   571/MODREC/14   
 
 The nature, aims and risks of the research have been explained to me. I have read and 
understood the Information for Participants and understand what is expected of me. All my 
questions have been answered fully to my satisfaction. 
 
 I understand that if I decide at any time during the research that I no longer wish to 
participate in this project, I can notify the researchers involved and be withdrawn from it 
immediately without having to give a reason. I also understand that I may be withdrawn from it 
at any time, and that in neither case will this be held against me or affect my clinical care. 
 
 I consent to the processing of my personal information for the purposes of this research 
study. I understand that such information will be treated as strictly confidential and handled in 
accordance with the provisions of the Data Protection Act 1998. 
 
 I agree to volunteer as a participant for the study described in the information sheet 
and give full consent. I understand that this includes the collection of additional blood and urine 
samples.  
 
 I understand that some specimens taken (blood, urine) may be transported out of the 
country for analysis. 
 
 This consent is specific to the particular study described in the Information for 
Participants attached and shall not be taken to imply my consent to participate in any 
subsequent study or deviation from that detailed here. 
 
Participant’s Statement: 
 
I  ________________________________________________________________ 
 
agree that the research project named above has been explained to me to my satisfaction and I 
agree to take part in the study. I have read both the notes written above and the Participant 
Information Sheet about the project, and understand what the research study involves. A signed 
copy of this form will be made available for your personal records 
 
Signature      Date       
or Thumbprint 
 
 
 
 
Impartial witness if patient is illiterate: 
 
Name  
 
Signature       Date 
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Next of Kin/Consultees if patient unable to consent: 
 
1. Name      2. Name 
 
Signature date    Signature date 
 
 
 
Investigator’s Statement: 
 
I  _________________________________________________________________ 
 
confirm that I have carefully explained the nature, demands and any foreseeable risks (where 
applicable) of the proposed research to the Participant. 
 
 
Signature      Date       
 
 
AUTHORISING SIGNATURES 
 
The information supplied above is to the best of my knowledge and belief accurate. I clearly 
understand my obligations and the rights of research participants, particularly concerning 
recruitment of participants and obtaining valid consent. 
 
 
Signature of Principal Investigator  
 
 
…………………………………………………… Date       
 
 
Name and contact details of Independent Medical Officer:  
 
Prof Saban Esen Tel: 0362 312 1919 ext 2797. 
 
Name and contact details of Principal Investigator:  
      
Dr Tom Fletcher (#local cell , tomfletcher@doctors.org.uk) or Prof Hakan Leblebicioglu (Unit 
Number).  
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Annex 6 
Sample Processing Turkey  
1. Inspect all samples on reception in the laboratory to ensure no gross blood 
contamination and the presence of unique patient identifiers on each blood tube.  
2. Wearing PPE (Gloves, Lab coat, Face shield) wipe each tube with 0.5% chlorine/vircon 
solution and allow to dry in the Class 1 BSC 
3. All blood samples (except PAXgene tubes) centrifuged at 2000g for 15 minutes at room 
temperature. 
4. Open the centrifuge and inspect the buckets for any leakage. 
5. Transfer the sealed buckets to the Class 1 BSC and only open them inside the cabinet 
wearing PPE. 
6. Serum samples: Pipette off serum from the centrifuged tube, and transfer into labelled 
cryovials (printed labels to indicate sample type, patient details, sample date). 1 x 
Serum sample tube into 2x1ml aliquots.  
7. Plasma/EDTA samples: Pipette plasma from the centrifuged tube, and transferred into 
labelled cryovials (printed labels to indicate sample type, participant number, sample 
date). 1 x EDTA sample tube into 2x1ml aliquots. 
8. Citrated plasma samples:  Separated using plasma 0.5cm above the base of the red cell 
layer only. The platelet poor plasma (PPP) from is then further processed to obtain 
platelet free plasma (PFP) or (Double spun plasma) by double spinning the plasma into 
a clean tube. Plasma is taken off with the plastic Pipette, and transferred into a clean 
transfer 75 X 12 mm tube, and re centrifuged for 15 minutes at room temperature to 
obtain platelet free plasma (PFP). The plasma that is left (in the primary blood tube) 
0.5mls above the base is put into the single spun cryovial (labelled Single spun plasma). 
After the second centrifuge PFP samples are then separated into 3 x cryovial tubes  in 
0.5ml aliquots. The plasma left in the bottom 0.5ml of the second centrifuge is again 
placed into the SS cryovial. 
9. Plasma and serum must be separated within a 3-hour period of being taken. If a delay 
occurs, then they must be placed at 4oC, and processed as soon as possible that day. 
10. Urine samples: Urine is pipetted directly from the universal container into labelled 1 x 2 
ml cryovial (printed labels to indicate sample type, participant number, sample date.) 1 
x urine sample tube into 1 x 2ml aliquot. 
11. PAXgene tube storage. No sample processing required. Place for 24hrs in -20 freezer 
then transfer to -80 freezer. 
 
